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MECHANISTIC AND FUNCTIONAL CHARACTERIZATION OF B AND T
LYMPHOCYTE ATTENUATOR (BTLA) IN CD8 TUMOR INFILTRATING
LYMPHOCYTES
Krit Ritthipichai, D.V.M., M.S.
Supervisory Professor: Patrick Hwu, MD
This dissertation project focused on understanding the functional role of BTLA
on CD8+ Tumor Infiltrating Lymphocytes (TIL) from metastatic melanoma patients.
Clinical trials of adoptive T-cell therapy (ACT) using autologous ex vivo expanded TIL
have demonstrated the great potential of this immunotherapy with an overall clinical
response rate 40-50% for stage IV metastatic melanoma patients. We have investigated
a number of biomarkers in both the infused TIL and the tumor microenvironment for
their association with clinical response. Surprisingly, a subset of CD8+ TIL expressing
the co-inhibitory molecule BTLA (B-and-T lymphocyte attenuator) was highly
associated with clinical response, while expression of other co-inhibitory molecules
such as PD-1, TIM-3, and Lag3 did not associate with response. BTLA is expressed by
T cells, B cells, and NK cells and serves as a T cell differentiation maker whereby high
expression of BTLA associates with less differentiated T cell phenotype. While the
suppressive function of the ITIM and ITSM motifs of BTLA are well described, the
Grb2 motif’s function remains understudied.
In this study, we sought to determine the functional characteristics of the
CD8+BTLA+TIL subset and define the contribution of the Grb2 motif of BTLA in T
cell co-stimulation. We have uncovered a survival advantages of the BTLA+ subset that
allows for serial killing of target tumor cells, which may explain our previous
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correlation between this subset and response to TIL ACT. BTLA-HVEM interaction
during T cell activation led to the specific activation of SRC kinase. In addition, our
results unveiled a role for the BTLA-associated Grb2-binding motif in T cell
proliferation and IL-2 production following TCR engagement that was independent of
the inhibitory function of ITIM/ITSM motifs.
Overall, our study first unveil the dual role of BTLA as both a co-stimulatory
and co-inhibitory molecule. The integration of the positive and negative signals
transduced by BTLA promotes IL-2 secretion while reducing certain effector function
of T cell. Altogether, the combination of both BTLA signaling and inherent attributes
of less differentiated T cells could promote T cell survival, persistence, and anti-tumor
function.
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CHAPTER 1

General Introduction

1

1.1 Cancer Immunotherapy
Recently, the second edition of hallmarks of cancer proposed by Robert
Weinberg and Douglas Hanahan have included evading immune system destruction as
one of the biological properties that transformed cells require during multistep
carcinogenesis (1, 2). In the past two decades, our extensive gain in knowledge of
cancer immunology has solidly proved that the immune system plays both a positive
and negative role during cancer development. The first evidence of the immune
system’s role in tumor control was demonstrated by William B. Coley in 1893 when
he treated inoperable malignant sarcoma with inactivated bacterial lysates that
consisted of Streptococcus pyogenes and Bacillus prodigiosus, which triggered an
immune response resulting in tumor regression in a patient for almost 26 years until his
death (3). Although the finding suggested that the activated immune system could
promote tumor regression, there was no strong evidence to support this clinical
observation.
In early 1909, Paul Ehrlich first postulated that the immune system could
recognize and destroy cancerous cells (4). Five decades later, Lewis Thomas and
MacFarlane Burnet proposed their immunosurveillance hypothesis, which suggested
the existence of effector cells that can sentinel the transformed cells in the body and
eliminate them through a specific mechanism (4-6). Later on, a number of extensive in
vivo and in vitro studies have refined and included immunosurveillance as a part of
“cancer immunoediting”, which more precisely defines the involvement of the immune
system in tumor development in three phases; elimination, equilibrium, and escape.
Elimination (or immunosurveillance) is the first step, in which immune cells recognize
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tumor cells and destroy cancer cells. In the equilibrium phase, some tumor cells are not
targeted by immune-mediated killing. Emerging new tumor cell variants are then
selected to grow and flee from immune detection in the escape phase (7-9).
1.1 a) Highlights of major discoveries in cancer immunotherapy

1950: Evidence from Llyod Old, and other scientists emphasized the importance of
the immune system in tumor control (10, 11).
1961 to 1970:
-

Hellstorm and colleagues demonstrated specific tumor recognition by immune
cells (12).

-

Alpha fetoprotein (AFP) was identified as the first tumor-specific antigen by
Irlin’s group (13).

-

Gershon and Kondo revealed the suppressive role of T cells, leading to
immunotolerance theory (14).

1971 to 1980
-

Discovery of dendritic cells by Ralph Steinman, leading to cancer vaccine study
(15).

-

Identification of Natural killer cells by Eva Klein and Hans Wigzell, leading to
the development of NK cell therapy (16).

-

Francis W. Ruscetti, Doris A. Morgan, Robert Gallo and colleague discovered
Interleukin-2, the first effective immunotherapy in cancer treatment and also
used in combination with other immunotherapies (17-19).
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1981 to 1990
-

FDA approved Rituxan, the first monoclonal antibody for B cell lymphoma
treatment developed and tested by Ronal Levy. A few years later, Greg Winter
successfully generated the world’s first humanized antibody (20, 21).

-

Dr. Steven Rosenberg first used high-dose IL-2 as a single therapy for cancer
patients with advanced diseases and treated the first melanoma patient with
tumor infiltrating lymphocytes (TILs) (22).

-

Discovery of T cell receptor by Phillippa Marrack, John Kappler, and James
Allison (23).

-

CTLA-4 was identified by Golstein and colleagues (24).

1991 to 2000
-

Tyrosinase was the first tumor antigen on melanoma cells recognized by HLAA2 restricted tumor reactive T cells (25).

-

Drew Pardoll demonstrated the effectiveness of the cancer vaccine GVAX to
stimulate a long-lasting anti-tumor response in a phase I clinical trial (26).

-

The first report of using dendritic cells as a cancer vaccine in melanoma by
Bijay Mukherji (27)

-

James Allison and colleagues first revealed the effect of anti-CTLA-4 antibody
in tumor control using murine model (28, 29).

-

FDA approved Transtuzumab (Herceptin) for metastatic breast cancer
treatment (30).
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2001 to 2010
-

Fully humanized monoclonal antibody (anti-human Epidermal Growth Factor
Receptor, Ranitumumab) was approved by FDA for metastatic colorectal
cancer (31).

-

FDA approved Gardasil and Cervarix vaccines protecting against the Human
Papilloma Virus (HPV), which causes approximately 70% of cervical cancer
cases (32).

-

Immunoscore was firstly introduced as a novel approach to evaluate cancer
progression (33).

-

Strong evidence demonstrating the effectiveness of the anti-CTLA-4 antibody
in tumor regression in human studies (34).

2010 to present
-

First dendritic cell vaccine (Sipuleucel-T) was approved by FDA for the
treatment of prostate cancer (35)

-

Clinical studies demonstrated an improved survival with ipilimumab metastatic
melanoma patients that led to FDA approval (36, 37).

-

Clinical trials of using anti-PD-1 blockade successfully showed improved
clinical outcomes in metastatic melanoma, renal cancer, lung cancer, and colon
cancer which led to FDA approval for anti-PD-1 antibody, Nivolumab and
Pembrolizumab (38, 39).

-

Success of CAR T cell therapy trials led by Carl June and Steven Rosenberg
demonstrated approximately 90% objective clinical response in Hematological
(40).
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Current strategies in cancer immunotherapy
On the basis of our current knowledge, the immune system plays a protective
role in pathogen infection as well as cancer control. Although the immune system is
powerful enough to protect and control tumors, the remaining question is why cancers
still occurs in normal people with healthy immune system. Indeed, tumors are able
create a microenvironment that inhibits immune mediated cancer cell killing.
Overcoming the immunosuppressive environment requires the coordination between
antigen-presenting cells and T cells. Antigen-specific T cells need to receive an optimal
priming in order to develop robust effector functions as well as long-lasting immune
response. Several strategies have been extensively investigated to improve the function
of immune cells including enhancing tumor antigen presentation and promoting
effector function and memory development of antigen-specific T cells. Several types
of tumor immunotherapy have been investigated and employed to foster innate and
adaptive immune system. Here, four major types of cancer immunotherapy are
discussed including; cytokine, checkpoint blockade inhibitor, vaccine, and cell-based
therapy (Figure 1.1)
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Figure 1.1. Schematic diagram demonstrates four major types of cancer
immunotherapy.
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1.1 b) Checkpoint blockade inhibitors
The effector functions of T cells, including cytokine production, proliferation,
and target cell killing are regulated by the coordination between co-stimulatory and coinhibitory molecules after encountering tumor antigens (41). Immune checkpoints are
pivotal for the maintenance of self-tolerance and preventing an overreacting immune
response (42, 43). However, excessive function of co-inhibitory molecules can benefit
tumor cells to escape the immune response. Blockade of co-stimulatory molecules
potentially breaks the physiological tolerance and enhances the anti-tumor response
(42). Using antagonist antibodies against T cell co-inhibitory molecules has proved
promising in cancer therapy. Targeting checkpoint molecules does not directly affect
tumor cell death itself, instead this strategy prevents T cell from receiving inhibitory
signal from tumor cells, resulting in improvement of its effector function in mediating
tumor killing (42, 43). Currently, the effect of immune checkpoints’ blockade on
immune response has been widely investigated at both pre-clinical and clinical models.
Targeting different inhibitory molecules have provided a great potential to manipulate
immune response by different mechanisms such as enhancing effector T cell function,
depleting regulatory T cells from tumor microenvironment, and facilitating T cell
migration. Thus, combinatorial blockade is a worthwhile strategy for cancer
immunotherapy.
CTLA-4
CTLA-4 was initially reported following the discovery of the first costimulatory molecules, CD80 and CD86, in 1991 (24). Due to the high sequence
similarity between CTLA-4 and CD28 it was initially believed that CTLA-4 was a
positive T cell co-stimulatory receptor (44). However, the inhibitory function of CTLA8

4 on T cells was revealed by James Allison’s laboratory later in 1995 (45). CTLA-4
was shown to strongly suppress T cell proliferation by outcompeting CD28 from
binding CD80 and 86 expressed by APCs during antigen stimulation (46). Thus far, the
specific signaling pathway of T cells targeted by CTLA-4 has not been identified. Some
studies suggest that the downstream pathway of CD28 might be dampened by CTLA4 via activation of SHP2 proteins, a phosphatase protein that attenuates proximal TCR
signals (47). In addition, the cytotoxic lymphocytes (CTL) proliferative dysregulation
observed in in CTLA-4 knock-out mice confirmed its inhibitory role(48). The
inhibitory function of CTLA-4 strongly affects the effector function of CD8+ T cells,
however CTLA-4 was found to directly enhance the suppressive function of
CD4+CD25+Foxp3+ T reg (Regulatory T cell, Treg). Thus, blockade of CTLA-4 can
improve effector function of CD8+ and attenuate the inhibitory function of T regulatory
T cells (49). This results in boosting anti-tumor immunity in the tumor
microenvironment. Preclinical studies demonstrated improvement of the antitumor
response in partially immunogenic tumor-bearing mice when treated with anti-CTLA4 as a single therapy (28). However, in poorly immunogenic tumor models, vaccination
in conjunction with anti-CTLA-4 blockade was required to achieve a similar anti-tumor
response (28, 50).
Based on preclinical evidence, two pharmaceutical companies have developed
antibodies targeting CTLA-4, including Bristol Myer Squibb (ipilimumab) and Pfizer
(tremelimumab). In phase III clinical trials, approximately 20% of patients with
metastatic melanoma had achieved long-term-survival of at least two years when
combined CTLA-4 treatment with gp100 vaccination (36, 51). Interestingly, ten-year
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survival was also reported in some patients. On the basis of overall survival benefit for
patients with advanced melanoma, ipilimumab was approved by FDA in 2011 (52).
However, phase I and II clinical trials for melanoma with tremelimumab were
discontinued in 2008 due to no statistical significance for improving overall survival
(53). The successful story of CTLA-4 blockade has strengthened the concept of
checkpoint blockade in cancer immunotherapy and fostered the needs for further
studies on other checkpoint inhibitors such as PD-1, TIM-3, and LAG-3.
PD-1
PD-1 is characterized as a co-inhibitory molecule expressed by T cells. PD-L1
and PD-L2 are the two identified PD-1 ligands. Recruitment of phosphatase (SHP1 and
2) into ITIM and ITSM motifs is responsible for an inhibitory function of PD-1 (54,
55). It has been shown that PD-1 specifically targeted Akt and cell cycle pathways to
suppress T cell proliferation (56). Although PD-1 and CTLA-4 are both negative
stimulatory molecules, it is believed that their downstream targets are relatively
distinct. CTLA-4 predominantly inhibits T cells during early activation, supposedly
during T cell priming phase, while PD-1 mainly suppresses effector functions of T cells
primarily residing in peripheral tissues and tumor bed due to the presence of its ligand
(PD-L1) highly expressed by tumor cells.
PD-1 is widely expressed by several immune cells including B and NK cells,
and its ligand is expressed by tumors. In contrast, expression of CTLA-4 is limited in
T lymphocytes, and its ligand is mostly expressed by APCs (54). Thus, blockade of the
PD-1 pathway is likely to affect more broad-range targets than CTLA-4. PD-1
blockade, considered to enhance effector T cell function, may also improve the function
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of natural killer cells in mediating tumor regression, and indirectly boost humoral
immunity against tumors mediated by B cells as well (57).
In several chronic diseases such as some viral infections and cancers, T cells
are repetitively stimulated by antigens due to the persistence of diseases. This condition
can induce high expression of PD-1 on T cells, resulting in T cell anergy or exhaustion
(58). In murine models, it has been shown that blockade of PD-1 partially reversed the
effector function of T cells during chronic viral infection (59).
Expression of PD-L1 has been indentified in several human tumors including
melanoma, breast cancer, glioblastoma, and ovarian cancer. IFN-γ secreted by CTL
was found to up-regulate PD-L1 on tumor cells, epithelial cells, and stromal cells (60).
It was thought that the PD-L1 ligand itself had no role in tumor cell signaling based on
the fact that the cytoplasmic domain is relatively short. However, a recent report in
glioblastoma has demonstrated that PD-L1 enhanced PTEN degradation resulting in
constitutive activation of the AKT pathway (61).
Suppression of anti-tumor immunity upon ligation between PD-L1 and PD-1
has been noted in several murine models. Defects in T cell-mediated tumor immunity
were observed upon overexpression of PD-L1 in mouse tumor cells (62, 63). The use
of PD-L1 expression as a prognostic marker in clinical trials using PD-1 blockade
antibody has been controversial. This might be due to some difficulties in performing
cross comparisons with variations in technique, type and stage of cancers, and prior
treatment.
Strong evidence from mouse models demonstrating the effect of PD-1 blockade
in improving tumor control combined with the observation of high expression of PD-
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L1 in several cancers has led to the development of several human therapeutic
antibodies targeting the PD-1 pathway including anti-PD-1 antibodies; (nivolumab
(BMS) and pembrolizumab (Merck)),

and anti-PD-L1 antibodies; (BMS-936558

(BMS), MPDL3280A (Genentech), MEDI4736 (Medimmune), MSB0010718C (EMD
serono)) (38, 64). In phase I studies, nivolumab successfully improved the three-year
survival rate to 40% among 107 treated melanoma patients (65). In 2014, FDA has
approved nivolumab for the treatment of patients with metastatic melanoma with no
response to prior treatment as well as squamous non-small cell carcinoma. Comparison
of nivolumab and conventional chemotherapy (dacarbazine) in phase III clinical trails
has successfully confirmed the phase 1 result with a superior response rate (40% versus
13%) (65).
1.1 c) Cancer vaccine
A knowledge of tumor antigens recognized by the immune system has shed
light on developing vaccines as an alternative approach for cancer therapy. On the basis
of vaccine components, it can be classified into three categories: cell-based, peptidebased, and genetically-based vaccines.
Cell based vaccine
Tumors derived from patients were first used as a vaccine to test the proof of
principle that providing tumor antigens with an adjuvant (BCG) can boost the antitumor response. The patients vaccinated with irradiated autologous tumors alone did
not achieve a favorable clinical response (66). However, tumors engineered to secrete
granulocyte-macrophage colony-stimulating factors (GM-CSF) was found to trigger
tumor regression when combined with anti-CTLA-4 antibodies (50). Autologous tumor
cell preparation is labor intensive and limited to only some solid tumors. Hence, an
12

alternative approach of using an allogenic whole tumor cell vaccine was developed to
overcome this limitation. The use of canavaxin, irradiated whole cells from three
melanoma cell lines in combination with BCG, has been evaluated in phase III clinical
trials and witnessed slightly improved overall survival rate in metastatic melanoma
patients as compared to the control (49% versus 37%) (67). However, this approach
was discontinued later on since two independent randomized trials failed to prove antitumor efficacy. Because tumor antigens from tumor cell lysate require effective antigen
processing and presentation, another strategy of using dendritic cells for active
immunotherapy has been developed. Sipuleucel-T (Dendreon Corporation) is the first
dendritic cell vaccine approved by FDA for the treatment of asymptomatic and
minimally symptomatic metastatic castration-resistant prostate cancer (35). Phase III
trials have demonstrated a slightly improved median overall survival in patients treated
with Sipuleucel-T as compared with a placebo control (25.8 months versus 21.7
months) (68). In our TIL therapy program at M.D. Anderson Cancer Center, we have
observed that the combination of TIL therapy using TIL products containing MART-1
reactive CD8+ TIL with the infusion of autologous dendritic cells pulsed with MART1 peptide did not improve the efficacy of treatment from what is seen with the infusion
of TIL alone in a small cohort of 19 patients (data not shown, personal communication
from the TIL program).
Peptide vaccine
Several tumor-associated antigens (TAAs) are identified in many types of
cancers such as MAGE, NY-ESO-1, gp100, MART-1, E75, and so forth. TAAs can be
up-taken, processed, and presented on the cell surface of mature APCs (69). It is crucial
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for dendritic cells to receive appropriate signals for maturation, migration to the
regional lymph node, and presentation of TAAs to naïve T cells. Thus, the adjuvant is
required for appropriate TAAs priming by APCs. Mimicking innate immune alarm
using synthetic pathogen-associated molecular patterns (PAMPs) such as TLR agonists
can activate APCs and enhance the desired anti-tumor response. Investigating the use
of TLR agonists for cancer vaccine is currently under way in clinical trials, including
TLR3, TLR4, and TLR9. So far, only three TLR agonists are approved by FDA for
therapeutic use in humans including BCG (TLR 2, and 4 agonists), monophosphoryl
lipid A (MPL, TLR4 agonist), and imiquimod (TLR7 agonist) (70). Identification of
melanoma TAAs recognized by T cells including gp100, MART-1, NY-ESO-1, and
survivin strengthens the use of vaccine as an alternative therapy for cancer. In phase III
clinical trials, a combination of gp100 and IL-2 has demonstrated improved response
rate in relative to IL-2 alone (16% versus 6%) (71). However, vaccination of melanoma
stage III patients with MAGE-A3 failed to prolong disease-free survival in phase III
clinical studies. Recent study on cocktail antigen vaccination with melanoma antigens,
including gp100, MAGE-A1, MAGE-A2 and MART-1 and tyrosine kinase, exhibited
extended survival time as compared with placebo controls (21 months versus 8 months)
(72). In pancreatic adenocarcinoma (PDA), phase III clinical studies of telomerase
vaccine (GV1001) with chemotherapy demonstrated no improvement in survival as
opposed to chemotherapy alone (73). Immunization with IMA901 vaccine in
conjunction with cyclophosphamide and GM-CSF increased overall survival rate in
patients with reactive T cells against peptide IMA901, but did not benefit patients who
had no pre-existing immune response (74).
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Genetically based vaccines
Recombinant DNA vectors are carriers for protein overexpression in
mammalian cells. This gene delivery approach can be used to deliver and express TAAs
to enhance antigen recognition by T cells. Using optimization of codon usage can
improve TAA expression when its gene-containing codons have rare tRNA. The major
advantages of DNA vaccines are simple and flexible design, lack of adverse effects,
heat labile, and cost effectiveness. In addition, DNA structure itself can also act as an
adjuvant to activate innate immune systems through TLR, which can provide optimal
priming to elicit potent adaptive immune (75). The introduction of DNA vaccines
through intradermal and intramuscular injections was shown to have limited DNA uptaking, and resulted in low transfection efficiency. A novel technology using the Gene
Gun to deliver DNA coated with gold particles can increase DNA uptake, which makes
it feasible for clinical applications. Another approach to increase the uptake of DNA
plasmid is the use of electroporation which works by permeabilizing the cell membrane
with electric pulses. By this mean, not only does the efficiency of DNA delivery can
increase approximately 1,000-fold, but also lead to the recruitment of APCs at the
vaccination site due to tissue damage (76).
The first successful DNA vaccine (Oncept, Merial) was initially tested in canine
spontaneous melanoma using a human tyrosinase recombinant DNA vector. The use of
Oncept has demonstrated prolonged survival in dogs with advanced melanoma without
toxicity. Thus far, Oncept is one-and only DNA vaccine approved by USDA. In human,
DNA vaccine for cancer treatment has not yet been approved by FDA (77). However,
several clinical trials are being extensively conducted in different types of cancers. In
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melanoma, using the gp100 DNA vaccine has shown no benefit in progression-free
survival regardless of patient immune response. Only a subtle increase in IFN-γ in
CD8+gp100+ T cells has been observed in some patients (78). A number of studies of
tumor antigens in other cancers are currently ongoing including human epidermal
growth factor receptor 2 (HER2), carinoembryonic antigen (CEA), prostate acid
phosphatase (PAP), and E6/E7 (human papilloma viral proteins). An increase in
effector function of tumor-specific antigen reactive T cells was found in breast cancer
and colorectal cancer patients, but failed to prolong the survival time (79).
An application of mRNA vaccines is another approach used extensively in
small animal models. RNA structure can be recognized by TLR and help prime an
innate immune response. Because RNA is vulnerably instable and prone to degrade
upon delivery, several strategies have been focused on protecting RNA from
degradation such as RNA-loaded nanoparticles, protamine-condensed RNA, and
encapsulated RNA. Instead of immunization with naked RNA, adoptive transfer of
autologous dendritic cells transfected with the RNA of target antigens has also been
studied in several types of cancers including melanoma, lung cancer, colorectal cancer,
prostate cancer, and pancreatic cancer. In a study in humans, transfection of DCs with
RNA directly isolated from autologous tumors has demonstrated the expansion of
tumor-reactive T cells mediating autologous tumor cell lysis (80). Currently, the
clinical study of RNA vaccines is still limited to phase I/II trials. In melanoma, using
naked RNA purified from an autologous tumor improved clinical response rates, mixed
response (15%) and no evidence of disease (23%) (81). In renal cell carcinoma, patients
immunized with a cocktail of RNA of tumor antigens (MUC1, CEA, HER-2/neu,
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telomerase, surviving, and MAGE-1) has illustrated only 7% partial response and 40%
stable disease, and an increase in the effector function of CD8+ and CD4+ T cells was
also observed in some patients (82).
1.1 d) Cytokine therapy for cancers
Cytokine, a small molecule secreted from cells, can act as a mediator for
intercellular communication. Engagement of cytokine and receptors on immune cells
can rapidly stimulate cell signaling and function in multiple facets including cell
proliferation, migration, and cytotoxicity. In cancer immunology, cytokines are very
critical to enhance maturation of innate immune cells such as dendritic cells as well as
the effector function of cytotoxicity T cells (CTLs). Nevertheless, some cytokines such
as IL-10 and TGF-β can inhibit effector function of CTLs. Currently, only two
cytokines have been approved by FDA through the use of cancer therapy, including IL2 and IFN-α (83). In addition, a number of several cytokines such as IL-7, IL-15, IL18, and IL-21 are being focused in both preclinical and clinical studies for cancer
treatment.
IL-2
IL-2 is a cytokine mainly secreted by activated CD4+ T cells. IL-2 mediates T cell
proliferation similar to the cytokines that share common gamma chain receptors such
as IL-4, IL-7, IL-9, IL-15, and IL-21. The IL-2 receptor consists of three subunits; alpha
(CD25), beta (CD122), and gamma (CD132). The alpha subunit is involved in binding,
while the other subunits play an important role in downstream signaling. Unlike T cells,
IL-2 receptor in NK cells and B cells contains only gamma and beta subunits, thus
mediate less binding affinity than T cells (84). Engagement of IL-2 and its receptor on
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T cells does not only stimulate cell proliferation, but also promotes T cell
differentiation into different subsets such as memory, effector, and terminallydifferentiated subsets (85).
Discovery of IL-2 has unleashed new possibilities for in vitro expansion of T cells for
functional study. Successfully shown to be effective in tumor control in murine model,
the use of IL-2 was then quickly applied into cancer therapy (19). High dose IL-2 was
given intravenously at 600,000 to 720,000 IU/kg every eight hours for two cycles; first
and second cycle began on D1 to D5 and D15 to D19 respectively. Clinical response
was evaluated within a month following the second cycle of treatment. It has been
demonstrated that IL-2 treatments in melanoma patients with advanced stages achieved
approximately 20% clinical response, and intriguingly 5 to 7% had a durable complete
response (86). The success of high dose IL-2 therapy in metastatic melanoma and renal
cell carcinoma has eventually led FDA approval in 1998. Currently, the use of high
dose IL-2 treatment becomes a conventional therapy used concurrently with other types
of immunotherapy such as T cell therapy and cancer vaccination. Patients administered
IL-2 require an intensive monitoring due to its toxicity, including febrile, hypotension,
and capillary leak syndrome (87). Although major toxicities of IL-2 can be harmful,
this effect is completely reversible following the completion of treatment. With proper
management, IL-2 can be safely used either as a single treatment or in conjunction with
other immunotherapies.
IL-7
IL-7 is known as a cytokine promoting the growth of hematopoietic cells. It is majorly
produced by epithelial cells in thymus and stromal cells in bone marrow, but not
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lymphocytes. Its receptor contains a gamma subunit commonly shared with IL-2. IL7 plays a critical role in promoting differentiation of hematopoietic stem cells into
lymphoid lineage cells (88). It has been also shown that IL-7 enhanced cell survival
and proliferation of B cells and NK cells (89, 90). In T cells, IL-7 is critical for early
development of thymocytes during double-negative stage (91). Together with stem cell
factor (SCF), IL-7 promotes proliferation of TN precursors and provides survival
signals through regulation of bcl-2 family members (92). It is known that IL-7 also
enhances T cell activation, particularly in suboptimal conditions. IL-7 preferentially
stimulates a type I immune response resulting in an increased IFN-γ and IL-2. A recent
report also indicated that IL-7 directly boosts the cytolytic capacity of CTL as well as
NK cells, NKT cells, and γδ T cells (93). Functional studies of IL-7 are still limited to
in vitro settings and preclinical murine models. Two clinical trials are currently
underway regarding the role of IL-7 in cancer immunotherapy. Early results have
shown the promise of IL-7 in enhancing T recovery following chemotherapy treatment
with minimal toxicity (94-96).
IL-15
IL-15 is a unique cytokine that is secreted in a complex form of IL-15 and IL-15
receptor alpha (IL-15Rα) (97). Monocytes are a major source for IL-15 production (98).
Upon activation with the IFN or engagement of the CD40 ligand, dendritic cells can
upregulate IL-15 and IL-15Rα expression, and to trans-present to CD8+ memory T cells
or NK cells expressing IL2/IL-15 receptor beta (IL-15Rβ) (99). Similar to other
cytokines in the gamma receptor family, IL-15 stimulates proliferation of T cells and
NK cells, and also enhances immunoglobulin production in activated B cells.
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Downstream signal of IL-15 through the JAK/STAT pathway can promote
phosphorylation of Src family proteins and the PI3K/Akt pathway (100). This results
in an increased Bcl-2 and Bcl-xL proteins, which help protect memory CD8 T cells
against apoptosis from activation-induced cell death mechanism (AICD) (101).
IL-21
IL-21 is a type I cytokine predominately produced by NKT cells, T follicular helper
cells (Tfh), and Th17 cells (102). Unlike other cytokines in the type I receptor
superfamily, IL-21 mainly activates STAT1 and STAT3 instead of STAT5 (103). IL21 has a pleotropic effect as its receptor is expressed by a broad range of several
immune cells, including lymphoid lineage as well as myeloid cells. In B cells, IL-21
can enhance immunoglobulin G production by promoting class switching (104). IL-21
can also promote both NK cells and T cell proliferation and cytotoxic function without
causing AICD, but suppresses FOXP3 expression in Treg cells (105). It has been
evident that IL-21 promoted cytotoxic function of NK cells through antibodydependent cell cytotoxicity (ADCC), and effector function of T cells by enhancing
granzyme and IFN-γ production (106). In our observation, IL-21 at low dose tends to
preferentially promote CD8+TIL expansion, while attenuation of TIL proliferation has
been observed with those expanded with IL-21 at high doses. Interestingly, recent
findings showed that IL-27 can stimulate CD8+ T cells to secrete IL-21, which act as
an autocrine regulator (107). In murine models, IL-21 has been shown to suppress the
growth of melanoma and fibrosarcoma by enhancing the function of NK and CD8+T
cells. Because IL-21 effectively promotes the function of CTL and NK cells, the use of
IL-21 become attractive for an application in cancer treatment as either single therapy
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or combination with other treatments. Systemic administration of IL-21 is likely to
benefit tumor regression by enhancing the function of CD8+ and NK cells without
vascular leakage, which provide an advantage over high dose IL-2 therapy. However,
an adverse effect in enhancing pro-inflammation cytokine such as IL-6 and IL-17 might
raise some concerns in clinical use. An alternative approach is adoptive transfer of
autologous dendritic cells transfected with IL-21 transcript. Transferred dendritic cells
can provide IL-21 locally to TIL in tumor microenvironments with minimal unwanted
side effects (108). Another approach is to use IL-21 for ex-vivo expansion of TIL for
Adoptive T cell therapy (ACT). Analysis of the immunophenotype of TIL expanded
with IL-21 revealed a less differentiated phenotype (CD27hi and CD28hi) with
increased cytotoxic capacity. Because poorly differentiated TIL is associated with
persistence following TIL transfer, the expansion TIL with IL-21 could be a potential
approach to improve TIL quality and clinical response (109).

1.2 Cell based therapy for malignant diseases
1.2 a) NK cell therapy
Natural killer cells (NK) are innate immune cells derived from lymphoid progenitor
cells in the bone marrow. As they are derived from a lymphoid lineage, NK cells can
be defined as CD45+CD3-CD56+ cells. The expression level of CD56 can further
classify NK cells into to two subsets; CD56brightCD16- and CD56dimCD16+.
Peripheral blood is highly enriched for the CD56dimCD16+ subset, while
CD56brightCD16- subset primarily resides in the lymph nodes and tonsils. Unlike T
cells, NK cells recognize transformed cells such as virus-infected cells, stressed cells,
and tumor cells in non-MHC-restricted settings. The mechanism of NK-mediated target
cell killing relies on the balance between activating signals and inhibitory signals from
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cell surface receptors (110). The activating receptor, such as NKG2D, NKp30, and
DNAM-1, can trigger signals by phosphorylating the immunoreceptor tyrosine-based
activating motif (ITAM) in the cytoplasmic domain. This results in recruitment of Syk
and ZAP70, leading to degranulation of perforin and granzymes as well as cytotoxic
cytokines such as IFN-γ and TNF-α. On the other hand, inhibitory receptors, such as
Ly49C, KIR2DL1, and KLRG1, attenuate signals through immunoreceptor tyrosinebased inhibitory molecules (ITIMs), resulting in sequestration of phosphatase SHP1 or
2 and dephosphorylation of phosphoproteins in activating pathways. Under normal
physiological condition, the cytotoxic activity of NK cells is suppressed by engagement
of NK cell inhibitory receptors and MHC expressed by normal cells. Down-regulation
of MHC expression in tumor cells and can relieve the suppressive function of the
inhibitory receptor, which allows NK cells to become activated and destroy target cells.
Moreover, up-regulation of danger signals by tumor cells can enhance the cytolytic
capacity of NK through engagement of activating receptors (111). Under the selective
pressure in tumor microenvironments, tumor cells tend to escape T cell recognition by
down-regulation of MHC class I. This mechanism somehow aids NK cells to become
more activated and attack tumor cells better. On the basis of its anti-tumor activity,
several strategies have been developed to use adoptive transfer of NK cells for cancer
treatment (112).
NK cells can be generated from different sources such as peripheral blood, bone
marrow, umbilical cord blood, and stem cells. The combination of IL-15 and
hydrocortisone to propagate NK cells has become general practice guideline for ex vivo
NK cell expansion. Although autologous NK can be successfully expanded for clinical
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treatment, these expanded cells do not develop full cytolytic function following
adoptive transfer, resulting in an unfavorable clinical outcome (113). It has been
suggested that some tumor cells still maintain MHC class I expression, which is
effective enough to suppress cytotoxic function of NK cells. Thus, another strategy is
the use of allogenic NK cells with KIR mismatch which could circumvent the
suppressive effect of MHC I and allow activating receptors to exhibit positive signals
mediating tumor killing. It has been demonstrated that the KIR haplotype of the donor
is associated with a survival benefit. Patients who received donor KIR haplotype group
B have been shown to have improved overall survival as compared to those who
received the KIRT haplotype group, mainly due to the high enrichment for activating
receptors in the KIRT haplotype. Nevertheless, allogenic NK cells are eventually
eliminated by the host immune system due to MHC mismatch (114). Currently, early
clinical trials in adoptive NK cell therapy are under way in several countries, including
the United States, Korea, France, Spain, and Singapore. The efficacy of NK cell therapy
is evaluated mainly in hematological malignancies including leukemia, lymphoma, and
multiple myelomas. A clinical trial conducted at Masonic Cancer Center in acute
myeloid leukemia (AML) demonstrated that 26% of patients receiving haploidentical
NK cells exhibited durable clinical outcomes. Recent studies have also demonstrated
NK cell therapy in some solid tumors such as non-small cell carcinoma, hepatocellular
carcinoma, and neuroblastoma. The clinical outcome of trials conducted in multiple
institutions are promising for NK cells therapy (115). A more in-depth understanding
of the signaling that regulates cytotoxic function is warranted for further improvements
in NK cell therapy.
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1.2 b) T cell therapy
Discovery of the TCR in early 1980 has driven a leap in understanding T cell
biology in the context of antigen recognition through MHC. This knowledge does not
only foster basic immunology research, but also extends a great benefit for cancer
immunotherapy. Based on the fact that T cells can recognize and destroy tumor cells,
this notion has attracted scientists and physicians to utilize T cells for cancer treatment.
Adoptive T cell therapy can be categorized on the basis of the source of T cells
and type of gene modification approach used. T cells used for therapy can be derived
from different sources, including the Tumor infiltrating lymphocytes (TIL), sorted
antigen-specific T cells from peripheral blood, and normal peripheral blood
mononuclear cells (PBMC). T cells can also be genetically modified to overexpress
either chimeric antigen receptors or T cell receptors specific for tumor antigens by
using bioengineering methods.
TIL therapy (ACT)
History of ACT
In late 1987, a progress study on adoptive transfer of lymphokine-activated
killer (LAK) cells with IL-2 was first investigated in 157 patients with metastatic
melanoma. A combination of LAK and IL-2 was found to have advantages over IL-2
alone due to the durable complete responses (22). The limited efficacy of LAK has
suggested the used of TIL, which are already present in tumor bed and more enriched
for tumor-reactivity (116).
Several efforts were made to conduct adoptive transfer T cells for cancer
therapy in murine models. One of the most successful murine models was established
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in Dr. Alex Fefer’s lab in Fred Hutchinson Cancer Research Center. Adoptive transfer
of T cells from immunized mice with the Friend virus-induced leukemia, FBL-3 was
shown to be effective following intravenous administration in both local tumors and
disseminated metastasis (117). Although the concept of using adoptive transfer of
tumor-specific T cells to destroy cancer was proved, incapability of expanding antigenspecific T cells against spontaneously growing human cancers was a major hindrance.
The approach of using adoptive transfer of TIL as an immunotherapy of cancer was
proposed shortly after the success of using syngeneic TIL plus IL-2 therapy in murine
model to eradicate established hepatic metastasis (118).
The observation that specific tumor-reactive T cells can be grown from resected
metastatic melanoma tumor with IL-2 was a critical step to support further investigation
of large scale TIL expansion for therapeutic use. TIL expansion protocol initially used
only IL-2 to grow TIL from digested tumor fragments. The fold expansion ranged from
3 to 9 X 108-fold over 14 to 100 days (119). Shortly after, a pilot study using a
combination of IL-2 and TILs was first reported from the Surgery Branch at the NCI
(120). This report was considered as a huge leap for cancer immunotherapy and the
beginning of the era of TIL ACT.
Current TIL ACT therapy
ACT is an effective immunotherapy for cancer using autologous tumorinfiltrating lymphocytes (TIL) isolated from cancer patients. TIL can be generated from
either small pieces of resected tumor fragments (approximately more than 1 cm) or
tumor digestion followed by density gradient centrifugation. TILs are initially grown
in 24-well plates with high dose IL-2 (6,000 IU/ml) for approximately three to five
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weeks. The cells are then further propagated with a rapid expansion protocol (REP)
using irradiated peripheral blood mononuclear feeder cells as feeders, anti-CD3, and
high dose IL-2, for 14 days (Figure 1.2) (121). Recent studies have shown that
genetically modified artificial antigen-presenting cells derived from K562 cells
overexpressing CD19, CD64, CD86, and CD137L could be substituted for the feeder
cells without perturbing REP fold expansion (122).
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Figure 1.2. Schematic diagram of the TIL expansion (Pre-expansion and Rapid
expansion) and TIL therapy.
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Based on the studies in animal models, lymphodepletion in combination with
ACT was shown to be critical for an effectiveness of transferred TIL. This helps
eliminate the Treg cells and myeloid-derived suppressive cells (MDSCs) and preparing
space for transferred cells (123). Currently, lymphodepletion prior to ACT has become
a conventional practice widely used in multiple institutions including the Surgery
Branch at NCI, M.D. Anderson Cancer Center, Moffit Cancer Center, and Sheba
Medical Center in Israel. In non-myeloablative regimens (NMA), patients with
metastatic disease undergo lymphodepletion with cyclophasphamide (30 or 60 mg/kg
per day) and fludarabine (25 mg/m2 per day) for two and five days, respectively, prior
to TIL transfer. High dose IL-2 (720,000 IU/kg) is administered starting one day after
TIL infusion every 8 hours to tolerance (124). In myeloablative regimens, patients are
given total body irradiation (TBI) in combination with cyclophosphamide and
fludarabine followed by CD34+ hematopoietic stem cell transfer (125).
TIL: tumor recognition in melanoma tumor cells
Identification of tumor-specific cytolysis in human melanoma TIL was evident
based on the existence of tumor-specific antigens recognized by T cells. The expression
of T cell co-stimulatory molecules such as 4-1BB, ICOS and OX40, as well as coinhibitory molecules like PD-1, is triggered upon antigen stimulation and therefore is a
marker of activation. The observation that TIL contain subpopulations of recently
activated T cells (CD8+4-1BB+), and are enriched for chronically activated T cells
(CD8+PD-1+) as compared to the blood suggests that a high fraction of TIL are
recognizing tumor antigens. In addition, secretion of cytotoxic cytokines such as IFN-
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γ, TNF-α, and/or GM-CSF upon stimulation with autologous tumors also indicates
tumor recognition by TIL (126).
Most tumor-associated antigenic peptides identified are restricted by commonly
shared HLA subtypes such as HLA-A1, -A2, -A24, -A31, -B8, and –Cw. However,
HLA-2 is the most intensively studied due to high prevalence in Caucasian populations
(approximate 45%) (127). It has been shown that TIL clones from HLA-A2+ patients
were able to lyse HLA-A2+ melanoma cell lines derived from different patients, but did
not lyse non-melanoma cells lines and other types of cancers. This suggested that
melanoma tumor-associated antigen peptides in melanoma cells are commonly shared
among patients in a HLA-A2 restricted fashion. In addition, overexpression of HLAA2 in HLA-A2 negative melanoma cell lines enables HLA-A2+ TIL to mediate tumor
cytolysis (128). Melanoma associated antigen 1 (MAGE) was identified as the first
melanoma antigen recognized by HLA-A1 restricted melanoma TIL. Although
MAGE-1 is also expressed by non HLA-A1 melanoma tumors, HLA-A2 specific CTL
has never been reported. In addition, HLA-A2 antigen specific TIL were found not to
lyse HLA-A2+ fibroblast cell lines overexpressing the MAGE-1 gene. Several HLAA2-restricted melanoma cytotoxic T lymphocytes derived from TIL recognizing other
tumor antigens were also identified, including MART-1, gp100, and tyrosinase.
Although most tumor antigen-specific CTLs were described in the HLA-2 restricted
subtype, the MAGE-3 antigen expressed by melanoma and other types of cancers such
as breast cancer, colon cancer, and lung cancer, was also recognized by the HLA-1
restricted CTLs (129).
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Effectiveness of ACT in melanoma and other cancers
ACT is one of the most effective treatments in metastatic melanoma in inducing
durable clinical responses as compared with other types of immunotherapy. The first
preliminary report in 1988 of adoptive transfer of TIL was conducted in 12 patients
with metastatic melanoma at the Surgery Branch, NCI. Objective tumor regressions
occurred in 60% (9/15) of patients who had never been treated with IL-2 and 40% (2/5)
of patients who were refractory to IL-2 therapy (130). In another trial in 2002 at the
NCI, it was shown that 13 HLA-A2+ metastatic melanomas treated with TIL ACT had
40% (6/13) objective clinical response to treatment. Rapid clonal repopulation of
MART-1 reactive T cells was observed in two patients, resulting in the off-target
destruction of normal cells expressing the MART-1 antigen (131). Several studies both
in murine models and humans suggested that lymphodepletion is a critical factor for
the positive clinical outcome of ACT (124). The NMA regimen using
cyclophosphamide and fludarabine treatment prior to adoptive transfer was included in
the standardized ACT protocol (132). In a recent study, myeloabalation using total
body irradiation (TBI) concurrently with ACT has been investigated in 93 patients at
the Surgery Branch, NCI. The clinical trial was assigned to patients into three cohorts;
1) NMA regimen (n=45), 2) myleoablation with TBI 2 Gy (n=25) 3) myeloablation
with TBI12 Gy (n=25). Overall objective response rates in each cohorts were 49%
(21/49), 52% (13/25), and 72% (18/25) respectively. In the NMA cohort, the complete
response rate was around 10%, however in the TBI groups, over 20% of the patients
achieved a complete response 20% underwent a complete remission more than 3 years.
In a subsequent randomized study with more patients (101 patients; NMA (n=51) and
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NMA plus TBI (n=50), the addition of TBI to the regimen did not improve the
incidence of complete responses (133). Overall objective clinical response across
multiple institutions is relatively similar to NCI, including M.D. Anderson Cancer
Center (Houston, TX) (48%, 15/31 patients), Moffitt Cancer Center (Tampa, FL) (38%,
5/13), and Sheba Cancer Research Center, (Israel) (40%, 23/34) (121).
Functional role of TIL subsets in ACT: Tumor reactivity and persistence
Different T cell lineage in TIL
A high proportion of CD8+ TIL in infused TIL has been shown to associate with clinical
response in melanoma TIL-treated patients (134). It is known that CD8+ T cells have a
predominant role in the cell-mediated cytotoxic capability to induce cell death in
pathogen-infected cells and transformed cells. The superior advantage of T cells over
innate immune cells, which also mediate cell death, such as NK cells, is due to their
specificity, adaptability, and durability. These properties allow CD8+ TIL to recognize
both tumor specific antigens and mutated peptides and provide long lasting immune
response. The mechanism used by CD8+ TIL to mediate tumor killing in has been well
characterized. Following TCR recognition of peptide presented by tumor cells, both
perforin (a membrane disrupting protein) and granzymes (serine proteases) secreted
from effector TIL can cooperatively activate caspase-3 mediating tumor cell death
(135). Occasionally, we have observed that TIL-treated patients somehow respond to
the therapy even though the proportion of CD4+TIL is relatively high. CD4+T cells are
generally not considered as key players in cell-mediated cell death, but coordinately
facilitate CD8+ function by providing cytokines such as IL-2, TNF-α, and IFN-γ that
are critical for proliferation and effector functions of CD8+TIL. On the other hand, Treg
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can also suppress the anti-tumor function of CD8+ by secreting immunosuppressive
cytokines such as IL-10 and TGF-β (135).
We have occasionally observed outgrowth of γδ TIL during initial expansion, but the
dominant outgrowth of this subset following REP is rarely observed. Zoledronate was
reported to facilitate expansion of γδ TIL. A Phase I ACT clinical trial in several cancer
patients with metastasis using γδ TIL expanded with zoledronate has shown no clinical
response even though the migration of transferred T cells into the tumor bed was
observed due to high expression of chemokine receptors such as CXCR3, CXCR5,
CCR5, and CCR7 (136). This suggests that these cells were capable of trafficking into
the tumor site, but might not be able to recognize tumor cells or might lack the effector
function.
T cell differentiation and T cell persistence following adoptive transfer.
Although the CD8+ TIL subset is pivotal for tumor-mediated regression, only a subset
of TIL-treated patients with a high number of CD8+ achieved a complete remission. It
remains inconclusive as to what exact CD8+TIL subset(s) is/are responsible for the
clinical response. After encountering tumor antigens presented by APC, naïve T cells
undergo clonal expansion and further differentiate into effector T cells (TEF), followed
by the development of effector memory T cells (TEM) and central memory T cells
(TCM) for long-term recall response. Effector T cells will then undergo further
differentiation and become terminally differentiated and eventually undergo clonal
deletion. It has been controversial whether memory development involves a transition
to effector phase prior to memory commitment or if memory cells are exclusively
arising from pluripotent effector cells (137). It remains unclear what signals control the
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decision fate in memory development, but recent studies suggest that the strength of
antigen stimulation and cytokines might be critically involved (138). In human CD8+
T cells, the combination of CD45RA and CCR7 markers is most commonly used to
distinguish different
(CD45RA+CCR7+),

memory T cells into the following subsets: naïve
effector

memory

(TEM)

(CD45RA-CCR7-),

terminally

differentiated (TEMRA) (CD45RA+CCR7-), and central memory (TCM) (CD45RACCR7+) (139). In addition, the combination of co-stimulation molecules such as CD28
and CD27 is also used to further characterize the differentiation status of CD8 into three
stages; undifferentiated (CD28+CD27+), intermediate differentiated (CD28-CD27+),
terminally differentiated (CD28-CD27-) (140). Recently, we and others demonstrated
that B and T lymphocyte attenuator, a co-inhibitory molecule, also serve a T cell
differentiation marker, where high expression of BTLA is observed in less
differentiated T cell (141, 142). Persistence of infused TIL in the peripheral blood one
month following adoptive transfer has shown to be associated with clinical response
(134, 143). A recent study unveiled the phenotype of a memory T cell subset with stem
cell-like properties (TSM) which exhibited a least differentiated phenotype with
enhanced proliferative capacity (144). Adoptive transfer of this T cell subset showed
improved memory T cell survival and superior anti-tumor immunity. A report from the
NCI indicated that the CD28+CD27+ TIL subset had longer telomeres with enhanced
persistence in circulation after adoptive transfer (140). In line with this observation, we
found that a high proportion of CD8+BTLA+ (less differentiated CD8+ TIL phenotype)
in infusion product positively correlate with improved clinical response of TIL ACT
treated patients (134).
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Chimeric antigen receptor T cell therapy (CAR)
TIL from several tumors have been shown to recognize and destroy the
autologous tumor cells, but very few tumor-reactive T cells recognizing more broadly
antigens have been identified. Most tumor antigens appear to be unique to the patients.
This limitation strongly hampers the selection and enrichment of tumor-specific T cells
for adoptive T cell therapy. Several shared cell surface tumor-associated antigens in
several types of cancer have been more extensively identified. This type of antigen can
be targeted by an antibody. One approach to improve recognition of these antigens is
to couple the high affinity recognition of an antibody to the killing machinery of a T
cell by engineering an artificial T cell receptor on a T cell made up of an antibody
linked to the intracellular domains of the TCR and its co-stimulation molecules.
Therefore, the use of genetic engineering method to overexpress chimeric antigen
receptor (CAR) on T cells can be used to improve tumor specific antigen recognition
and enhance tumor killing (145).
Chimeric antigen receptors (CAR) contain two major parts; 1) an extracellular
binding region of target proteins and 2) an intracellular signaling domain. The
extracellular part contains a single chain variable fragment (scFv), variable regions of
light chain and heavy chain of immunoglubin. scFV is designed to interact with the
potential tumor antigen targets expressed by tumor cells. The intracellular signaling
domain consists of a CD3 ξ chain, which exhibit the downstream signal mimicking
TCR activation signals during the engagement of the extracellular part and the potential
target. In the second and third-generation of CAR, its intracellular domain has been
further modified with additional of signaling domains of CD28 and co-stimulatory
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molecules such as OX-40 (CD134) and 4-1BB (CD137). Second-generation CAR has
been found to be more effective than the first-generation because co-stimulatory signal
can enhance cell survival and prevent T cell exhaustion. Generation of CAR T cells is
far more complicated than TIL therapy, as T cells are required to undergo genetic
modification prior T cell expansion. Several approaches are used to deliver modified
genes including viral transduction, sleeping beauty, and CRISPR/Cas9 gene editing.
Once modified genes are inserted, T cells then undergo propagation with artificial
antigen-presenting cells (aAPC), which can provide a proper co-stimulatory signal,
prior to adoptive transfer into the patients (145, 146).
CAR T cell therapy has been widely used in hematological malignancies,
including B cell malignancy, T cell malignancy, and myeloma. The durable clinical
outcome in B cell malignancy patients treated with anti-CD19 CAR T cell therapy has
demonstrated a promising model for other types of cancer. A number of targets of CAR
T cell therapy for acute myeloid leukemia (AML) that are currently under investigation
in an early phase clinical trials include CD33 (myeloid specific lectin), CD123 (IL-3
receptor alpha chain), CD44v6 (adhesion molecule expressed by some subset of AML
and multiple myeloma) (147-149). Clinical trials of CAR T therapy also are currently
expanding into solid tumors, including glioblastoma multiforme, mesothelioma,
ovarian cancer, and pancreatic cancer (145). Selection of targets can be very
challenging, as solid tumors are much more heterogenous as opposed to hematological
cancers. Because of a few instances of treatment-related fatal toxicity, such as in colon
cancer patients treated by anti-HER-2/neu CAR T cell therapy, off-target toxicity from
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targeting antigens commonly present in normal tissue is also a major safety concern for
CAR therapy (150).
Endogenous T cell therapy
Detection of tumor-reactive T cells in the peripheral blood of cancer patients has
provided a rationale for attempting their selection and expansion for adoptive T cell
therapy. Tumor-reactive T cells in circulation are present at a very low frequency (less
than 0.5%), which presents a challenge (151). If the tumor antigen is known, the T cells
can be stained with fluorescence conjugated peptide-MHC tetramer and sorted by flow
cytometry. A current strategy used to amplify circulating antigen-specific T cells is to
stimulate PBMCs with APCs or insect cells expressing MHC class II pulsed with the
peptide of interest. This helps expand and enrich tumor-reactive T cells prior to further
selection processes by cell sorting, cloning, or performing immuonmagnetic selection
(152).. If amplification of unselected tumor-reactive T cells is desired, hundreds of T
cell clones can be screened for tumor reactivity and immunomagnetic selection
methods can be performed to capture cytokine-secreting cells using dual-specific
antibodies that can bind both CD45+ (lymphocyte marker) and IFN-γ (151). The
enrichment and selection method can increase the number of cells to 1 to 5 millions of
CD8+ T cells with the frequency greater than 80% of tumor-reactive T cells. The final
expansion with high dose IL-2, anti-CD3, and feeders can rapidly increase the number
of tumor-specific T cells to a billion cells with 90% specificity within two weeks.
Unlike TIL adoptive transfer, patients are treated with low dose IL-2 without or
minimal lymphodepletion, thus endogenous T cell therapy confer less adverse effects
(153).
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There have been several attempts to improve T cell quality with enhanced in
vivo persistence. It is known that persistence of T cells following transfer is critical for
positive clinical outcomes in adoptive T cell therapy. It has been shown that
lymphodepletion with fludarabine alone or high dose cyoclophosphamide alone could
improve engraftment and persistence of transferred T cells (133). Another report has
indicated that central memory (TCM)-derived CTLs were the only phenotypes that
exhibited in vivo long-term persistence (154). Consistently, a murine model also
demonstrated that Tcm-derived CTLs were much more effective for tumor control due
to superior replicative capacity when compared with effector and effector memory
subset (144). In a recent study in human, CD8+MART+T cells expanded with IL-21 upregulated CD28 and IL-7R and maintained the expression for several weeks following
adoptive transfer. In addition, cancer patients treated with endogenous T cells expanded
with IL-21 exhibited better tumor control and some of those underwent a complete
durable response (155).
A major challenge of endogenous T cell therapy is to develop a novel approach
to identify, select, and enrich tumor antigen-specific T cells that are of very low
frequency in circulation. T cells recognizing well characterized shared tumor antigens
such as MART-1, gp100, NY-ESO can be selected for treatment. However, tumors
may not uniformly express those antigens and therefore the development of alternative
methods such as cloning and immunomagnetic selection to enrich tumor-reactive T
cells will be warranted. Moreover the transfer of T cells specific for one antigen may
initiate an immunoselective pressure which allows immune escape through antigen loss
and the development of resistance.
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1.3 Biomarker of immune cell: Immunoscore
The TNM (Tumor Node Metastasis) system, a standard criteria to evaluate the
degree of tumor spread, has been widely used in cancer centers all over the world. This
classification system aids physicians in planning treatment, making prognoses, and
evaluating effectiveness of therapy. Disease progression used in TNM solely relies on
the spreading of the tumor itself and does not include other factors in the tumor
microenvironment. In recent years, it has become clear that the immune system plays
a critical role in tumor control and progression (156). Thus, immune cells should also
be included in evaluation of tumor progression criteria. Recently, Jerome Galon, a
scientist at INSERM laboratory in France, has proposed a novel method to incorporate
immune cells into the clinical assessment of cancer patients (157).
The concept of “immunoscore” has emerged from a meta-analysis of more than
120 independent studies on the impact of immune cells in tumor microenvironments.
It has been demonstrated that the presence of CTL, memory T cells, and the CD4 Th1
subset in all types of cancers is associated with extended survival time. On the basis of
these analyses, the quantification of three surface markers on T cells including CD3,
CD8, and CD45RO in combination with location in the tumor bed, the core of the tumor
(CT) and the invasive margin (IM) are used to tabulate the immunoscore. The score is
graded on the density of immune cells diffused in both the core tumor and the invasive
margin from “no” or lowest (Immunscore 0, I0) to the highest (Immunoscore 4, I4)
(157). A recent report from two independent cohort studies has demonstrated the ability
to predict the recurrence of colorectal cancer in patients who had no detectable
metastasis in either lymph nodes or distant organs. It appeared that patients with a high
immune score (I4) exhibited a low chance of tumor recurrence (less than 5%), while
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patients with a low immune score (I1) were very likely to develop recurrence
(approximately 72%) (158). Based on the fact that Immunoscore is the only system that
helps predict disease recurrence, the critical role of the immune system in the tumor
microenvironment becomes very clear.
Immunoscore is a task force established in collaboration with multiple
institutions worldwide. The method standardization of immunohistochemistry and
analysis software is currently being validated to ensure the accuracy and reproducibility
across laboratories. Immunohistochemistry of immune markers is already routinely
performed in the diagnostic pathology laboratory, it is possible that immunoscore will
become a part of a conventional system for cancer treatment in the near future. Together
with the TNM system, immunoscore can enhance the ability to evaluate disease
progression, prognosis, as well as aid in developing a decisive plan for immunotherapy.
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1.4 Co-signaling molecules on T cells
Co-signaling molecules on T cells
Engagement of TCR by peptide-MHC class I or II complexes determines the strength
of TCR activation. Without additional co-signaling, T cells become unresponsive and
undergo clonal deletion eventually. It is known that co-signaling molecules play a key
role in steering the outcome of TCR signaling by either enhancing or inhibiting the
downstream signals during TCR activation. This outcome is crucial for regulating the
fate of T cell differentiation, effector function, cell proliferation and survival (159).
1.4 a) Co-stimulatory molecules
A co-stimulatory molecule is a receptor expressed on T cells whose signaling provides
positive effect on T cell functions. On a structural basis, co-stimulatory molecules can
be classified into two major groups; the Tumor Necrosis Factor Receptor superfamily
(TNFRSF) and the Immunoglobulin super family (IgSF). TNFRSF requires a cluster
formation of at least two molecules for the full activation, while only one molecule of
IgSF is sufficient for the full function (159).
Tumor Necrosis Factor Receptor superfamily (TNFRSF)
TNFRSF family members consist of at least one subunit of extracellular cysteine-rich
domains (CRDs). Most TNFRSF members such as 4-1BB, CD40, OX40, and HVEM
exhibit signals through NF-kB and mitogen-activated protein kinases (MAPK)
pathways. However, some TNFRSF receptors contains dead domains (DD) such as Fas
and TRAIL and are able to promote apoptosis. TNFRSF members expressed by T cells
mostly synergize with T cell survival function rather than promote T cell apoptosis. A
number of TNFRSF have been extensively studied in T cell and other cell types. Here,
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only selected TNFRSFs that have potential in clinical application for cancer
immunotherapy will be discussed (160).
4-1BB
4-1BB is an inducible molecule, which is up-regulated within only a few hours
following T activation, and its expression declines within a few days. 4-1BB is
preferentially expressed by activated CD8+, NK cells, and dendritic cells. Although 41BB can be shed from the cell surface, the soluble form is not able to exert signals
when engaged with its ligand (161). It has been shown that the soluble form of 4-1BB
is highly associated with severity of patients with rheumatoid arthritis (162). In T cells,
4-1BB mediates signals through NF-kB and activating protein-1 (AP-1), which triggers
several downstream pathways including MEK, and JNK. 4-1BBL, identified as a
binding partner for 4-1BB, is mainly expressed by antigen-presenting cells including
dendritic cells, B cells, and macrophages. It has been demonstrated that the 4-1BB
pathway in T cells enhances T cell proliferation and cell survival and prevents AICD
(163). Although the 4-1BB pathway plays an important role in enhancing TCR
activation signals, the 4-1BB pathway might not be a substitute for CD28 for long term
protective tumor immunity. In murine lymphoma models, engagement of 4-1BB and
4-1BBL did not rescue the killing capacity of T cells against T cell lymphoma cell line
A20. When lacking CD28 signaling, cytotoxicity and survival of T cells were
significantly impaired, resulting in a decrease in cytokine production, particularly IL-2
(164). Thus far, 4-1BB is a key target for immunotherapy, with agonistic antibodies in
clinical development for systemic use and for in vitro selection of antigen specific T
cells. It has been shown that co-expression of PD-1 and 4-1BB serves as a marker for
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tumor-reactive T cells, thus developing selection methods to expand CD8+4-1BB+PD1+ becomes critical to enrich tumor antigen-specific T cells for T cell therapy (126). In
addition, agonistic anti 4-1BB antibody has also been used to expand T cells from
tumor fragments as well as REP as it provides a great benefit in selective expansion of
CD8+ subset expansion. TIL expanded with anti-4-1BB antibody also demonstrated
protective capacity against AICD (165).
CD40
CD40 is TNFRSF receptor expressed by antigen-presenting cells, particularly
in B cells and dendritic cells. CD40L expression, a ligand for CD40, is observed in
activated T cells as well as non-immune cells such as endothelial cells, and epithelial
cells. Interaction between CD40L and CD40 plays a critical role in the maturation of
dendritic cells and the development of plasma cells and memory B cells. Like other
TNFRSF members, engagement of CD40 and CD40L requires clustering of CD40
receptors for the recruitment of TNFR-associated factors (TRAF) into the cytoplasmic
domain, which leads to the activation of NF-kB, MAPK, PI3K, and PLCy pathways
(166). In addition, JAK3 was shown to interact with the CD40 cytoplasmic region
through the STAT5 pathway (167). CD40/CD40L engagement is known enhance both
humoral and cell-mediated immune response. It has been shown that activated T helper
cells promote B cell differentiation, antibody production, and memory development
through CD40 signaling pathway (168). In addition, disruption of CD40L and CD40
engagement was found to down-regulate expression of CD28 by dendritic cells, which
directly attenuated T cell priming due to insufficient co-stimulatory signal (169). The
CD40/CD40L pathway has been demonstrated to promote an optimal anti-tumor
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responses both in vitro and in murine models. A number of studies have demonstrated
that CD40 activation enhanced dendritic cell maturation and optimal priming, which is
critical for developing a long term anti-tumor response (170).
CD27
CD27 is mainly expressed by T cells, NK cells, and memory B cells. CD70
expression, known as a CD27 ligand in TNFSR, is constrained in only activated T or
B cells, and mature dendritic cells (171). Although CD27 is expressed at the baseline
level in naïve T cells, its expression is further up-regulated following T cell activation.
In addition, CD27 can be shed from the cell surface of activated T cells and
competitively prevent CD70 from binding the membrane-bound form of CD27. Upon
engagement with CD70, CD27 recruits TRAF 2 and 5 into the cytoplasmic domain,
which then activates the NF-kb and JNK pathways. CD27 plays an important role in
promoting T cell priming, clonal expansion following recent activation, and memory T
cell generation (172). CD27/CD70 interaction prevents T cells from apoptosis through
increasing anti-apoptosis protein expression, such as B cell lymphoma-extra large (BclxL) as well as suppressing FasL expression by CD4+T cells (173). In a murine model,
engagement of CD27 and CD70 could harness Treg expansion, thus could suppress
with the CTL function of CD8+ in the tumor microenvironment (174). Expression of
CD70 by antigen-presenting cells such as B cells and dendritic cells was found to
improve antitumor immunity against murine lymphoma (EL4) and murine melanoma
(B16) (175). Based on studies conducted in a non-human primate model, anti-CD27
(1F5) has shown no toxicity and caused a decrease in Treg subset. In humans, a fully
humanized agonistic anti-CD27 antibody (1F5) is currently under investigation in
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phase I clinical trials in several cancers including renal cell carcinoma, melanoma, and
B cell malignancies (176).
Immunoglobulin superfamily (IgSF)
CD28
CD28 is classified into the immunoglobulin superfamily and the CD28
subfamily. It contains a single extracellular immunoglobulin variable-like domain with
a short cytoplasmic domain. This structure is also observed in other CD28 subfamilies
including ICOS, CTLA-4, PD-1, VISTA, and BTLA. CD28 is abundantly expressed
by naïve CD4+ and CD8+ and down-regulated following T cell activation. Two
receptors in the B7 subfamily (CD80 and CD86) are identified as ligands of CD28.
CD80 and CD86 are mainly expressed by activated antigen-presenting cells, but also
observed in activated T cells as well (177). The CD28 cytoplasmic region consists of
YMNM and PYAP motifs. YMNM of CD28 was shown to interact with the SH2
domain of PI3K, Grb2, and the Grb2-related adaptor downstream of Src (GADS).
Recruitment of the p85 subunit of PI3K subsequently results in activation of protein
kinase B (PKB) and the Akt pathway. The PKB pathway is involved in a broad range
of downstream targets including mTOR, Glycogen synthase kinase 3 (GSK3), and antiapoptotic proteins (Bcl-XL and BAD). Moreover, interaction between PI3K with
adaptor proteins VAv and SLP-76 can also enhance gene transcription and stabilization
of IL-2 mRNA, which helps promote cell proliferation and survival. PYAP is known
to interact with LCK, Grb2, and GADS. It has been shown that PYAP plays a role in
cell proliferation and IL-2 production through the interaction of Vav and LCK (178).
CD28 is considered one of the most important signals required during T cell priming.
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Upon ligation with CD80/CD86, CD28 exhibits positive signals that enhance cell
proliferation, cytokine production (particularly IL-2 and IL-4), and protection from
activation-induced cell death (AICD) (179). In addition, CD28 also plays a critical role
in T cell differentiation and T-cell subset generation.
ICOS
ICOS is a co-stimulatory molecule in the CD28 subfamily. Its expression is upregulated following T cell actvation. ICOS expression is found in activated T cells
(particularly the CD4+subset), memory T cells, and activated NK cells, but not in naïve
T cells. ICOS-L, an ICOS ligand, is expressed by immune cells such as CD33+ cells in
bone marrow, B cells, dendritic cells, and T cells. Its expression was also found in nonimmune cells including epithelial cells, endothelial cells, and liver, kidney, and lung
cells. IFN-γ can induce ICOS-L expression in B cells and dendritic cells, while GMCSF/TNF-α enhance ICOS-L expression in CD33+ cells in bone marrow. The
cytoplasmic domain of ICOS contains the YMFM motif, which is also present in the
CD28 and CTLA-4 (180). Engagement of ICOS and ICOS-L was shown to recruit p50
alpha and p85 subunits of PI3K, which then activated PDK1, PKB, and GSK3 (181).
Although the downstream pathway of ICOS shares some similarity with CD28, lacking
Asn residue in the YMFM motif disables ICOS to activate JNK pathway and IL-2
production through interaction with the Grb2 adaptor protein. Moreover, the TCRinduced transcriptional profile of ligation of CD28 and ICOS receptors demonstrated
that CD28 induced gene expression much more than ICOS. However, some genes were
selectively induced by ICOS, but not CD28, such as unconventional myosin (MYL1)
and T-lymphocyte maturation-associated protein (MAL), suggesting that the
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downstream pathway of ICOS is somehow distinct from CD28 even though overlap in
signaling pathways has been demonstrated (180).
1.4 b) Co-inhibitory molecules
Co-inhibitory molecule is considered as a checkpoint to negatively regulate T cell
function including cell proliferation, cytokine production, and effector function.
Because phosphorylation of downstream T cell signaling proteins is critical for T cell
activation, the commonly shared suppressive mechanism by co-inhibitory molecules
mainly through dephosphorylation by phosphatase. Unlike co-stimulatory molecules,
the all co-inhibitory molecule belong to Immunoglobulin superfamily, consisting of an
immunoglobulin variable (IgV)-like domain and immunoglobulin constant (IgC)-like
domain in the extracellular region (182).
PD-1
PD-1 is an inhibitory molecule in the CD 28 subfamily of the Ig superfamily.
PD-1 is up-regulated upon T cell activation. Its expression is also found in activated B
cells, activated natural killer cells, and TIL from different cancers. PD-L1 and PD-L2
are known as ligands for PD-1. PD-L1 is expressed in broad range of cell types
including T and B cells, macrophages, dendritic cells, and tumor cells (60). PD-L1 is
constitutively expressed by tumor cells and IFN-γ was found to enhance PD-L1
expression (183). Up-regulation of PD-L1 expression in tumor cells is thought to be a
protective mechanism from T cell killing. Basal expression level of PD-L2 is restricted
in dendritic cells and macrophages at low level (64).
Two cytoplasmic motifs of PD-1, ITIM and ITSM, were shown to suppress T
cell function. Upon PD-1/PD-L1 ligation, SHP1/2 are recruited into ITIM and ITSM
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motifs and attenuate proximal TCR activation. This inhibits T cell proliferation,
cytotoxic function and cell survival (55). Downstream targets of PD-1 pathway are
partially known. It has been demonstrated that the recruitment of SHP2 inhibited
PI3K/AKT3, Ras, and MEK-ERK pathways (56). PD-1 pathway is known to exhibit
an inhibitory function in CD8+ antigen-specific T cells, but instead enhances the
generation of Treg cells. PD-1 expression is up-regulated following antigen exposure
and down-regulated when stimuli no longer exists. Under chronic stimulation such as
in cancer or latent infection, PD-1 expression can be maintained and affect the effector
function of T cell. This condition is defined as “T cell exhaustion” (58). In tumor
microenvironments, high PD-L1 expression by tumor cells and myeloid cells can
suppress the effector function of T cells and prevent tumor killing. A novel strategy to
block PD-1/PD-L1 engagement is the use of blocking anti-PD-1 antibodies. This
approach led to improved tumor burden control and survival in several murine tumor
models as well as multiple cancer types including melanoma, non-small cell lung
carcinoma, and renal cell carcinoma. At present, anti-PD-1 agents have been FDA
approved for the treatment of melanoma and lung cancer and more clinical trials are
under investigation in multiple institutions to gain a better understanding about
mechanisms involved in blockade of the PD-1 pathway and clinical response (62).
CTLA-4
CTLA-4 is known as a member of the Ig superfamily. CTLA-4 is highly
expressed in T cells following activation, similar to PD-1. Constitutive expression of
CTLA-4 was also reported in T regulatory cells. Interestingly, intracellular CTLA-4 is
highly abundant in memory T cells and can translocate to the cell surface membrane
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during T cell activation (184). CTLA-4 gene transcription is controlled by nuclear
factor of activated T cells (NFAT). Down-regulation of CTLA-4 expression is
enhanced when NFAT is inactivated by cylclosporine A. CTLA-4 shares amino acid
sequence similarity with CD28, and also interact with CD28 ligands, CD80 and 86
(44). Initially, it was thought that CTLA-4 was a co-stimulatory molecule, as the
YVKM motif has been demonstrated to interact with PI3K. Later, it was found that this
motif can also interact with SHP2, which can recruit phosphatase and attenuate TCR
activation (47). In addition, CTLA-4 was shown to inhibit lipid raft formation and
prevent microcluster of Zap70 during T cell activation. Moreover, CTLA-4 was shown
to attenuate CD28 signal by competitive binding to CD80 and 86, which prevent T cell
from full activation during priming (45). In murine models, CTLA-4 deficient mice
developed severe myocarditis, pancreatitis, and lymphadenopathy with massive
infiltration of activated T cells with high expression of CD69 and CD44. In addition,
CTLA-/- T cells exhibited high proliferative capacity upon activation and were also
susceptible to FasL mediated apoptosis. Altogether, these finding support the inhibitory
effect of CTLA-4 (28).
CTLA-4 plays a critical role during T cell priming, which is critical for memory
T cell generation. Thus, CTLA-4 blockade can be used to enhance the memory T cell
pool generation under immunosuppressive environment in tumor bed. Several
preclinical models have shown effectiveness in tumor control in both solid and
hematological malignancies. The use of anti-CTLA-4 as a single agent in the clinic was
very successful with the significant improvement in overall survival seen in melanoma
patients leading to FDA approval in 2011 (185).
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1.5 B and T lymphocyte attenuator (BTLA)
1.5 a) Discovery of BTLA and its ligand
B and T lymphocyte attenuator (BTLA) was first identified from the microarray
analysis of T helper type 1 cells treated with IL-12 and IL-18 (186). BTLA transcripts
were highly abundant in lymphoid organs such as the spleen and lymph node, but not
in somatic tissues. BTLA is considered as the third co-inhibitory receptor found
following the discovery of CTLA-4 and PD-1, respectively. BTLA belongs to the
immunoglobulin superfamily as well as CD-28, ICOS, PD-1, and CTLA-4. The first
report on the discovery of BTLA demonstrated that an orphan B7 (B7X) was a natural
ligand for BTLA due to specific interaction between B7X-Ig fusion protein and with T
cells overexpressing BTLA (186). Later, Sedy et al. found no direct interaction between
NIHT3 cells overexpressing B7X and Fc fusion proteins of BTLA. A functional
cloning strategy was used to indicate the actual ligand of BTLA. Cells transduced with
retroviral cDNA libraries generated from mouse splenocytes were screened with
tetramers of the extracellular domain of BTLA. Plasmon resonance imaging assay was
used to confirm the direct interaction at the molecular level (187). From these results,
HVEM (Herpes Virus Entry Mediator) was found to have a specific interaction with
BTLA, and defined as an actual BTLA ligand. In addition, engagement of BTLA and
HVEM triggered phosphorylation of tyrosine residues and inhibited T cell function.
This finding unveils a novel concept of cross interaction between receptor in the
immunoglobulin family and TNFR superfamily.
HVEM as well as other TNFR family members consists of three subunits of
TNF ligands. The extracellular domain contains three cystein-rich domains (CRDs),
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CRD1, CRD2, and CRD3, which can interact with its binding partners including
LIGHT, lymphotoxin, Herpes virus 1 glycoprotien D (HSV1 gD), and BTLA. CRD2
and CRD3 have been shown to interact with LIGHT and lymphotoxin, while HSV1 gD
and BTLA bind to CRD1 and CRD2 subunits. BTLA and LIGHT can interact with
HVEM at distinct areas in a non-competitive fashion. It is possible that BTLA and
LIGHT can bind HVEM concomitantly. It is known that UL144, a viral protein derived
from human cytomegalovirus (CMV) can also bind to BTLA due to the shared structure
with the first two CRDs of HVEM (188, 189). It has been proved that UL144
effectively suppresses T cell function upon ligation with BTLA, but recruitment of
SHP1 and SHP2 has not been elucidated.
BTLA and HVEM expression in immune cells
BTLA expression was first observed in B and T cells, but later evidence was
found that dendritic cells, macrophages, and NK cells also express BTLA. In mouse T
cells, BTLA is up regulated upon T cell activation, particularly in Th1 cells, but not
Th2 cells (190). It remains unclear what transcription factors controls BTLA expression
in conventional T cells. On the other hand, it was indicated that transcription factor
retinoid-related orphan receptor gamma (RORt) dampens the expression of BTLA,
whereas IL-7 augments BTLA expression, which helps maintain homeostasis of the
normal gamma delta T cell subset (191). BTLA is expressed at low level in early stages
of B cell development (pro-B cells and pre-B cells) and gradually increases upon
maturation stages. High expression of BTLA is generally found in circulating B cells.
HVEM is highly expressed in naïve T cells, and its expression gradually decreases
following T cell activation. High expression of HVEM is observed in naïve and
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memory human B cells, but not on germinal center B cells (188). On the other hand,
mouse B cells express HVEM at low level. Upon ligation with LIGHT, B cells become
activated and down-regulate HVEM expression. In immature dendritic cells, HVEM
expression decreases upon engagement with LIGHT. Typically, HVEM expression is
high in naïve immune cells, but the expression declines following cell activation (190).
1.5 b) BTLA structure and functions
The cytoplasmic region of BTLA consists of three signaling motifs including
Grb2, ITIM and ITSM. Grb2 motif is present in CD28, and ITIM and ITSM motifs are
commonly found in other co-inhibitory molecules such as PD-1 (186). Based on the
BTLA gene sequence analysis, the three signaling motifs are highly conserved across
different species including humans, mice, rats, dogs, and non-human primates. It was
shown that a few tyrosines in BTLA signaling motifs were phosphorylated following
cross-linking of BTLA at the cell surface with anti-BTLA antibodies, suggesting that
these motifs might contribute in regulating downstream signaling pathways during
TCR activation (189). The Immunoreceptor tyrosine-based inhibitory motif (ITIM) and
Immunoreceptor tyrosine-based switch motif (ITSM) contain two tyrosine residues in
both mice and humans. Similar to PD-1, ITIM and ITSM of BTLA could recruit and
phosphorylate SHP1 and SHP2 tyrosine phosphatases, resulting in attenuation of TCR
activation. It has been shown that T cell proliferation was suppressed following
engagement of BTLA by HVEM, suggesting that BTLA functions as a co-inhibitory
molecule by suppressing TCR activation (187).
The downstream signaling pathway of BTLA inhibited by SHP1 and SHP2
remains understudied. It has been suggested that the downstream targets of SHP1 and
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SHP2 might be phosphorylated proteins involved in proximal TCR signals. A recent
report has demonstrated that ITIM and ITSM motifs of PD-1 targeted the PI3K-AKT
pathway, resulting in inhibition of T cell proliferation. Besides inhibitory motifs, BTLA
also contains Growth factor receptor bound protein 2 (Grb2) motifs, commonly shared
in co-stimulatory molecules like CD28. A biochemical assay using synthetic peptide
demonstrated that Grb2 motifs of BTLA interacted with the p85 subunit of PI3K.
Although using BTLA phosphotyrosile-containing peptide might not reflect the
physiological binding of cellular protein during BTLA–HVEM interaction, it could
provide indirect evidence leading to further study. The Grb2 motif of BTLA contains
YXN, but not the YMNM sequence found in CD28. It has been well understood that
Grb2 of CD28 could activate the PI3K-AKT pathway, resulting in an increased IL-2
production and cell proliferation (192). Thus far, there is no direct evidence that
supports a positive role for the Grb2 motif of BTLA. Immunoprecipication assay and
functional studies in cell lines or primary immune cells are required to determine an
actual interaction between phosphorylated Grb2 motifs and Grb2 protein or PI3K. This
will aid in gaining a better understanding of the role and regulation of the positive and
negative motifs resulting in the physiological function of BTLA in T cells.
An early report on mouse and human BTLA indicated a highly conserved
protein sequence in the three signaling motifs. In addition, inhibition of the function of
BTLA on T cells and B cells were also consistent in both species. The study led by
Riley’s laboratory showed that the conserved ITIM sequences in both human and
mouse BTLA was necessary for the suppressive function of BTLA. BTLA expression
at high levels is observed in human naïve and central memory T cells, with a gradual
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decrease of BTLA expression as T cell differentiation occurs (193). In contrast, there
is no BTLA expression in naïve mouse T cells, but up-regulation of BTLA is seen
following TCR activation. These marked differences between the kinetics of BTLA
expression between mouse and human T cells suggest that the gene regulation of BTLA
in mice and humans is completely different.
1.5 c) BTLA in murine disease models
Multiple studies have been demonstrated the role of BTLA in innate immune
response. A report in acute experimental sepsis induction in mice (CLP) has revealed
the role of BTLA in the CD11C+ and CD11B+ innate immune cell subsets, which
generally are macrophages, dendritic cells, and monocytes. An increase in
BTLA+HVEM+ innate inflammatory cells in the peritoneum contributed to worsened
mortality and morbidity in mice administered with lipopolysacccharide (LPS). BTLA
expression hindered activation of innate inflammatory cells with increased IL-10, but
not of other pro-inflammatory cytokine production. This resulted in inhibiting the
recruitment of innate inflammatory cells and limiting bacterial clearance from the body
(194). Furthermore, an increased BTLA expression by innate inflammatory cells such
as macrophages, dendritic cells, and granulocytes was also observed in septic ICU
patients, suggesting a link between mouse models and human studies. In agreement
with another study, there was a significant increase in CD4+BTLA+ in peripheral blood
of ICU patients with septicemia as compared with non-septic individuals. Furthermore,
more than 80% of patients with high CD4+BTLA+ in circulation experienced extended
hospital stays as they became more susceptible to nosocomial infections (195). Another
study using a NOD (non-obese diabetic) murine model, BTLA was expressed by
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dendritic cells and mediated CD8+ T cell tolerance which reduced the severity of
diabetes. T cell proliferation and cytokine production were suppressed by dendritic
cells overexpressing BTLA. In addition, NOD mice immunized with dendritic cells
overexpressing BTLA reduced the incidence of diabetes. This results indicated
inhibitory effect of BTLA on dendritic cell function (196, 197).
In an experimental malaria models, BTLA was found to impair both adaptive
and innate immune responses to Plasmodium yoelii strain 17NL during blood stage
infection. Humoral immune response, considered as a key mechanism for controlling
infection, was suppressed by BTLA expression. Furthermore, BTLA also inhibited the
innate immune compartment, as double deficient RAG1 and BTLA improved the
capability to control parasitemia over RAG1 deficient animals (198). On the other
hand, another study demonstrated the favorable role of BTLA in preventing the
pathogenesis of cerebral malaria. BTLA was shown to increase in peripheral blood as
well as in the brain during the blood stage infection of Plasmodium berhei. The
incidence of cerebral malaria significantly diminished when mice treated with agonistic
anti-BTLA (clone 6A6), which correlated with the reduction of infiltrating T cells in
brain tissue. It was confirmed that anti-BTLA agonist antibody attenuates the cytokine
production including IL-6, IL-18, and IFN-γ (198). This suggests that the inhibitory
function of BTLA helped prevent brain destruction due to strong immune reaction.
Consistent with the graft-versus-host disease (GVHD) model, targeting BTLA
with agonistic anti-BTLA (clone 6A6) has been shown to prevent GVHD regardless of
the presence of HVEM. The agonistic anti-BTLA antibody was shown to directly
inhibit cytokine production and cell proliferation of the donor effector CD4+Foxp3- T
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cells, resulting in expansion of the pre-existing donor Treg population. This created a
new balance between the effector and Treg population that helped prevent GVHD
without global immunosuppression (199). In addition, the inhibitory function of BTLA
has been shown to extend the survival of mice with partial MHC class I and II
mismatches in cardiac allograft, whereas PD-1 played a critical role in full MHC
mismatch settings. Both BTLA and PD-1 were up-regulated upon allogenic antigen
stimulation and high expression of HVEM and PD-L1 were observed in cardiac
transplant tissues. Engagement of BTLA and PD-1 to their ligands could attenuate T
cell responses to alloantigen by inhibiting T cell proliferation and Th1 cytokine
production, resulting in alleviation of allograft rejection (200).
Interestingly, the role of BTLA in T cell survival has also been observed in the
non-irradiated parental-into-F1 mouse model of acute GVHD. BTLA knockout (BTLA
KO) donor lymphocytes were unsuccessfully engrafted in the host body. A similar
finding was also observed when engagement of BTLA and HVEM was blocked using
anti-BTLA antibody (clone 6A6). Donor lymphocytes lacking BTLA had less
proliferative capacity prior to contraction as compared with wild type, resulting in
engraftment failure. In addition, BTLA KO also impaired the re-expression of IL-7R
alpha, considered as an important factor for homeostasis in naïve T cells. Another study
has also shown that anti-HVEM antibodies specifically blocking HVEM and BTLA
interaction ameliorated the graft versus host reaction in lethally irradiated parental-intoF1 murine models of GVHD. Blockade of HVEM and BTLA dampened donor CD8+
T cell activation and IFN-γ secretion, which helped minimize donor anti-host rejection
(201).
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Previous studies in adaptive immune cells have shown that BTLA KO mice
were able to produce more pro-inflammatory cytokine for the clearance of pathogen
infections in several models such as malaria and listeria. However, it has been shown
that macrophages lacking BTLA alleviated liver destruction in fulminant hepatitis
models, caused by murine hepatitis virus strain-3. Macrophages were responsible for
the pathogenesis of hepatitis as they carried and spread the virus during migration to
the liver. A rapid increase in macrophage apoptosis mediated by the TRAIL receptor
following virus infection was found to lower of the viral load and attenuate
inflammatory response in the liver (202).
It has been shown that MRL/Mp-Fas (MRL-Ipr) mice, a systemic autoimmune disease
model for systemic lupus erythematosus (SLE) in humans, become exacerbated when
lacking BTLA. High infiltration of lymphocytes in salivary glands, lungs, pancreas,
kidneys, and joints was observed in BTLA-/-MRL-lpr/lpr mice as compared with the
wild type counterparts. In addition, BTLA-/-MRL-lpr/lpr mice developed necrotizing
hepatitis with increased autoantibodies, which was similar to autoimmune hepatitis
(AIH)-like disease. This suggests that BTLA plays an important role in protection
against autoimmune diseases (203).
Although BTLA signaling itself is known to suppress immune cell function, a recent
report has shown that BTLA could provide HVEM-dependent signals that harness T
cell survival during bacterial infection. In Listeria monocytogenes infection models,
engagement of HVEM expressed by CD8+T cells and BTLA expression in the host
microenvironment was critical for CD8+T cell expansion and survival (204). This
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suggests that BTLA can mediate positive signals through HVEM in trans con
figurations, but inhibits HVEM signal in cis interactions.
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1.6 Main theoretical questions posed in this dissertation
An emerging checkpoint blockade strategy has successfully demonstrated ameliorated
clinical outcomes for cancers in an advanced stage. Targetting co-inhibitory molecules
using monoclonal antibodies clearly improves T cell function, resulting in tumor
regression. It is known that CD8+T cells are prone to dysfunction in the tumor
microenvironment due to high expression of inhibitory receptors such as PD-1, BTLA,
TIM-3, and LAG-3 on the cell surface. We have investigated a number of biomarkers
in both T cells and the tumor microenvironment. These included T-lymphocyte subsets
(CD4 and CD8), effector-memory differentiation markers (e.g., CD27, CD28, CD57,
KLRG1, CD45RA, CD62L), positive (4-1BB, OX40, ICOS) and negative costimulatory molecules (PD-1, BTLA, TIM-3, LAG-3). As expected, the total number
of TIL and the frequency of CD8+ was associated with a favorable clinical response. It
as a surprise when we found that BTLA, a negative co-stimulatory molecule appeared
to be the only marker highly associated with clinical response, while other inhibitory
molecules such as PD-1, TIM-3, and Lag3 did not. BTLA is known as a maker for T
cell differentiation. BTLA is highly enriched in less differentiated T cells such as naïve
and memory T cells, however its expression is progressively lost in CTL
differentiation. This suggests that the association of patients receiving a high proportion
of CD8+BTLA+ in TIL infusion products with favorable clinical response might be due
to the multifunctional properties of less differentiated T cells. It has been reported that
tumor-bearing mice adoptively transferred with minimally differentiated T cell
phenotypes exhibited greater tumor control as these cells persisted much longer in the
body when compared to more differentiated ones. Consistent with this data, we have
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found that CD8+BTLA+TIL susbset is a less differentiated TIL subset that persists
longer in vivo following TIL transfer in ACT treated patients. Thus far, it remains
inconclusive whether the BTLA signaling pathway is also involved in the favorable
clinical response to adoptive T cell therapy. The BTLA cytoplasmic domain consists
of three signaling motifs including Grb2, ITIM, and ITSM. It is clearly known that
ITIM and ITSM motifs are essential for BTLA to exert a suppressive effect by
recruiting SHP1 and 2 during TCR activation. On the other hand, the BTLA
cytoplasmic tail also contains a predicted recruitment site for Grb2, which is present in
the cytoplasmic tail of costimulatory molecules such as CD28 and ICOS. Recent
studies have shown that the predicted Grb2 binding site was not only able to recruit
Grb2 protein, but also interacted with p85 PI3K even though there is no reported
consensus motif for p85 recruitment.
Previous studies have suggested the roles of BTLA in T cell differentiation and coinhibitory signal. However, it remains unclear how less differentiated T cell
characteristics could contribute in improving the clinical outcome of ACT treated
patients. In addition, several unanswered questions still remains concerning whether
the Grb2 motif of BTLA could provide a positive signal. If so, mechanisms defining
the integration of the inhibitory and positive signals during engagement of BTLA and
HVEM remain to be elucidated.
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1.7 Overall hypothesis and specific aims
Our goal is to characterize the function of the CD8+BTLA+TIL subset and the
molecular mechanism and function of BTLA upon HVEM ligation. We are
hypothesizing that the less differentiated T cell phenotype of CD8+BTLA+ TIL together
with BTLA signalling may provide a survival advantage and translate in a better
persistence of TIL following antigen restimulation. In this dissertation, we tested our
hypothesis under the following specific aims;

Specific Aim #1: To characterize the survival and anti-tumor function of
CD8+BTLA+TIL and CD8+BTLA-TIL subsets using in vitro assays and NSG
mouse model for adoptive T cell therapy.
Specific Aim#2: To dissect the function and downstream signals of BTLA using
BTLA mutant retroviral constructs.
Specific Aim #3: To investigate the role of BTLA in the generation of memory
upon vaccination with gp100 in a Pmel-1 mouse model.
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CHAPTER 2

Transcriptional analysis of BTLA in metastatic melanoma patients
and comparative study of the kinetics of BTLA expression in
CD8+T lymphocyte
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2.1 Rationale and Hypothesis
Our phase II clinical trials of adoptive T cell therapy at MD Anderson Cancer
Center using autologous ex vivo expanded tumor infiltrating lymphocytes (TILs) have
demonstrated the great potential of this immunotherapy for stage IV metastatic
melanoma. We have investigated a number of biomarkers in infused TIL for their
association with clinical response. These included markers of T lymphocyte subsets,
effector-memory differentiation markers, as well as positive and negative
costimulatory molecules. Unexpectedly, we observed that BTLA is the only maker that
is associated with positive clinical response in TIL treated patients (134).
BTLA is characterized as a co-inhibitory receptor belonging to the Ig
superfamily (186). It has been demonstrated that several co-inhibitory molecules
including PD-1, CD160, TIM-3, LAG-3 are tightly associated with T cell exhaustion
phenotype (205). As activated T cells progress toward exhaustion they gradually
upregulate the expression of these co-inhibitory markers which results in a gradual loss
of T cell effector function defining T cell exhaustion. By the same token, T cells
expressing one of these molecules, for example CD8+PD-1+ T cells in peripheral blood
of healthy donors or antigen-specific T cells circulating in melanoma patients are not
essentially functionally defective. A recent report has clearly demonstrated that the
majority of co-inhibitory receptors such as PD-1, CD160, 2B4, as well KLRG1 were
inducible upon T cells activation. On the contrary, BTLA is highly enriched in naïve T
cells and gradually down-regulated following T cell activation, suggesting that BTLA
marks a “young T cell phenotype” (141). It was demonstrated that human effector CD8+
T cells derived from naïve cells exhibit a minimally diferentiated phenotype with
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superior ability to expand and retain longer telomere. These findings suggest that a less
differentiated phenotype is tightly associated with enhanced proliferative capacity and
persistence following T cell transfer, which is linked to an effective clinical response
in ACT (206).
Thus far, the study of BTLA has been largely restricted to its inhibitiory
function in studieusing models such as autoimmune diseases and infectious diseases
(191, 202, 207, 208). Our unexpected findings suggest that BTLA could play an
important role in tumor immunology, particulary for adoptive T cell therapy. We have
witnessed an improved clinical response in patients treated with high proportion of
CD8+BTLA+ in their infusion products. However, our findings are based on the
expression of BTLA on in vitro expanded TIL and it is unclear whether high expression
of BTLA in the tumor tissue could be associated with improved survival in metastatic
melanoma patients. Although BTLA expression was preliminarily reported in human
and mouse T cells, the kinetic expression of BTLA in different T cell subsets has not
yet been investigated, particularly in murine T lymphocytes.
In this study, we aimed to investigate the transcription level of BTLA in stage
III metastatic melanoma patients to investigate the association between BTLA
trancription and patient survival. In addition, we also determined the kinetics of
expression of BTLA in both human and mouse to comparatively examine BTLA
regulation between two species.
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2.2 Results
High CD8a and High BTLA gene expression strongly linked to an improved
survival of stage III metastatic melanoma patients.
We previously demonstrated that CD8+BTLA+ subset is highly associated with
favorable clinical response in TIL treated metastatic patients, but not other coinhibitory molecules such as PD-1, TIM-3, as well as LAG-3 (141). It remains
understudied whether metastatic melanoma patients with high expression of BTLA,
CD8 or both markers, in the tumor tissue also conferred superior survival rate
regardless of given therapy.
To further examine whether CD8+BTLA+ is linked with better survival, we
analyzed integrated data generated by The Cancer Genome Atlas (TCGA) Research
Network. The data from 96 stage III metastatic melanoma patients were retrieved from
the database for survival analysis using a Kaplan-Meier analysis method. A nonparametric statistic was used to evaluate the fraction of patients alive for a period of
time following therapeutic intervention. In this study, we performed transcription
analysis by evaluating the association between transcripts of CD8a, CD19, NRC1, and
BTLA, with survival in metastatic melanoma patients. Gene transcription level was
categorized into high and low based on the expression being higher or lower than the
median value respectively.
We found that the patients with high transcripts of either CD8a or BTLA had
much superior survival when compared with either CD8a low or BTLA low (Log Rank;
CD8a high vs CD8a low, P=0.0007, N=42; BTLA high vs BTLA low, P=0.001, N=42)
(Figure 2.1A and 2.1B). When both CD8a and BTLA were considered, high
transcription level of CD8a and BTLA was the strongest link with better survival.
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Interestingly, patients with low CD8 but high BTLA had better survival as compared
to high CD8 paired with low BTLA. (Log Rank; CD8a high BTLA high vs CD8a low
BTLA low, P =0.0007, N =98) (Figure 2.1C).
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Figure 2.1. Association of high CD8a and high BTLA transcription level and
improved patient survival in stage III metastatic melanoma.
Kaplan-Meier survival curves in stage III metastatic melanoma from The Cancer
Genome Atlas (TCGA) consortium depicts; (A) CD8a expression; CD8a high versus
CD8a low (B) BTLA expression; BTLA high versus BTLA low (C) Combined CD8
and BTLA expression; CD8a high BTLA high versus CD8a low BTLA high versus
CD8a high BTLA low versus CD8a low BTLA low. Total number of patients=98,
(high- above median, low-below median). Statistical significance was determined
using a log-rank. (P <0.001 and P <0.0001). CD8a high BTLA high, N=42; CD8a high
BTLA low, N=7; CD8a low BTLA high, N=7; CD8a low BTLA low, N=42.

66

Since BTLA can be expressed by other cell types, we also further investigated
the association of BTLA with other immune cells such as B cells (defined as CD19)
and NK cells (defined as asNCR1). We found that high CD19 transcription level was
linked with better survival, particularly in combination with low BTLA (Figure 2.2A).
The worst survival was observed in the patients with low transcription level of both
CD19 and BTLA; however, patients with low CD19 and high BTLA had much superior
survival as compared with low CD19 and low BTLA P =0.024, N=40 (Figure 2.2B).
Next, we determined the gene expression level of NK cells and BTLA, we observed
that low NCR1 and high BTLA was correlated with the greatest survival. Within the
BTLA high group, NCR1 expression defined worst survival. Overall the high
expression of BTLA in conjunction with either high CD8, high/low CD19 or low NCR1
was most predictive of best survival, indicating that BTLA might be a good predictor
for stage III metastatic melanoma patients.
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Figure 2.2. Correlation of CD19, NRC1, and BTLA transcription level with
patients in stage III metastatic melanoma.
Kaplan-Meier survival curves in stage III metastatic melanoma from The Cancer
Genome Atlas (TCGA) consortium depicts (A) CD19 and BTLA expression in the
following combinations; CD19 high and BTLA low (black), CD19 low and BTLA high
(yellow), CD19 high and BTLA high (red), and CD19 low and BTLA low (green). (B)
NCR1 (NK cell marker) expression and BTLA expression in the following
combinations; NCR1 low and BTLA high (yellow), NCR1 high and BTLA high (red),
NCR1low and BTLA low (green), and NCR1 high and BTLA low (black). Total
number of patients=98 (high-above median, low-below median). Statistical
significance was determined using a log-rank. CD19 high and BTLA low, N=9; CD19
low and BTLA high, N=9; CD19 high and BTLA high, N=40; and CD19 low and
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BTLA low, N=40. NCR1 low and BTLA high, N=10; NCR1 high and BTLA high,
N=39; NCR1low and BTLA low, N=39; and NCR1 high and BTLA low, N=10.
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Human BTLA is downregulated upon cell differentiation and expansion.
BTLA was first characterized as a co-inhibitory molecule expressed by B cells,
T cells, dendritic cells, as well as NK cells (186). Several in vitro and in vivo studies
have consistently shown that BTLA attenuated T activation through its inhibitory
motifs, ITIM and ITSM. Unlike other inhibitory molecules, BTLA is down-regulated
following T cell activation as opposed to the increased expression commonly seen with
PD-1, TIM-3, and LAG-3. Transcriptional analysis of CD8+BTLA+ versus
CD8+BTLA+ has indicated that CD8+BTLA+ T cell subset is highly enriched in genes
associated with less differentiated T lymphocytes including CD28, whereas a gene
signature typical of more differentiated T cells is highly up-regulated in CD8+BTLAT cell subset (142).
Based on this finding, we further performed immunophenotypic analysis of T
cells in PBMCs to determine the expression level of BTLA in different T cells subsets.
Human PBMCs isolated from five donors were stained with CD3, CD8, CD45RA,
CCR7, and BTLA. CD8+T cells were categorized into five subsets on the basis of the
expression of CCR7 and CD45RA; Naïve (CD45RA+CCR7+), Central memory
(CD45RA-CCR7+),

Effector

(CD45RA-CCR7-),

memory

Effector

memory

intermediate (CD45RAint, CCR7-), and terminally differentiated (CD45RA+, CCR7-)
(Figure 2.3A). Highest BTLA expression was observed in naïve T cells (nondifferentiated cells), and terminally differentiated had the lowest BTLA expression.
BTLA expression between naïve and central memory was comparable (P=0.06), but
the expression was significantly higher than effector memory and terminally
differentiated cells respectively (naïve versus effector memory, P= 0.028, N=6; naïve
versus terminally differentiated, P =<0.001; central memory vs terminally
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differentiated, P=0.03) (Figure 2.3B and C). This indicates that BTLA is highly
enriched in less differentiated T cells, and that its expression level is down-regulated
upon differentiation. Thus BTLA expression level marks T cell differentiation status.
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Figure 2.3. BTLA expression correlates with differentiation status of T cells.
PBMCs were isolated form five human donors. The cells were stained with anti-human
CD3, CD8, CD45RA, CCR7, and BTLA. (A) Zebra plot depicts different CD8+ T cell
subsets defined by the expression of CD45RA and CCR7; Naïve (CD45RA+CCR7+),
Central memory (CD45RA-CCR7+), Effector memory (CD45RA-CCR7-), Effector
memory intermediate (CD45RAint, CCR7-), and terminally differentiated (CD45RA+,
CCR7-). (B) Histogram plot demonstrates mean fluorescence intensity (MFI) of BTLA
expression in Naïve, Central memory (CM), Effector memory (EM), Effector memory
intermediate (EMRAint), and Terminally differentiated (TEMRA). (C) Bar graph
depicts percentage expression of BTLA in different CD8+T cell subsets. BTLA
expression was down-regulated upon T cell differentiation.
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Upon T cell activation, T cells undergo proliferation as well as differentiation.
Because BTLA expression correlates with T cell differentiation, we further
investigated whether T cell expansion could lead to BTLA down-regulation. BTLA
expression level was compared between pre and post-expansion of sorted BTLA+ TIL
propagated using the REP protocol. BTLA was found to be significantly decreased in
post-expansion of sorted BTLA TIL as compared to pre-expansion, indicating that
BTLA is down-regulated upon T cell expansion and differentiation (P=0.001) (Figure
2.4A and B).
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Figure 2.4. BTLA is down-regulated upon T cell expansion and differentiation.
CD8+BTLA+ TIL from four patients were sorted and propagated with the Rapid
expansion protocol using irradiated PBMC, anti-human CD3, and IL-2 (6000 IU/ml)
for 14 days. The cells were stained with anti-human CD8 and BTLA. The expression
level of BTLA by CD8 TIL was assessed by flow cytometry. (A) BTLA expression
was significantly decreased following TIL propagation using REP. (N=4, P=0.0131)
(B) Pseudo color plots demonstrates BTLA expression. Representative example of
CD8+TIL (TIL #2405) demonstrates post-sort purity (left panel) and a decreased BTLA
expression following REP (right panel).
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Mouse BTLA is up-regulated upon T cell activation.
We previous demonstrated the expression of BTLA in different human T cell
subset. In this study, we explored the kinetic of BTLA expression in different subset of
mouse CD8+T lymphocytes. Mouse CD8+T cells were categorized into three subsets
on the basis of the expression of CD62L and CD44; Naïve (CD44-CD62L+), Central
memory (CD44+highCD62L+), Effector memory (CD44+CD62L-) (Figure 2.5A).
Splenocytes from OT-1 mouse were stained with anti-CD3, anti-CD8, anti-CD44, antiCD62L, and anti-BTLA.
High expression of BTLA was observed in CD44+CD8+ T cells, particularly in
CD44high and CD62L+CD8+T cells, suggesting that BTLA expression correlates with
T cell activation as CD44+ is highly expressed by activated T lymphocytes (Figure
2.5B and C). Unlike human T cells, the expression of BTLA in mouse naïve T cells
was undetectable.
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Figure 2.5. High expression of BTLA correlates with CD44.
Splenocytes were isolated from wild type OT-1 mouse, lysed with ACK buffer, then
stained with anti-CD3, anti-CD8, anti-CD44, anti-CD62L, and anti-BTLA. (A) Mouse
CD8+ T cell subset defined by the expression of CD44 and CD62L; Naïve (CD44CD62L+), Central memory (CM, CD44+CD62L+), and Effector memory (EM,
CD44+CD62L-). (B) High expression of BTLA correlates with CD44. (C) The highest
BTLA expression was found in Memory T cell subset (CD44 very hi and CD62Lhi),
while CD44 low and CD62L subset had the lowest expression of BTLA.
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Next, we further examine the kinetic of BTLA expression in different mouse T
cell subsets following T cell activation. Either sorted naïve T cells (CD44-CD62L+) or
Memory T cells (CD44+CD62L+) were labeled with eflour®670 and stimulated by coculturing with bulk splenocytes of OT-1 mouse and anti-mouse CD3 (Figure 2.6A).
BTLA expression was determined every other days following T cell activation. Downregulation of BTLA was observed in mouse T lymphocytes, which is similar to the
kinetic of human T cells. In mouse naïve T cells, BTLA expression was inducible upon
T cell activation, and gradually declined within five days (Figure 2.6B). Interestingly,
re-stimulation with anti-mouse CD3 failed to trigger the expression of BTLA regardless
of the dose of antibody (Figure 2.6C).
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Figure 2.6. The kinetic of BTLA expression in mouse T cells.
(A) Naïve (CD44loCD62Lhi) and Memory T cells (CD44very hi and CD62L hi ) were
sorted from bulk splenocytes of OT-1 mouse, labeled with efluor670®, and activated
by co-culturing with bulk splenocytes with mouse anti-mouse CD3 at concentration of
300 µg/ml. Activated T cells were harvested and stained with anti-CD44, anti-CD62L,
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and anti-BTLA on day 0, 1, 3, and 5 respectively. (B) Sorted cells were gated on
efluor670®+CD3+CD8+cells and analyzed for expression of BTLA, CD44, and
CD62L. BTLA in naïve T cell was up-regulated shortly after activation and return to
basal level within 5 days, while BTLA expression in memory T cell subset was
continuously decrease within a day upon activation. (C) On day 7, the cells were restimulated with antimouse-CD3 at concentration of 0.01, 0.25, and 1 mg/ml. There was
no BTLA expression detected within 24 hours following re-stimulation.
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2.3 Discussion
Transcriptional analysis has demonstrated that the gene expression of CD8a and
BTLA in the tumor tissue is associated with an extended survival of stage III metastatic
melanoma patients, while no correlation of survival benefit was seen with the coexpression of BTLA and other immune cells such as NK and DC cells. This finding is
in agreement with our previous observation indicating that high proportion of
CD8+BTLA+TIL in the infusion product associated with positive ACT clinical outcome
(134). The association between the expression of BTLA and CD8 and survival from
the TCGA data strengthens our results making the point that the co-expression of
BTLA and CD8 is a good prognostic factor for patient survival regardless of the therapy
they eventually receive.
Our data on correlation of the high expression of human BTLA in less
differentiated T cells is in agreement with a previous report from Speiser’s lab (142).
A recent report also suggested that BTLA could be a maker for B cell differentiation
as decreased BTLA expression was observed in aged B cells minimally responsive to
influenza vaccination (209). Altogether, these results indicate that BTLA serves as a
cell differentiation marker in both B and T cells.
We found that BTLA expression in mouse T cells did not correlate with cell
differentiation. In fact, we did not observe BTLA expression in naïve T cells isolated
from C57B6L mouse. During T cell activation, mouse BTLA expression is upregulated rapidly within 24 hours, and the expression declines over 7 days. The kinetic
of expression of BTLA in mouse is similar to the general expression pattern of coinhibitory molecules such as PD-1 and CTLA-4 (184, 210).
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In conclusion, human BTLA serves as a cell differentiation maker in both B
and T cells. In contrast, the kinetic of expression of BTLA in mouse is similar to other
co-inhibitory molecules and not considered as a differentiation marker. This finding
suggest BTLA gene regulation in mouse and human is different, possibly result from
dissimilar epigenetic regulation of gene expression.
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CHAPTER 3

Characterization of the anti-tumor function of the CD8+BTLA+ TIL
subset
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3.1 Rationale and Hypothesis
In the previous chapter, we and other have demonstrated that BTLA is considered as a
marker for human T cell differentiation. BTLA is highly enriched in minimally
differentiated T cells such as naïve and central memory T cells, while low expression
is found in more differentiated phenotype (142). CD8+BTLA+TIL abundantly contains
gene signature of less differentiated T lymphocyte including CD28, CD127 (also
known as IL7R), and CX3CR1 (also known as CX3C chemokine receptor 1), while
CD8+BTLA-TIL are highly enriched in more differentiated T lymphocyte gene cluster
such as TYROBP (TYRO protein tyrosine kinase-binding protein), KIR2DL-1, -2, and3 (Killer cell immunoglobulin-like receptor) (141). It has been demonstrated that
minimally differentiated CD8 T lymphocytes are less potent in effector cytokine
production such as IFN-γ, perforin, and granzymes, as well as cytotoxic function as
compared to the more differentiated CD8 T lymphocyte counterpart. Several studies
have also indicated that more differentiated T lymphocyte are more effective in
mediating cytotoxic killing (206). However, we have observed that our ACT treated
patients who received high proportion of CD8+BTLA+ TIL subset achieved better
clinical response relative to those who were infused with less proportion of
CD8+BTLA+ TIL (141). Less differentiated T lymphocytes are thought to be less
effective in effector mediating killing (141, 143). However, several studies have been
reporting that less differentiated T lymphocyte subset have superior proliferative
capacity and persistence as compared to more differentiated T lymphocyte (140, 143,
206). We hypothesized that CD8+BTLA+ TIL may be less potent effectors but may be
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able to proliferate and survive longer to repeatedly mediate tumor killing and therefore
be able to better control tumor growth than their CD8+BTLA- counterpart.
In this study, we aimed to perform an extensive investigation of the cytotoxic function
of both CD8+BTLA+ TIL subset and CD8+BTLA-TIL subset. We utilize in vitro tumor
killing assay as well as an in vivo model of immunodeficient NOD-scid IL2Rgammanull
model for adoptive TIL transfer to evaluate tumor burden control. To extensively
determine the dynamic interaction between tumor target cell and effector T cell in
isolated killing events, we conducted single cell T cell/Tumor cell killing assay using
TIME. This allowed us to gain a comprehensive understanding of the fate of the T cell
after tumor killing at single cell level and helped us understand the outcome of the in
vivo tumor challenge.
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3.2 Results
In vitro tumor killing capacity is relatively comparable between CD8+BTLA+ and
CD8+BTLA- subsets regardless of tumor antigen restricted setting.
It is known that more differentiated T lymphocytes are more effective in tumor killing
relative to those of less differentiated T cell subset. Unexpectedly, we observed TIL
treated patients who were infused with high percentage of less differentiated phenotype
(CD8+BTLA+TIL subset) achieved superior clinical response instead of those patients
who received high percentage of more differentiated phenotype (CD8+BTLA+TIL
subset). We previously reported that the T cell repertoire of CD8+BTLA+TIL and
CD8+BTLA-TIL subsets almost completely overlaps (>95% of the TCR CDR3
sequences are shared) using high throughput CDR3 sequencing. This suggests that
tumor-reactive T cells are not selectively enriched in one subset and the assumption is
that they are equally distributed among two subset. With this bias removed, the overall
killing capacity of each subset is determined on the basis of intrinsic cytotoxicity. We
performed an in vitro killing assay to evaluate the killing capability of CD8+BTLA+
and CD8+BTLA- subsets in cultures where the antigen recognized by TIL are unknown
(non-antigen restricted killing) and also with TIL that were sorted for HLA-A2
restricted recognition of MART-1 tumor antigen (antigen-restricted killing). To
investigate CTL-mediated tumor killing in tumor antigen restricted setting, we selected
two TIL lines containing MART-1 recognizing TCR population (TIL#2559 and 2765).
We co-incubated either sorted CD8+BTLA+MART-1 tetramer positive or CD8+BTLAMART-1 tetramer positive TIL with MEL526 (human melanoma tumor cells
expressing the MART-1 antigen) at the ratio of effector T cells to target tumor cells of
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1:1, 1:3, and 1:10 (Figure 3.1). Percentage of caspase-3 positive MEL526 tumor cells
was used to compare tumor killing capacity between the two subsets. We found that
the killing capability in two MART-1 antigen specific TIL lines were equally
comparable (TIL# 2559; 1:1, BTLA+ (33%) vs BTLA-(29.1%), 1:3, BTLA+(13.95%)
vs BTLA-(16.2%), 1:10, BTLA+(5.5%) vs BTLA-(5.6%), TIL#2765; 1:1, BTLA+
(2.5%) vs BTLA-(2%), 1:3, BTLA+ (7.7%) vs BTLA- (7%), 1:10, BTLA+ (11.8%) vs
BTLA-(13.7%). Consistently, we did not observe any difference in tumor killing
capacity in using bulk TIL from another patient in a non-antigen restricted setting (TIL#
2549; 1:1, BTLA+ (64%) vs BTLA-(71%), 1:3, BTLA+(46%) vs BTLA-(63%), 1:10,
BTLA+(38%) vs BTLA-(49%). In conclusion, CD8+BTLA+ and CD8+BTLA- exhibit
equivalent in vitro tumor killing.
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Figure 3.1. Evaluation of in vitro killing capacity between CD8+BTLA+TIL and
CD8+BTLA-TIL subset.
MART1-reactive CD8+ TIL (left and mid panel) and TIL 2549 (right panel) were sorted
into BTLA+ and BTLA- subsets. MEL 526 (melanoma tumor expressing MART-1
antigen, left and mid graph) or autologous tumor line 2549 (right graph) were stained
with eFluor670® and co-cultured with TIL at the following TIL-to-tumor cell ratios
(1:10, 1:3, and 1:1). Tumor cell death is measured by the percentage of caspase-3
positive cells. Comparable tumor killing capacity was found between two subsets.
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CD8+BTLA+TIL subset confers superior tumor control in NSG mouse model for
adoptive T cell therapy as compared to CD8+BTLA-TIL counterpart.
Our results indicated comparable intrinsic tumor killing ability between CD8+BTLA+
and CD8+BTLA- subsets. This result disagreed with the previous knowledge
demonstrating that more differentiated T cells are more effective in mediating tumor
killing as compared to those less differentiated T lymphocyte phenotypes (211).
Because in vitro killing capacity testing was conducted in short time (3 hours) and in a
confined environment, this setting might not reflect an actual physiological interaction
between tumor and TIL. We thus further determined the killing capability of TIL using
an in vivo setting with the NOD-scid IL2Rgammanull (NSG) mouse model for adoptive
T cell therapy. NSG mice lack immune cells including mature T cells, B cells, as well
as NK cells. In addition, the innate immune system and multiple cytokines are also
defective in NSG mice (212). The NSG mouse model is widely used to examine the
function of human T cell for the therapy of cancer, particularly in genetic modified T
lymphocytes. In this study, we compared the potency of in vivo tumor control between
CD8+BTLA+TIL versus CD8+BTLA-TIL subsets in both a tumor-antigen restricted
manner (MART-1 antigen) and a non-tumor restricted setting. In the tumor-antigen
restricted setting, two TIL lines containing MART-1 recognizing TCR populations
(TIL#2559 and 2765) were sorted on either CD8+BTLA+MART-1 subset or
CD8+BTLA-MART-1 TIL subset, and further propagated using the REP for 14 days.
These expanded cells were adoptively transferred into NSG animals that were engrafted
with 10 x 106 cells of MEL526 human melanoma tumor line expressing MART-1
antigen. IL-2 was administered immediately following T cell transfer and daily for
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three days to support the in vivo TIL expansion. Tumor measurements were used to
determine the potency of in vivo tumor control. Similarly, in the non-antigen restricted
setting, TIL#2549 were sorted on either CD8+BTLA+ or CD8+BTLA-, propagated with
the REP for 14 days, and adoptively transferred into NSG mice engrafted with
autologous tumor generated from TIL#2549 patient. We found that the transfer of
CD8+BTLA+ in tumor-bearing NSG mice conferred significantly better tumor control
relative to those NSG mice infused with the CD8+BTLA- TIL counterpart in both
tumor-antigen restricted (TIL#2559; P = 0.002, 2765; P=0.04) and non-tumor-antigen
restricted setting (TIL#2549; P=0.049). This suggests that the CD8+BTLA+ subset has
a superior capability to mediate in vivo tumor control from an equivalent TCR
repertoire therefore implying intrinsic differences (Figure 3.2A).
To evaluate the persistence of TIL in NSG mouse following TIL transfer, peripheral
blood was collected every other day and stained with anti-human CD45 and anti-human
CD8+. We observed that TIL were barely or no longer detected in peripheral blood of
NSG mice approximately 6 to 8 days following TIL transfer. This could suggest that
TIL do not efficiently engraft in the NSG host. We found that NSG treated with
CD8+BTLA+MART+ had significant higher absolute number of CD45+CD8+ cells than
those treated with CD8+BTLA+MART+ (TIL#2559MART+; D4, P=0.0021,
TIL#2765MART+; D2, P=0.0021, D4, P=0.02). In NSG treated with non-antigen
restricted TIL, the absolute number of CD45+CD8+ cells in peripheral blood are
comparable in NSG mice treated with either CD8+BTLA+ or CD8+BTLA- (TIL#2549;
D2, P=0.06) (Figure 3.2B).
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(A) CD8+BTLA+TIL subset exhibited superior in vivo tumor control as compared to
their CD8+BTLA-TIL counterpart. Ten million sorted CD8+BTLA+ or sorted
CD8+BTLA- TIL were intravenously injected into tumor bearing mice previously
subcutaneously implanted with either MEL526 or autologous melanoma tumor line
2549. Tumor burden was measured for 15 days following TIL transfer using calipers
and the diameter was graphed as mm2. (B). To determine TIL persistence following
TIL transfer, peripheral blood was collected every other day and lysed with lysed with
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ACK buffer, then stained with anti-human CD45 and anti-human CD8. Bar graphs
demonstrate percentage of absolute number of CD45+CD8+. CD8+BTLA+TIL subset
persisted significantly longer following adoptive transfer in antigen-restricted TIL lines
(2559 MART-1+ and 2765 MART-1+).
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Exploring the dynamic interaction between TIL and tumor cell at a single cell
level using TIMING.
We observed that CD8+BTLA+ displayed superior in vivo tumor control using
NSG mouse model as compared with their CD8+BTLA- counterpart; however, no
difference in in vitro tumor killing capacity was observed between these two subsets.
The in vivo setting provides a broader picture relevant to an actual physiological
situation and we chose to next look at the dynamic interaction between TIL and tumor
at the cellular level over a longer period of time to elucidate functional differences
between the two subsets. We utilized Timelapse Imaging Microscopy In Nanowell
Grids (TIMING) to study the dynamic interactions between individual tumor targets
and effector cells in a high-throughput setting. The nanofabricated array was used to
restrict the effector TIL and tumor targets in small volumes. Functional features of TIL
and tumor cells were sequentially monitored for 8 hours by automated time-lapse
fluorescence microscope in each individual wells of nanofabricated array (213, 214).
In this study, we evaluated the tumor killing capacity of TIL by measuring the
survival of tumor cells following the interaction with TIL and we also determined the
survival of TIL after a killing event. MART-1 recognizing TIL line was used to reduce
the bias of heterogeneity of the tumor recognition capacity. TIL (either sorted
CD8+BTLA+MART-1 TIL or CD8+BTLA-MART-1 TIL) and MEL526 human
melanoma tumor line were labeled with Vybrant Violet and Cell Tracker Red
respectively, and loaded onto nanowell chip at two separate effector-to-target ratios of
1:1 and 1:2. Dynamic interaction between TIL and tumor was monitored for 500
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minutes using digital fluorescence microscope attached underneath the nanowell chip
(Figure 3.3A and B) (213, 214).
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A

B

Figure 3.3. Schematic diagram demonstrating single-cell cytotoxic analysis using
nanofabricated array based analysis.
Nanowell array-based cytolysis assay was used to determine tumor killing capacity at
the single cell level. Effector cell and Tumor target are labeled in different colors and
loaded into the nanowell at effector-to-target cell ratios of 1:1 and 1:2. Interaction
between effector and target cells is monitored by automated time-lapse camera coupled
with a fluorescence microscope. (A) Schematic diagram demonstrates nanowell chips
loaded with effector cell and tumor target cells. (B) Timelapse images depict effector
cells and tumor target cell interaction over 8 hours following co-incubation; tumor cell,
T cells, and apoptotic cells are labeled in red, blue, and green respectively.
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CD8+BTLA-TIL subset accelerates tumor cell death by shortening t contact and
t death.
The kinetics between TIL and tumor were evaluated using these three following
sequential parameters (tseek, tcontact, and tdeath).1) Time needed to establish conjugation
between the T cell and tumor target (tseek), 2) duration of the contact between the T cell
and the tumor target (tcontact), and 3) time between the first T cell contact with the tumor
cell and tumor cell apoptosis (tdeath) (Figure 3.4A). Intriguingly, the CD8+BTLA+
subset was more effective in tumor seeking at effector-to-target cell ratios of 1:1 as
time that T cell used to initiate first contact with tumor target was significantly less in
CD8+BTLA+ as compared to CD8+BTLA-subset (N= 3319, tseek; ratio 1:1, P<0.0001)
(Figure 3.4B). This difference was not observed when two targets were present in the
well. (N= 3319, tseek; ratio 1:2, P<0.22) (Figure 3.4B). This finding could imply that
CD8+BTLA+ TIL subset may be more bioenergetically efficient than the CD8+BTLAcounterpart.
However, the CD8+BTLA- subset was found to spend less time in contact with
the tumor cell target (tcontact; 1:1 and 1:2, P<0.0001) and the time from first contact to
apoptosis of the tumor target was considerably shorter for the CD8+BTLA- subset at
both E:T ratios (tdeath; 1:1 and 1:2, P<0.0001) (Figure 3.4C and D). These findings
support the functional role of BTLA in both signaling and cell differentiation. The coinhibitory role of BTLA signal attenuate TCR activation, resulting in extending the
time used for TIL to reach and initiate interaction with a tumor. In addition, shortened
tdeath observed in CD8+BTLA-TIL subset is in agreement with the previous knowledge
demonstrating that more differentiated T lymphocytes are more potent in cytotoxic
function relative to those of less differentiated phenotype.
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In summary, CD8+BTLA+TIL subset are more active in seeking the tumor cell
than CD8+BTLA-TIL subset, but perform tumor cell death with slower kinetics. These
behavioral features might be explained from both distinct differentiation status and
BTLA signaling.
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Figure 3.4. CD8+BTLA-TIL subset extend t seek, but shorten t contact and t death.
(A) Schematic diagram demonstrating the sequential events in which effector cells seek
(tseek), contact (tcontact), and mediate tumor cell death (tdeath). Either
CD8+MART1+BTLA+ or CD8+MART1+BTLA- subset was co-incubated with MEL
526. Time (min) between each sequential event is evaluated. Dot plots depict tseek (B),
tcontact (C), tdeath (D) in comparison between CD8+BTLA+ (blue) and CD8+BTLA-
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(red) subsets. All error bars depicts the mean ± s.e.m. All P-values were calculated
using a two-tailed Student’s t-test. (N=497).
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CD8+BTLA+ subset conferred survival capacity that mediates tumor serial killing.
We previously have shown that CD8+BTLA- TIL are effective in tumor killing
as the time used to form contact (tcontact) and mediate tumor cell death (tdeath) was
significantly less than CD8+BTLA+ subset. In contrast, we found that the two subsets
had comparable tumor killing capacity when used for in vitro tumor killing in bulk
setting.
We next examined whether the overall killing capacity between the two subsets
was any different by evaluating tumor target cell survival following 8 hour of coincubation with TIL. In general, we found that both T cell subsets equally killed tumor
target (Figure 3.5A, 18% of tumor target killed at an E:T ratio of 1:1). Interestingly, at
the E:T ratio of 1:2 the CD8+BTLA+ subset was able to kill a total of 21% of tumor
targets upon contact as compared to only 14% for the CD8+BTLA- (Figure 3.5A).
When two tumor targets were in the presence of one effector T cell, the CD8+BTLA+
subset was twice as likely to kill both targets (Figure 3.5A, 14% for the BTLA+ versus
7% for the BTLA-).
Next, we evaluated tumor target cell survival through time following effector
target cell killing over 500 minutes. In the first 250 minutes, we found that the
CD8+BTLA- TIL subset was more potent in tumor killing capacity as survival of tumor
cells being killed by CD8+BTLA- TIL was significantly less than tumors co-incubated
with the CD8+BTLA+ TIL counterpart at both effector TIL to target tumor cell ratio of
1:1 and 1:2 (Figure 3.5B and C, survival of contacted tumor target cells; 1:1, P<0.03,
1:2, P<0.0001). In the last 250 minutes, we found that the two subsets had comparable
tumor killing capacity at effector TIL to target tumor cell ratio of 1:1; however,
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CD8+BTLA+ became more effective in tumor killing when effector TIL to target tumor
cell ratio increased to 1:2 (Figure 3.5D and E, survival of contacted tumor target cells;
1:1, P<0.54, 1:2, P<0.0001).
When we cautiously determined the survival capability of T cells following
tumor killing events, we found that the CD8+BTLA- subset was more susceptible to
undergo apoptosis in comparison with the CD8+BTLA+ counterpart (Figure 3.5D,
survival of effector cells following target tumor cell killing; ratio 1:1, P<0.01). This
demonstrates that the CD8+BTLA+ subset is prone to survive better after tumor killing,
and thus is able to repeatedly kill additional tumor cells.
Overall, our results suggest that CD8+BTLA- is more effective in tumor killing,
but also more susceptible to undergo apoptosis following killing as compared to
CD8+BTLA+.
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Figure 3.5. CD8+BTLA+ TIL subset exhibit improved survival following tumor
target killing.
(A) Donut charts demonstrate the frequency of tumor cell death following effector cell
killing by either CD8+BTLA+ (left) or CD8+BTLA-(right) subset. Inner circle and outer
circle depict E:T ratio of 1:1 and 1:2 respectively. Kaplan-Meier survival curves of T
cell-contacted tumor targets resulting in a killing event in the first 250 minutes in
comparison between CD8+BTLA+ and CD8+BTLA-subsets at effector-to-target cells
ratios of 1:1 (B) and 1:2 (C). Kaplan-Meier survival curves of T cell-contacted tumor
target resulting in a killing event in the last 250 minutes; comparison between
CD8+BTLA+ and CD8+BTLA-subset at effector-to-target cells ratios of 1:1 (D) and 1:2
(E). Statistical significance was determined using a log-rank. (N=3319). (***P
<0.0001). (F) Kaplan-Meier survival curves of tumor-contacted effector cells
following tumor cell death in comparison between CD8+BTLA+ and CD8+BTLAsubsets at an effector-to-target ratio of 1:1. Statistical significance was determined
using a log-rank. (N= 3319) (*P<0.05).
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Discussion
Previous knowledge indicates that more differentiated T lymphocytes are more
potent at performing effector function, suggesting that CD8+BTLA- subset (more
differentiated T cell) might be endowed with better tumor killing capacity as compared
to the CD8+BTLA+ counterpart. However, we observed comparable in vitro tumor
killing capacity between these two subsets regardless of tumor antigen recognition
ability. A recent report showed that the BTLA blockade in γδ T cells had no effect on
tumor killing (215). Because we did not observe difference in killing capacity between
these two subset, we thus further examined the potency of in vivo tumor burden control
using NSG mouse model. We observed that the CD8+BTLA+ TIL subset was
significantly more potent at controlling in vivo tumor growth than its CD8+BTLAcounterpart. In addition, we found that CD8+BTLA+TIL tended to persist longer
following adoptive transfer. This finding is in accordance with our clinical observation
indicating that CD8+BTLA+TIL persisted longer following TIL transfer (141).
Discerning the difference between the two BTLA subsets required to carry out
the killing assay for a long period of time (8h) and looking at the fate of both T cells
and tumor cells. Utilizing Timelapse Imaging Microscopy In Nanowell Grids
(TIMING), we demonstrated that CD8+BTLA+ TIL subset has a heightened capability
of killing multiple tumor targets through enhanced T cell survival. This finding
provides a rationale for the improved in vivo efficacy of the CD8+BTLA+ TIL subset.
We previously demonstrated that CD8+BTLA+ TIL subset has superior
mitochondrial function and spare respiratory capacity (SRC) as compared to its
CD8+BTLA- counterpart. It has been shown that memory CD8+ T cells manifested high
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SRC with increased number of mitochondria, which is distinct from naïve and effector
T cell subset (216). This unique bioenergetic attribute was shown to play a role in cell
survival and establishment of the memory T cell pool.
Overall, our findings suggest that BTLA signaling itself might not affect the
tumor killing capability. In fact, the intrinsic attributes of the less differentiated
phenotype of the BTLA+ subset provide a pro-survival signal enhancing the “serial
killing” capacity.
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CHAPTER 4

Functional study of B and T lymphocyte attenuator in murine model
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4.1 Rationale and Hypothesis
BTLA is well characterized as an inhibitory molecules belonging to the Ig
superfamily. Its cytoplasmic domains composes of three motifs (Grb2, ITIM, and
ITSM), which are highly conserved between mouse and human. As mentioned before
the inhibitory role of ITIM and ITSM motifs of BTLA through recruitment of SHP1/2
is well documented (186, 189, 192, 207). BTLA also contains the Grb2 motif, which
also exists as a cytoplasmic motif in CD28. It is known that Grb2 motif contributes to
CD28 signaling pathway to promote T cell proliferation. However, the function of the
Grb2 motif of BTLA has not been addressed. Evidence suggest that it might transduce
a positive signal. An in vitro binding assay first demonstrated the potential interaction
of the Grb2 binding motif with the Grb2 adaptor protein and the p85 subunit of
phosphatidylinositol 3-kinase (p85 PI3K). Moreover gene expression analysis of
mouse T cells following activation of anti-CD3 and anti-BTLA demonstrated a highly
overlapping transcription profile with that produced by anti-CD3 in combination with
positive co-stimulators but not inhibitory molecules (192).
We hypothesize that the Grb2 motif might exert positive signal that could
contribute to BTLA’s function besides transducing an inhibitory signal from
ITIM and ITSM motifs. Previous studies demonstrated that BTLA inhibited T cell
function by suppressing effector cytokine production and cell proliferation upon TCR
triggering. Thus far, no study has focused on comprehensively understanding BTLA
signaling on CD8 T cell function in both human and murine setting.
In this study, we generated retroviral constructs containing wild type BTLA
(WT BTLA), BTLA with inactivating mutation of ITIM and ITSM motifs (∆ITSM),
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and BTLA with an activating mutation of Grb2 motif (∆Grb2), and overexpressed those
constructs in BTLA knockout OT.1 mouse T cells (BTLA-KO-OT.1). To dissect the
function of BTLA, we performed tumor killing assays to investigate the role of BTLA
in mediating cytotoxic function. In addition, we also evaluated intracellular effector
cytokine production and secretion during antigen re-stimulation using either dendritic
cells pulsed with OVA peptide or anti-mouse CD3 with HVEM-Fc fusion protein.
Furthermore, we assessed the impact of BTLA signaling on the T cell proliferation
induced upon antigen re-stimulation using dendritic cells pulsed with OVA peptide to
determine proliferative capacity following T cell re-stimulation.
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4.2 Results
Generation of retroviral vectors containing wild type BTLA and BTLA mutants
for functional study using BTLA-KO-OT.1 mouse T cells.
The functional role of BTLA signaling motifs remains understudied; therefore, site
directed mutagenesis was conducted to inactivate BTLA signaling motifs. This was
achieved by substitution of tyrosine for phenylalanine in the two different motifs of
WT BTLA cytoplasmic tail to generate two different BTLA mutants; the Grb2 mutant
∆Grb2 (Y245F) and the ITIM and ITSM mutant ∆ITSM (Y274 and Y299F) (Figure
4.1A). We utilized pRVKM retroviral vector with GFP reporter as a gene delivery
system to overexpress WT BTLA or its mutants in BTLA-KO-OT.1 mouse T cells
(Figure 4.1B). Briefly, the splenocytes of BTLA-KO-OT.1 mouse were stimulated
with anti-mouse CD3. After 24 hours, the cells were transduced with the retroviruses
containing either WT BTLA or the inactivating mutations of BTLA. On day 3, GFP+
T cells were sorted and expanded for 7 days prior to functional studies (Figure 4.1C).
Comparable expression of BTLA was observed in BTLA WT and its mutants (Figure
4.1D)
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Figure 4.1. Generation of retroviral vector containing wild type BTLA and
inactivating mutations of BTLA for functional study using BTLA-KO-OT.1
mouse model.
Substitutions of tyrosine for phenylalanine in three different motifs of the cytoplasmic
tail of BTLA generated 2 mutant constructs; the Grb2 mutant ∆Grb2 (Y226F), as well
as the ITIM and ITSM mutant ∆ITSM (Y274 and Y299F) (A) Schematic diagram
depicts the structure of BTLA WT (Top), BTLA ∆Grb2 (middle), and BTLA ∆ITSM
(bottom). (B) Schematic diagram demonstrates the pRVKM retroviral construct
containing GFP and BTLA genes (left). Signaling motifs with Tyrosine and
Phenylalanine are indicated in blue and red respectively (right). (C) Schematic diagram
depicts viral transduction and generation of BTLA-KO-OT.1 mouse T cells
overexpressing either BTLA or its mutants. (D) Histogram plots showing BTLA
expression in BTLA-KO-OT.1 mouse T cells. The cells were gated on GFP positive
and AQUA negative cells (live cells). BTLA WT (Yellow), BTLA ∆Grb2 (Green), and
BTLA ∆ITSM (Blue) positive cells, were gated using empty vector controls (tinted
red).
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BTLA signaling motifs have no effect on tumor killing capacity.
Our previous result unveiled that the CD8+BTLA+ TIL subset have superior survival
benefit following tumor target killing as opposed to CD8+BTLA- subset therefore is
able to repeatedly mediate killing of additional tumor targets. This superior serial
killing attribute can result from either 1) properties of less-differentiated T cell
phenotype or 2) BTLA signaling itself. We set out to further determine whether BTLA
signaling pathway might be involved in the superior killing capacity. Here, we
conducted in vitro assays using murine T lymphocytes and B16 melanoma tumor cells,
which express high levels of HVEM (Figure 4.2A and B).

111

A

B

Figure 4.2. Expression level of HVEM in B16 melanoma cell lines.
Histogram plots showing HVEM expression in (A) B16 OVA and (B) B16F10 mouse
melanoma tumor cells. Live tumor cells were defined as AQUA negative. HVEM
positive cells (red) were gated using FMO controls (tinted gray).
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Virally transduced BTLA-KO-OT.1 mouse T cells overexpressing of WT
BTLA, BTLA with mutation of the Grb2 motif (∆Grb2), BTLA with mutation of ITIM
and ITSM motifs (∆ITSM), or empty vector control (EM) were incubated with either
B16F10 (negative for OVA antigen) or B16OVA cells (positive for OVA antigen) that
were labeled with efluor 670 at an effector to target ratio of 1:1, 1:3, and 1:10. After
three hours, apoptotic tumor cells were determined by intracellular staining for cleaved
capase-3. We found comparable levels of OVA-specific tumor killing regardless of the
presence of WT BTLA or BTLA mutants (T cell: B16OVA, ratio 1:1, P=0.67; ratio
1:3, P=0.46; ratio 1:10, P=0.29; T cells: B16F10; ratio 1:1, P= 0.43; ratio 1:3, P=0.69;
ratio 1:10, P=0.47) (Figure 4.3).
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Figure 4.3. In vitro tumor killing capacity of BTLA-KO-OT.1 mouse T cells
overexpressing of WT BTLA and it mutants.
B16 OVA (mouse melanoma tumor positive for OVA) or B16F10 (mouse melanoma
tumor negative for OVA) were stained with eFluor670® and co-cultured with OT-1
BTLA KO T cells overexpressing WT BTLA or BTLA mutants at the following T cellto-tumor cell ratios (1:10, 1:3, and 1:1). Tumor cell death is depicted by the percentage
of caspase-3 positive cells. N=3 independent experiments.
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Decrease in TNF-α production in BTLA-KO-OT.1 mouse T cells overexpressing
WT BTLA or its mutants.
Because we found the comparable in vitro killing tumor capacity of BTLA-KO-OT.1
mouse T cells regardless of BTLA expression, we sought to determine whether
overexpression of WT BTLA or its mutants could affect effector cytokine production.
In this experiment, we re-stimulated virally transduced T cells overexpressing WT
BTLA or its mutants with either dendritic cells alone or pulsed with OVA peptide at an
effector to target ratio of 1 to 40. After five hours, the cells were intracellularly stained
with IFN-γ and TNF-α. We found almost all effector T cells produced IFN-γ and TNFα, and comparable percentage of the effector T cells that produced IFN-γ and TNF-α
was observed (% of IFN-γ positive cells; P=0.11, % of TNF-α positive cells; P=0.59)
(Figure 4.4A). However, the quantity of effector cytokines being made by WT BTLA
was significantly less than that produced by BTLA negative cells (empty vector) alone
when re-stimulated with dendritic cells pulsed with OVA peptide (IFN-γ MFI; EM vs
WT, P=0.04, TNF-α MFI; EM vs WT, P=0.0045) (Figure 4.4B). This suggests that
BTLA signaling negatively impacts effector cytokine production. The suppressive
effect of BTLA was completely reverted by the inactivation of ITIM and ITSM motifs,
which implies that those motifs are responsible for the BTLA-mediated decrease in
IFN-γ and TNF-α effector cytokines upon TCR activation.
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Figure 4.4. Decrease in TNF-α production in BTLA-KO-OT.1 mouse T cells
overexpressing of WT BTLA and it mutants.
OT-1 BTLA KO T cells overexpressing WT BTLA or its variants were re-stimulated
with dendritic cells pulsed with OVA peptide. TNF-α and IFN-γ production by virally
transduced OT-1 BTLA KO T cells was evaluated by intracellular staining. Bar graph
depicts the percentage of positive cells (A) and mean fluorescence intensity (MFI) (B).
Each bar represents three independent experiments. (Two-way ANOVA; *P<0.05).
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BTLA signaling motifs affect T cell proliferation.
We have previously demonstrated that CD8+BTLA+TIL are more proliferative in
response to IL-2 and less differentiated. It has been shown that less differentiated T
cells were more metabolically active and superior in proliferative capacity. However
several studies have demonstrated that BTLA inhibited T cell proliferation upon
ligation with HVEM. It was shown that both ITIM and ITSM motifs were required for
the full function of BTLA to inhibit T cell proliferation and cytokine production
including IFN-γ, IL-2, and IL-10 (193, 217). A recent report indicated that the PD-1
receptor, which consisted of ITIM and ITSM motif, selectively inhibited the Akt and
Ras-MEK-ERK pathways. So far, it remains inconclusive whether BTLA utilizes a
similar mechanism as PD-1 to inhibit T cells as ITIM and ITSM motifs are commonly
shared between these two receptors. Thus, we sought to further determine whether
BTLA signaling motifs could play a role in proliferation of CD8+ TIL. BTLA-KOOT.1 T mouse cells overexpressing BTLA WT or its mutants were labeled with the cell
proliferation dye efluor670® and re-stimulated with dendritic cells pulsed with OVA
peptide for two days. Upon re-stimulation with dendritic cells pulsed with the cognate
peptide most T cells underwent proliferation. However, subtle differences are
appreciable between T cells expressing the different BTLA constructs. We observed
that BTLA-KO-OT.1 mouse T cells expressing a non-functional inhibitory domain
(∆ITSM) had lower mean intensity of fluorescence (MFI) as compared with empty
vector control (MFI: ∆ITSM versus EM; P=0.012, ∆ITSM versus WT; P=0.0057)
(Figure 4.5A and B). WT BTLA and EM control showed comparable proliferation as
no significantly different MFI was observed (MFI: WT versus EM; P=0.30). On the
contrary, attenuation of T cell proliferation was observed in T cells expressing a
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disrupted Grb2 domain (∆Grb2), (MFI: ∆Grb2 versus ∆ITSM; P=0.0003, ∆Grb2 versus
EM; P=0.0008, ∆Grb2 versus WT; P= 0.0009) (Figure 4.5A and B). Our findings
suggests that Grb2 motif plays a role in enhancing cell proliferation, while ITIM and
ITISM motif suppress the proliferative capacity of T cells.
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Figure 4.5. ITIM and ITSM motifs of BTLA attenuated T cell proliferation.
OT-1 BTLA KO T cells overexpressing WT BTLA or its variants were labeled with
eFluor670® and re-stimulated with dendritic cells pulsed with OVA peptide. Cell
proliferation was determined by the dilution of eFluor670®. (A) Histogram plots of
eFluor670® demonstrate proliferation of OT-1 BTLA KO T cells overexpressing WT
BTLA or its variants. (B) Bar graph depicts MFI of virally transduced T cells in the
same experiment shown in the left panel. N=3 *P <0.05, **P <0.001, ***P<0.0001.
All error bars depicts the mean ± s.e.m. All P-values were calculated using a two-tailed
Student’s t-test.
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Grb2 motif of BTLA enhanced IL-2 production.
Our previous study demonstrated that CD8+BTLA+TIL subset had increased
proliferative capacity due to enhanced IL-2 responsiveness (141). In mouse CD4+T
cells, however, it has been shown that engagement of BTLA and HVEM suppressed
cytokine production including IFN-γ, IL-2, and IL-10 (193). Thus far, the role of BTLA
in cytokine production of CD8 T cells remains unclear. To further investigate whether
BTLA signaling motifs might affect the cytokine production, we overexpressed in OT1 BTLA KO T cells the WT BTLA or its mutants, and re-stimulated with anti-CD3 in
the presence of HVEM-Fc fusion protein to engage the BTLA molecules. The
supernatants were collected after 24 hours to assess the cytokine secretion using a
MILLPLEX multiplex assay.
When ∆Grb2 T cells were re-stimulated with anti-CD3 and HVEM, we found
a significant decrease in GM-CSF, IL-6, and IL-10 production as compared with empty
vector control (GM-CSF; P=0.0004, IL-6; P=0.02, IL-10; P=0.002), but we did not
observe a significant increase in these cytokines in ∆ITSM T cells when compared with
empty vector control (GM-CSF; P=0.30, IL-6; P=0.72, IL-10; P=0.59) (Figure 4.6A).
The only cytokine induced to high levels by the introduction of BTLA was IL2. The BTLA-dependent IL-2 production was abrogated by the inactivating mutation
of Grb2 but unaffected by the inactivating mutations to ITIM/ITSM (WT versus EM;
P=0.02, ∆ITSM versus EM; P=0.005, WT versus ∆Grb2; P=0.02, ITSM versus∆ Grb2;
P=0.01, EM versus Grb2; P=0.79, WT versus ∆ITSM; P=0.32) (Figure 4.6B). Our
data show that BTLA signaling augments the TCR-driven IL-2 production and
highlight that Grb2 signaling on BTLA significantly contributes to the IL-2 production
following BTLA ligation during T cell activation.
120

A

B

Figure 4.6. Grb2 motif of BTLA augment IL-2 production upon HVEM ligation.
Virally transduced OT-1 BTLA KO T cells were stimulated with plate-bound antimouse CD3 and HVEM Fc. Supernatants were assessed for cytokine production
including (A) GM-CSF, IL-6, IL-10, and (B) IL-2 using by MILLIPEX MAP Mouse
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CD8+ T Cell Magnetic Bead Panel Assays. Each bar graph represents two independent
experiments. *P <0.05, **P <0.001. All error bars depicts the mean ± s.e.m. All Pvalue were calculated using a two-tailed Student’s t-test.
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Discussion
It is known that ITIM and ITSM signaling motifs are required for BTLA to
inhibit T cell function through the recruiting of phosphatases, SHP-1 and -2. Evidence
suggests that Grb2 motif of BTLA might transduce positive signal as an in vitro binding
assay demonstrated an interaction between Grb2 and p85 subunit of PI3K, suggesting
it may happen in physiological conditions. Thus far, it remains inconclusive whether
Grb2 motif could play a positive role on T cell function.
Our current study demonstrated that BTLA signaling has no effect on tumor
killing capacity even though subtle decreased in TNF-α and IFN-γ was found in BTLA
WT. In line with these observations, a recent report showing that BTLA blockade did
not improve T cell mediated tumor killing (215). This suggests that BTLA signaling
motif might not be directly involved in killing capacity.
We have shown that inactivated ITIM and ITSM motif ameliorated T cell
proliferation while malfunction of Grb2 decreased T cell proliferation. Interestingly,
we did not observe a significant impact of T cell proliferation when overexpressing
BTLA WT. Previous reports demonstrated that CD8+ T cells were less susceptible to
BTLA-mediated T cell inhibition as compared to CD4+ T cells in both mouse and
human contexts. This may explain our observation of the subtle inhibitory effect of T
cell proliferation when overexpressing BTLA WT.
Intriguingly, our result first unveil the importance of Grb2 motif of BTLA in
CD8+ T cells. We found that the Grb2 motif of BTLA mediates IL-2 secretion and
might not or minimally be affected by SHP1/2-mediated signaling attenuation.
Previous report have shown that Grb2-linked SLP-76 and Vav interaction is involved
in IL-2 production (218). Of note, Grb2 recruitment was found to be critical for CD28
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in mediating IL-2 production. Our work thus demonstrates that BTLA shares features
of a co-stimulatory molecule (CD28) as well as inhibitory properties of checkpoint
regulators such as PD-1 through its ITIM/ITSM motifs.
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CHAPTER 5

Dissecting BTLA signaling pathway in murine T lymphocytes
and human tumor infiltrating lymphocytes (TIL)

125

5.1 Rationale and Hypothesis
Very little is known about the downstream signaling pathways triggered by BTLA.
From its structure it is anticipated that ITIM and ITSM motifs will recruit SHP1 and 2
and that Grb2 binding motif will recruit Grb2, but beyond that much is to be learned.
Several studies demonstrated that ligation of BTLA and HVEM suppressed T cell
proliferation as well as cytokine production such as IL-6, IL-18, and IFN-γ (193, 219).
The downstream signaling protein targets of SHP1 and SHP2 of BTLA are not well
characterized, but it is suggested that protein involved in proximal TCR activation
might be attenuated by BTLA. A recent report has demonstrated that ITIM and ITSM
in PD-1 inhibited cytoplasmic proteins of the cell cycle, Cdk-activating phosphatase
Cdc25A, PI3K-Akt and Ras-MEK-ERK signaling axis, leading to T cell proliferation
inhibition (56). Unlike PD-1, BTLA also harbors Growth factor receptor bound protein
2 (Grb2) motif, commonly shared in co-stimulatory molecules like CD28 with
commonly shared YXN sequence. An in vitro binding assay using synthetic peptide
suggested that Grb2 motif of BTLA could interact with the p85 subunit of PI3K (192,
220). It is known that Grb2 motif of CD28 can activate PI3K-AKT signaling pathway
and result in increased cell proliferation and IL-2 production (218, 221). However, it
cannot be directly extrapolated that Grb2 motif of BTLA would function similar to that
of CD28 as an in vitro biochemical assay binding does not reflect physiological binding
of cellular protein during BTLA-HVEM interaction. Our previous chapter has
demonstrated that mouse BTLA signaling pathway did not affect tumor killing capacity
of T cells, but subtly inhibits TNF-α cytokine and IFN-γ production. In addition, an
increased proliferation of T cells was observed when ITIM and ITSM motifs were

126

disrupted, while inactivated Grb2 motifs attenuated T cell proliferation. We observed
that IL-2 production was enhanced in WT BTLA as well as with an intact Grb2 motif
in the ITIM/ITSM mutant but totally abrogated when a non-functional Grb2 motif was
introduced, indicating that Grb2 motif of BTLA could play a role in IL-2 production
and cell proliferation. Because we have witnessed that Grb2 motif of BTLA exhibited
positive function, we sought to gain a better understanding of the underlying
mechanism that might be responsible for its favorable functions. We hypothesized
that the Grb2 motif could exhibit positive signal(s) that are not targeted by ITIM
and ITSM during HVEM ligation. In this study, we further elucidated the
downstream signaling pathway of BTLA in BTLA-KO-OT.1 mouse T cells
overexpressing WT BTLA and BTLA mutants during TCR activation and HVEM
ligation. We used RPPA (Reverse Phase Protein Array) as a high-through put method
to determine differential changes in protein production as well as protein
phosphorylation. To exclude the bias of the overexpression of WT BTLA and
genetically modified BTLA in BTLA knockout mouse, we also investigated the
downstream signaling pathway of BTLA in non-modified human TIL.

127

5.2 Results
Dissecting downstream signaling pathway of mouse BTLA upon HVEM ligation.
We have previously demonstrated the positive effect of Grb2 motif on T cell
proliferation and IL-2 production. These findings prompted us to further dissect
signaling pathway of BTLA in each signaling motif. We overexpressed WT BTLA and
BTLA mutant for either Grb2 or ITIM and ITSM in BTLA-KO-OT.1 murine T cells.
Empty vector (EM) was used as a control to determine the basal level of CD3 activation
alone. Murine T cells were re-stimulated with plate-bound anti-CD3 with or without
the presence of HVEM-Fusion protein. The cell lysates were harvested for protein
extraction at 12 hours following re-stimulation. We performed Reverse Phase Protein
Array (RPPA), a high-throughput method developed for functional proteomic studies,
to evaluate protein changes in both quantity and phosphorylation status upon TCR
activation either with or without HVEM ligation.
When we compared the differential protein changes in ∆ITSM versus WT BTLA and
∆Grb2 versus WT BTLA, we found that a higher number of the surveyed proteins were
significantly changed in ∆ITSM as opposed to ∆Grb2. (Figure 5.1A) (16 versus 2;
P<0.05). This analysis was complicated by the fact that each mutant construct bears a
mutated (inactivated) motif as well as a functional motif e.g. ∆Grb2 represents the
overexpression of an inactive Grb2 motif along with an active ITIM/ITSM motif while
∆ITSM construct overexpresses an inactive form of ITIM and ITSM paired with a WT
Grb2 motif. We found that the phosphorylation of Akt and a known substrate of AKT,
pPRAS40, were significantly attenuated in ∆Grb2 (pAkt S473; P=0.045, pRAS40
T246; P=0.007) (Figure 5.1B). This suggests that the Akt pathway was targeted by the
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SHP1/2 recruited by the active ITIM/ITSM motif of ∆Grb2 as the net result was a
dephosphorylation of these targets, not likely to be influenced by the effect of the Grb2
motif. In contrast, a remarkable enhancement of the phosphorylation levels of multiple
targets such as of pSrc at S527, Chk1 at S286, Chk2 at T68, GSK-3b at S9, and of BetaCatenin at T41 and S45 were observed in ∆ITSM (pSrc at S527; P=0.005, pA-Raf at
S299; P=0.01, and pC-Raf at S338; P=0.02, pChk1 at S286; P=0.01, pChk2 at T68;
P=0.02, GSK-3b at S9; P=0.04, Beta-Catenin at T41 and S45; P=0.04) (Figure 5.1C).
An increased number of phosphorylated proteins in ∆ITIM and ITSM is likely to
mainly be due to the defect in recruitment of SHP1 and SHP2 into BTLA cytoplasmic
domain caused by the disruption of ITIM and ITSM motifs rather than to the presence
of the functional Grb2 motif. To further elucidate whether increased phosphorylation
levels of specific targets are due solely to the presence of the Grb2 motif rather than to
the deficient ITIM and ITSM motifs, we then compared differential protein changes in
∆ITSM (which bears an intact Grb2 motif) versus EM (No BTLA) to isolate the effect
of Grb2 on the TCR stimulation alone. We found that only pSrc at S527 and JNK2
were remarkably higher in ∆ITSM (Figure5.1D). This indicated that those two
downstream signaling molecules may be activated through the Grb2 motif and may not
be targeted by SHP1 and SHP2. The list of differential protein changes with the
following comparisons; ∆Grb2 versus WT, ∆ITSM versus WT, and ∆ITSM versus EM
is demonstrated in Table 1.
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Figure 5.1. Dissecting downstream signaling pathway of mouse BTLA upon
HVEM ligation.
OT-1 BTLA KO T cells overexpressing WT BTLA or its variants were re-stimulated
with plate-bound anti-CD3 and HVEM-Fc for 8 h prior to harvest. Cells were lysed and
the protein supernatant was collected to perform RPPA. (A) Bar graph depicts the
differential protein expressions with the following comparisons: ∆Grb2 versus WT
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(red) and ∆ITSM versus WT (blue). Volcano plots depicts fold changes of proteins
with the following comparisons: ∆ITSM versus EM (B) ∆Grb2 versus WT (C), and
∆ITSM versus WT (D). Data shown represent two independent experiments. P <0.05.
P-value were calculated using Linear models and empirical Bayes methods.
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Table 1. Differentially expressed proteins in OT-1 mouse T cells overexpressing
either WT BTLA or BTLA mutant re-stimulated with CD3 and HVEM Fc fusion
protein at 8 h.
Table demonstrates the list of differential protein changes with the following
comparisons; ∆Grb2 versus WT, ∆ITSM versus WT, ∆ITSM versus EM. Data shown
represent two independent experiments. P <0.05. P-value were calculated using Linear
models and empirical Bayes methods.
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Table 1. Differentially expressed proteins in OT-1 mouse T cells overexpressing
either WT BTLA or BTLA mutant re-stimulated with CD3 and HVEM Fc
fusion protein at 8 h.

Log fold change

P-value

-1.0537676
-0.2976067
-0.2667402
-0.3295237
-0.4283460
0.1131972
-0.4439703
0.1775591
-0.5434096
-0.3454098

5.836064e-05
7.643870e-03
1.815897e-02
1.889904e-02
1.969070e-02
3.083201e-02
3.552049e-02
4.003768e-02
4.322444e-02
4.509359e-02

-1.09610694
0.77592249
0.25530383
0.32602047
0.52531068
0.36285815
0.34757270
0.35131897
-0.20031315
-0.59051723
-0.15537524
0.28491931
0.32200036
0.19753223
0.59568985
-0.23145741
0.19658953
-0.13128423
-0.16554607
0.27087240
-0.13505418
-0.14721028
-0.19768054
0.14868332

4.178212e-05
3.194537e-04
2.185063e-03
2.216354e-03
2.539887e-03
5.045994e-03
1.207815e-02
1.222602e-02
1.257107e-02
1.298821e-02
1.530438e-02
1.675901e-02
1.787957e-02
2.076754e-02
2.429322e-02
2.537912e-02
2.590506e-02
2.918579e-02
2.927126e-02
2.956589e-02
3.098111e-02
3.312001e-02
3.388986e-02
3.679310e-02

∆Grb2 versus WT
PI3K-p110-alpha-R-C_GBL1115582
PRAS40_pT246-R-V_GBL1115574
MIF-R-C_GBL1116364
AMPK-alpha-R-C_GBL1115509
EGFR-R-V_GBL1115620
Hif-1-alpha-M-C_GBL1116504
TFAM-R-V_GBL1116333
C-Raf_pS338-R-V_GBL1115523
YB1-R-V_GBL1115569
Akt_pT308-R-V_GBL1116492
∆ITSM versus WT
PI3K-p110-alpha-R-C_GBL1115582
RBM15-R-V_GBL1115629
Raptor-R-V_GBL1115625
Gys-R-V_GBL1116482
Stat3-R-C_GBL1116311
Src_pY527-R-V_GBL1115563
Gys_pS641-R-V_GBL1115603
LDHA-R-C_GBL1115596
FAK_pY397-R-V_GBL1116461
YB1_pS102-R-V_GBL1115584
Bcl2A1-R-V_GBL1116330
Chk1_pS296-R-V_GBL1116335
A-Raf_pS299-R-C_GBL1115605
Chk2_pT68-R-C_GBL1115522
ATM_pS1981-R-V_GBL1116464
SDHA-R-V_GBL1116334
C-Raf_pS338-R-V_GBL1115523
CD31-M-V_GBL1116506
Pdcd4-R-C_GBL1115583
PKC-delta_pS664-R-V_GBL1115593
ATR-R-C_GBL1115590
UQCRC2-M-C_GBL1116412
HER2_pY1248-R-C_GBL1115612
Mitochondria-M-V_GBL1116387
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Table 1 (continued). Differentially expressed proteins in OT-1 mouse T cells
overexpressing either WT BTLA or BTLA mutant re-stimulated with CD3 and
HVEM Fc fusion protein at 8 h.
∆ITSM versus WT
GSK-3b_pS9-R-V_GBL1115615
Jak2-R-V_GBL1116307
b-Catenin_pT41_S45-RV_GBL1116494
CDK1-R-V_GBL1115598
∆ITSM versus EM
PI3K-p110-alpha-R-C_GBL1115582
Raptor-R-V_GBL1115625
Gys-R-V_GBL1116482
RBM15-R-V_GBL1115629
b-Catenin_pT41_S45-RV_GBL1116494
Notch3-R-C_GBL1116354
Vimentin-M-C_GBL1116421
Stat5a-R-V_GBL1115565
MMP2-R-V_GBL1115540
YB1_pS102-R-V_GBL1115584
ACC_pS79-R-V_GBL1115507
Src_pY527-R-V_GBL1115563
PLK1-R-C_GBL1115575
GCN5L2-R-V_GBL1116463
JNK2-R-C_GBL1116442

Log fold change
0.12487282
-0.13055136

P-value
4.193362e-02
4.349372e-02

0.35325496

4.731829e-02

0.36169900

4.952413e-02

-0.7194512
0.2645821
0.3146227
0.5571886

0.001134154
0.001720536
0.002795612
0.003298385

0.5471095

0.005618371

-0.2137534
-0.3850135
-0.2380353
-0.2629724
-0.4568981
0.1714040
0.2308867
0.1276333
-0.1807406
0.1424863

0.007785951
0.034672688
0.040673318
0.040863077
0.042068010
0.043934614
0.046698220
0.049231222
0.049610757
0.049987949
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BTLA-HVEM axis in human TIL selectively suppresses MAPK, Akt, and NF-kB
pathways, but enhances Src pathway.
Thus far, our data uncovered the positive role of the Grb2 motif of BTLA in mouse T
cells in contributing to T cell proliferation and IL-2 production. In addition, RRPA
analysis in mouse suggested that Grb2 motif signals through Src at pY527 as a
significantly increased level of this phosphorylated protein was present in ∆ITSM when
compared with both WT and EM. On the other hand, we found that Akt at pT308 and
PRAS40, proteins in Akt signaling pathway, were suppressed when Grb2 was mutated
as compared to WT BTLA. This suggested that ITIM and ITSM motifs do not suppress
all downstream signaling pathways. It has been shown that mouse BTLA signaling
motifs are highly conserved with human BTLA. Overexpressing WT BTLA and BTLA
mutants allowed us to dissect BTLA signaling at each BTLA motifs. However,
downstream signaling pathway of genetically modified BTLA in BTLA might not be
physiologically relevant to human T cell signaling pathway. To exclude the bias of
BTLA KO mouse T cells, we further investigated BTLA signaling pathway in human
BTLA TIL, which is more clinically relevant to our observation in favorable clinical
outcome of TIL treated patients with high proportion of CD8+BTLA+ TIL subset.
In this study, we sorted the CD8+BTLA+ human TIL subset from five cultured human
TIL lines (pre-REP) isolated from melanoma patients treated at M.D. Anderson Cancer.
Because TIL from different patients might be variable in their susceptibility to TCR
activation, and because the strength of TCR activation could lead to different signaling
outcome, we then stimulated with increasing concentration of plate-bound anti-human
CD3 at concentrations of 10, 30, 100, 300, and 1000 ng alone or in the presence of
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HVEM-Fc, to look at TCR activation with or without BTLA engagement. After
activation for two hours, proteins were extracted from the cell lysates, and used to
perform RPPA to determine the differential proteins expression in both quantity and
phosphorylation status upon T cell activation.
We observed a general decrease in phosphorylation levels of proteins phosphorylated
in response to TCR engagement in the presence of HVEM-Fc. We found that the
MAPK kinase pathway (pP38 at T180; P=2.08 x 10-9, pP90RSK at T573; P=3.26 x 104

, pS6 at S235; P= 1.68x10-2), NF-Kb pathway (pNF-Kb p65 at S536; P=3.15 x 10-2),

the mTOR pathway (pP70-6K at T389; P=1.7 x 10-4), the Akt pathway (pAKT at S473;
P=9.6x10-3), the JNK pathway (pC-Jun at S73; P= 9.38x10-3 ), and the Beta-catenin
pathway (GSK-3a-b pS21; P=9.6x10-3) were significantly decreased in HVEM in
comparison to CD3 activation alone. (Figure 5.2A). Inhibition of these positive
signaling pathways clearly supported the role of BTLA as a co-inhibitory molecule.
Consistent with downstream targets of PD-1, we also found that AKT and MAPK
pathways were attenuated in BTLA. However activation of specific signaling pathways
were also observed when T cell activation happened in the presence of HVEM.
Interestingly, we found that the Src signaling pathway was activated due to an increase
in pSrc at S416 during HVEM ligation (pSrc at S416; P= 3.36 x 10-6) (Figure 5.2A).
Our results suggest that the TCR signaling pathway is not completely suppressed by
BTLA, but is specifically attenuated in certain pathways as indicated above and
specifically potentiated in very select pathways. Unexpectedly, we found that
phosphorylation of HER2 at tyrosine 1248 was prominently increased in an anti-CD3
dose-dependent manner regardless of the presence of HVEM (Figure 5.2B and C).
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This strengthens the notion that not all proteins are affected by the BTLA and HVEM
signaling axis. To further comprehensively understand the downstream signaling
pathway of human BTLA, we mapped a signaling network with Ingenuity pathway
analysis (IPA) utilizing the proteins that were differentially expressed during HVEM
ligation (Figure 5.2D). We observed that Src signaling node was exclusively separated
from Akt, mTOR, and NF-kB pathway nodes (Figure 5.2E). This likely suggests that
some downstream signals from the Grb2 motif and TCR activation are likely not
interfered by SHP1/2. The list of differential protein changes in with the following
comparisons; CD3+HVEM versus CD3 alone (Dose 100), CD3+HVEM versus CD3
alone (Dose300), CD3+HVEM versus CD3 alone (Dose1000), CD3 alone (Dose 0
versus 30), CD3 alone (Dose 0 versus 100), CD3 alone (Dose 0 versus 300), CD3 alone
(Dose 0 versus 1000), CD3+HVEM (Dose 0 versus 30), CD3+HVEM (Dose 0 versus
100) CD3+HVEM (Dose 0 versus 300) CD3+HVEM (Dose 0 versus 1000) is
demonstrated in the Table 2 A, B, and C.
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Figure 5.2. BTLA-HVEM axis in human TIL selectively suppresses Akt, and
NF-kB pathways, but enhances Src pathway.
Sorted CD8+BTLA+ TIL were stimulated with plate-bound anti-CD3 at following
concentrations (0, 10, 30, 100, 300, and 1000 ng/ml) alone or with HVEM-Fc for 8 h
prior to harvest. Cells were lysed and the protein supernatant was collected to perform
RPPA. Volcano plot depicts fold changes of proteins in CD8+BTLA+TIL upon T cell
activation with (A) anti-CD3 alone, (B) anti-CD3 + HVEM, and (C) anti-CD3 in
comparison with anti-CD3 + HVEM. (D) Bar graph demonstrates proteins that
significantly change in comparison between anti-CD3 activation alone (red) and antiCD3 + HVEM ligation (blue). (E) Signaling network from the proteins that
significantly change in (D) were clustered by Ingenuity Pathway Analysis. N=5, P
<0.05. P-value were calculated using Linear models and empirical Bayes methods.
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Table 2. Differentially expressed proteins in CD8+BTLA+TIL re-stimulated with
either CD3 or CD3 and HVEM at concentration of 0, 30, 100, 300, and 100 at 8 h

Table demonstrates the list of differential protein changes in with the following
comparisons; CD3+HVEM versus CD3 alone (Dose100), CD3+HVEM versus CD3
alone (Dose300), CD3+HVEM versus CD3 alone (Dose1000), CD3 alone (Dose 0
versus 30), CD3 alone (Dose 0 versus 100), CD3 alone (Dose 0 versus 300), CD3 alone
(Dose 0 versus 1000), CD3+HVEM (Dose 0 versus 30), CD3+HVEM (Dose 0 versus
100) CD3+HVEM (Dose 0 versus 300) CD3+HVEM (Dose 0 versus 1000). Data
shown represent five TIL lines. N=5, P <0.05. P-value were calculated using Linear
models and empirical Bayes methods.
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Table 2A. Differentially expressed proteins in CD8+BTLA+TIL re-stimulated with
either CD3 or CD3 and HVEM at concentration of 0, 30, 100, 300, and 100 at 8 h

CD3+HVEM versus CD3 alone
(Dose100)
GPBB.R.V_GBL1122116
p38_pT180_Y182.R.V_GBL1121998
CD3+HVEM versus CD3 alone
(Dose300)
p38_pT180_Y182.R.V_GBL1121998
NF.kB.p65_pS536.R.C_GBL1121996
CD3+HVEM versus CD3 alone
(Dose1000)
p38_pT180_Y182.R.V_GBL1121998
PKC.b.II_pS660.R.V_GBL1122088
YB1_pS102.R.V_GBL1122037
p90RSK_pT573.R.C_GBL1122101
Bad_pS112.R.V_GBL1121957
Hif.1.alpha.M.C_GBL1122215
Src_pY416.R.V_GBL1122013
c.Jun_pS73.R.V_GBL1122272
GSK.3a.b_pS21_S9.R.V_GBL1122282
Akt_pS473.R.V_GBL1122267
S6_pS235_S236.R.V_GBL1122011
CD3 alone (Dose 0 versus 30)
HER2_pY1248.R.C_GBL1122070
CD3 alone (Dose 0 versus 100)
HER2_pY1248.R.C_GBL1122070
GPBB.R.V_GBL1122116
CD3 alone (Dose 0 versus 300)
HER2_pY1248.R.C_GBL1122070
p38_pT180_Y182.R.V_GBL1121998
p16INK4a.R.V_GBL1122112
HES1.R.V_GBL1122148
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Log fold change

P-value

0.8555653
-0.4030583

0.01800838
0.03829165

-0.6544899
-0.9045702

5.908173e-05
3.154015e-02

-1.0040382
-0.4154961
-0.5119427
-0.5823908
-0.3764103
-0.2835044
0.3219323
-0.3778729
-0.6958194
-0.4338686
-0.8881963

2.089641e-09
3.921504e-05
3.268774e-04
3.268774e-04
7.738640e-04
3.368133e-03
3.368133e-03
9.382127e-03
9.619107e-03
9.619107e-03
1.685525e-02

0.4855243

4.248393e-09

0.3855653
-0.8828316

1.438851e-06
1.188161e-02

0.3577353
0.6541823
-0.2825169
-0.2216701

7.798521e-06
2.982066e-05
2.159478e-02
2.631820e-02

Table 2B. Differentially expressed proteins in CD8+BTLA+TIL re-stimulated with
either CD3 or CD3 and HVEM at concentration of 0, 30, 100, 300, and 100 at 8 h

CD3 alone (Dose 0 versus 1000)
p38_pT180_Y182.R.V_GBL1121998
HER2_pY1248.R.C_GBL1122070
p90RSK_pT573.R.C_GBL1122101
FAK.R.C_GBL1121979
YB1_pS102.R.V_GBL1122037
Bad_pS112.R.V_GBL1121957
HER2.M.V_GBL1122226
Akt_pS473.R.V_GBL1122267
S6_pS235_S236.R.V_GBL1122011
p16INK4a.R.V_GBL1122112
Src_pY416.R.V_GBL1122013
PKC.b.II_pS660.R.V_GBL1122088
Hif.1.alpha.M.C_GBL1122215
MEK1_pS217_S221.R.V_GBL1122071
c.Jun_pS73.R.V_GBL1122272
Bid.R.C_GBL1122269
Pdcd4.R.C_GBL1122036
GSK.3a.b_pS21_S9.R.V_GBL1122282
FAK_pY397.R.V_GBL1122111
Annexin.VII.M.V_GBL1122204
p70.S6K_pT389.R.V_GBL1122001
MEK1.R.V_GBL1122290
Cox2.R.C_GBL1122107
Myosin.IIa_pS1943.R.V_GBL1122096
Myosin.11.R.V_GBL1122090
MCT4.R.V_GBL1122301
Chk1_pS345.R.C_GBL1122046
HER3.R.V_GBL1122170
MEK2.R.V_GBL1122113
Rictor_pT1135.R.V_GBL1122087
MIG6.M.V_GBL1122201
CD31.M.V_GBL1122218
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Log fold change

P-value

1.0757191
0.4240169
0.7340010
0.4678432
0.5055596
0.3991817
0.6678777
0.5425173
1.1279666
-0.3265606
-0.3429326
0.3052046
0.2850831
0.2810258
0.3869022
-0.2585016
0.3287594
0.6531518
-0.3464483
0.3889564
0.2603769
-0.1943432
-0.1705135
-1.3589428
-0.2640302
-0.2318147
0.2649744
-0.1859548
-0.1887894
0.2460314
-0.1615994
0.1874872

3.002318e-10
7.277417e-08
5.278553e-06
1.294449e-04
2.426017e-04
2.426017e-04
2.426017e-04
5.814298e-04
8.810221e-04
8.810221e-04
8.810221e-04
1.206663e-03
1.464922e-03
2.243427e-03
3.748423e-03
4.012587e-03
5.809354e-03
1.033092e-02
1.706239e-02
1.706239e-02
1.706239e-02
1.706239e-02
2.006613e-02
2.242156e-02
2.659773e-02
3.155032e-02
3.529039e-02
3.995997e-02
4.325005e-02
4.366397e-02
4.856163e-02
4.856163e-02

Table 2C. Differentially expressed proteins in CD8+BTLA+TIL re-stimulated with
either CD3 or CD3 and HVEM at concentration of 0, 30, 100, 300, and 100 at 8 h

CD3+HVEM (Dose 0 versus 30)
HER2_pY1248.R.C_GBL1122070
Rab11.R.E_GBL1122074
EGFR_pY1068.R.C_GBL1122278
CD3+HVEM (Dose 0 versus 100)
HER2_pY1248.R.C_GBL1122070
CD3+HVEM (Dose 0 versus 300)
HER2_pY1248.R.C_GBL1122070
LC3A.B.R.C_GBL1122300
Dvl3.R.V_GBL1122051
HES1.R.V_GBL1122148
Cyclin.E1.M.V_GBL1122219
E.Cadherin.R.V_GBL1122077
CD3+HVEM (Dose 0 versus 1000)
HER2_pY1248.R.C_GBL1122070
FAK.R.C_GBL1121979
p16INK4a.R.V_GBL1122112
LC3A.B.R.C_GBL1122300
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Log fold change

P-value

0.3899450
-0.2834234
0.5953123

1.105288e-06
1.713254e-04
3.704580e-02

0.3146506

0.000110571

0.4133938
-0.4248823
0.3864097
-0.2175110
-0.5887974
0.3640928

2.725237e-07
7.798027e-03
2.657925e-02
3.269281e-02
3.810823e-02
4.438662e-02

0.3735338
0.4586727
-0.2893436
-0.3517036

2.979160e-06
3.676352e-04
1.604959e-02
4.125150e-02

Discussion

BTLA is a unique co-stimulatory molecule that contains both positive (Grb2)
and negative (ITIM and ITSM) signaling motifs. Although a previous study
demonstrated that Grb2 displayed potential interaction with Grb2 and p85 subunit of
PI3K, downstream signaling pathway of BTLA remains under investigation.
Because we have shown that Grb2 motif enhanced IL-2 production and T cell
proliferation, we then sought to gain in depth in downstream signaling pathway in both
human and mouse CD8+T cells. When we compared differential protein expression of
BTLA mutants (∆Grb2 and ∆ITIM and ITSM) using WT as a reference, we observed
that Akt signaling was remarkably suppressed when Grb2 was mutated. This suggests
that the intact effect of ITIM and ITSM specifically targets Akt pathway. In previous
study, it has been suggested that PD-1, which also consists of ITIM and ITSM motifs,
inhibited Akt and MAPK signaling pathways during TCR activation (56). This suggests
that an inhibitory effect of BTLA similarly shares downstream targets with PD-1.
However, we found that Src phosphorylation was enhanced when ITIM and ITSM
malfunction. Because Src might be enhanced due to either unleashed TCR activation
through disrupted negative regulation or through Grb2 activation, ∆ITIM and ITSM
differential protein expression was then also compared with both WT and EM to
distinguish these two effects. We found that Src phosphorylation remains consistently
present when using WT and EM as a reference, suggesting that Grb2 could activate Src
signaling pathway. In fact, a recent report has provided a direct interaction between
Grb2 and Src in NIH3T3 cells upon stimulated with Fibronectin. Additionally, it has

144

been shown that overexpression of Grb2 augments phosphorylation of Src at 416, but
the opposite result was obtained when Grb2 expression was disrupted (222).
Consistently, we found that Src enhancement was also observed in human
CD8+BTLA+ TIL activated with anti-CD3 and HVEM. In fact, we also observed an
attenuation of MAPK, NF-κB, and Akt signaling pathways in CD8+BTLA+ TIL during
engagement with anti-CD3 and HVEM as compared to anti-CD3 alone. This data
suggests that BTLA signaling pathways in both human and mouse share common
downstream targets.
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CHAPTER 6

Investigating the functional role of BTLA signaling pathway in
in vivo tumor control
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6.1 Rationale and Hypothesis
We have uncovered that CD8+BTLA+TIL subset exhibited superior tumor
control in tumor bearing NSG mouse when compared with CD8+BTLA-TIL subset, but
no difference in tumor killing capacity was observed in in vitro setting. It remains
unclear whether persistence of CD8+BTLA+TIL results from either the intrinsic
function of less differentiated phenotype or BTLA signaling itself.
We observed that BTLA signaling pathway did not contribute in tumor killing
capacity regardless of the changes introduced in BTLA signaling motifs. However, the
effector cytokine production such as IFN-γ and TNF-α were attenuated when Grb2
motif was attenuated. Intriguingly, we found an increased IL-2 production and T cell
proliferation when ITIM and ITSM were defective, suggesting the positive function of
the Grb2 motif.
Consistently, we observed an attenuation of the Akt pathway with enhanced Src
phosphorylation in CD8+ activated with anti-CD3 and HVEM in both human and
mouse setting, suggesting that BTLA provides dual signals both positive and negative.
We hypothesize that positive signal transduced by Grb2 motif could improve TIL
function and lead to better tumor control.
To determine to the functional role of the Grb2 and ITIM/ITSM motifs of
BTLA in human CD8+TIL, we used the NSG mouse model for adoptive transfer to
investigate the role of CD8+BTLA-TIL overexpressing WT BTLA, BTLA with
mutation of Grb2 or ITIM and ITSM during a study of in vivo tumor challenge.
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6.2 Results
Generation of retroviral vectors containing wild type human BTLA and human
BTLA mutants for functional study using NSG mouse model.
Because we have witnessed a dual role for BTLA as a co-stimulatory and co-inhibitory
receptor in human and mouse T cells, we next sought to dissect the potential
contributions of the Grb2 motif and the ITIM/ITSM motifs of BTLA in CD8+ TIL
mediated in vivo tumor control. To study the functional role of human BTLA signaling
motifs, we generated WT BTLA and mutants of the human Grb2 and ITIM/ITSM
motifs by substitution of tyrosine for phenylalanine using a site directed mutagenesis
method and thus generated ∆Grb2 mutant (Y226F and Y243F) and ∆ITIM and ITSM
mutant (Y257F and Y282F) (Figure 6.1A). We used pRVKM retroviral vector with
GFP reporter as a gene delivery system to overexpress WT BTLA and its mutants in
human CD8+BTLA-TIL. Comparable expression of BTLA was observed in BTLA WT and
its mutant (Figure 6.1B). Briefly, sorted CD8+BTLA-TIL were activated with anti-

human CD3 for 2 days. The cells were transduced with either WT BTLA or BTLA
mutants (∆Grb2 or ∆ITIM and ITSM). Over the next 14 days the cells were propagated
using the rapid expansion protocol (RFP). Because not all cells were transduced with
retroviruses, the GFP positive cells were further sorted and propagated for another 14
days prior to perform in vitro functional assays and adoptive TIL transfer (Figure
6.1C).
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A

B

C

Figure 6.1. BTLA singling motifs had no effect on in vitro tumor killing capacity.
Substitutions of tyrosine for phenylalanine were made in three different motifs of
human BTLA cytoplasmic tail; ∆Grb2 mutants (Y226F and Y243F), ∆ ITIM and ITSM
mutants (Y243F, Y257F, and Y282F) (A) Schematic diagram depicts the structure of
BTLA WT (Top), BTLA ∆Grb2 (middle), and BTLA ∆ITSM (bottom). (B)
(C) Schematic diagram depicts NSG mouse model for adoptive T cell transfer.
CD8+BTLA-were virally transduced with WT BTLA or its variants, and propagated by
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REP protocol for 14 days. The cells were then sorted based on GFP expression and
further expanded by REP protocol for another 14 days. Ten million virally transduced
TIL were intravenously injected into tumor bearing mice previously subcutaneously
implanted with autologous tumor line.
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BTLA signaling motifs have no effect on in vitro tumor killing capacity.
We previously showed the comparable in vitro tumor killing capacity between
CD8+BTLA+TIL and CD8+BTLA-TIL; however, we observed superior in vivo tumor
control of CD8+BTLA+TIL using the NSG mouse model. In addition, we also found
that CD8+BTLA+TIL subset circulated in the peripheral blood at higher frequency as
compared to CD8+BTLA-TIL subset counterpart. This finding is consistent with our
clinical observation demonstrating that the CD8+BTLA+TIL subset persisted longer in
the body following adoptive transfer in comparison to the CD8+BTLA-TIL subset.
Using BTLA-KO mouse T cells overexpressing WT BTLA or its mutants, we also
found that BTLA signaling motifs did not affect tumor killing capacity even though
effector cytokine production (IFN-γ and TNF-α) were significantly decreased when
Grb2 motif was mutated, in the presence of high levels of ITIM/ITSM. To further
determine whether BTLA signaling motif could contribute to the in vitro tumor killing
capacity, we co-incubated sorted CD8+BTLA-TIL (TIL#2549) overexpressing either
WT BTLA or mutant BTLA with the autologous tumor. We consistently observed that
the in vitro tumor killing capacity was comparable regardless of the presence of BTLA
or its mutants (Figure 6.2). (1:1, BTLA-EM (23.2%) vs BTLA-WT (23.8%) BTLA∆Grb2 (28.0%) vs BTLA- ∆ITIM and ITSM (26.5%); 1:3, BTLA-EM (8.2%) vs
BTLA-WT (8.5%) vs BTLA-∆Grb2 (14.8%) vs BTLA- ∆ITIM and ITSM (10.5%);
1:10, BTLA-EM (4.5%) vs BTLA-WT (3.2%) vs BTLA-∆Grb2 (5.6%) vs BTLA∆ITIM and ITSM (4.7%).
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Figure 6.2. BTLA signaling motifs had no effect on in vitro tumor killing capacity.
Autologous melanoma tumor line 2549 labeled with eFluor670® was co-cultured with
TIL at the following TIL-to-tumor cell ratios (1:10, 1:3, and 1:1). Tumor cell death is
evaluated by the percentage of caspase-3 positive tumor cells.
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Overexpression of inactivated ITIM and ITSM motifs in TIL enhanced tumor
burden control in NSG mouse model.
Because we found the comparable in vitro killing tumor capacity of cells
regardless of WT BTLA and it BTLA mutant expression, we sought to determine
whether overexpression of WT BTLA and its mutant could affect in vivo tumor control.
For in vivo tumor experiment, TIL overexpressing BTLA WT or BTLA mutants
were adoptively transferred into NSG tumor-bearing mice, and tumor burden was
measured every other day. We found that the transfer of TIL transduced with empty
vector (BTLA-) or TIL transduced with BTLA WT did not control the tumor and were
not significantly different from the non-treated group (NTx). However, the transfer of
TIL with a disrupted ITIM/ITSM domain (∆ITSM) resulted in greater tumor control
than the empty vector or non-treated groups early on day 2 (EM vs NTx; P= 0.08, ∆
ITSM vs NTx; P= 0.01, WT vs NTx; P=0.24, ∆Grb2 vs NTx; P= 0.92) (Figure 6.3A,
B, and C). However, the group that received TIL transduced with BTLA bearing a
malfunctioning Grb2 motif (∆Grb2) exhibited significantly worst tumor control as
opposed to those receiving TIL with empty vector control (EM) (EM VS WT; P=0.48,
EM VS ∆Grb2; P=0.04) (Figure 6.3A, B, and C). We found that only BTLAoverexpressing ∆ITIM and ITSM and empty vector control exhibited significantly
higher frequency in the blood on day 2 following transfer, while ∆Grb2 and WT
overexpressing TIL were not detected following TIL transfer.
Our result suggests that malfunction of Grb2 attenuated TIL function and
impaired tumor control. We observed that MEL526 tumor cells grown in NSG mice
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were explanted and stained for HVEM expression which was found to be still present
(Figure 6.4). In addition, HVEM expression is highly abundant in 2549 tumor cells as
well as other primary melanoma tumor cells (Figure 6.5A and B). This indicated that
melanoma tumor cells potentially provided a suppressive signal through BTLA
expressed by TIL in the tumor bed.
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B

C

Figure 6.3. Overexpression of inactivated ITIM and ITSM motifs in TIL enhanced
tumor burden control in NSG mouse model.
Ten million virally transduced TIL were intravenously injected into tumor-bearing
mice previously implanted subcutaneously with autologous tumor line 2549. Tumor
burden was measured using calipers and diameter graphed as mm2. N= 5-8 animals per
group. *P <0.05 and **P <0.001. Error bars are expressed as mean ± s.e.m. P-values
were calculated using a two-tailed Student’s t-test. The graphs show tumor volumes in
NSG mice adoptively transferred with TIL with following comparison; (A) ∆ ITSM
versus EM versus No Tx (B) ∆ Grb versus EM versus No Tx (C) WT versus EM versus
No Tx.
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Figure 6.4. Sustained expression of HVEM following injection into NSG mice.
Histogram plots demonstrating HVEM expression in MEL526 tumor cells (blue) and
MEL526 tumor cells isolated from NSG mice following engraftment for 10 days (red).
Live tumor cells were defined as AQUA negative and MCSP positive. The HVEM
positive population was gated using an FMO control (black).
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A

B

Figure 6.5. HVEM expression in 10 primary melanoma cell lines derived at
MDACC.
(A) Bar graph demonstrates the percentage of HVEM expression in 10 primary
melanoma cell lines derived at MDACC. Live tumor cells were defined as AQUA
negative and MCSP positive. HVEM expression was determined using fluorescence
minus one controls. (B) Representative immunohistochemistry (IHC) of HVEM
expression in paired melanoma tumor biopsies (TIL# 2420 and 2371).
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Discussion
We have shown that BTLA can provide positive function through Grb2 motif.
In this study, we have demonstrated that use of TIL overexpressing a disrupted
ITIM/ITSM motif to treat NSG tumor-bearing mice resulted in superior tumor control
as compared to EM control and non-treated group. Moreover, the mice received a
malfunctioned Grb2 motif had worse tumor control than the control groups. This result
indicates that Grb2 could play a role in mediating tumor control.
Although we have also shown that BTLA WT also transduced positive cosignaling function of T cells such as boosting IL-2 secretion, it remains unclear why
WT BTLA transduced TIL failed to exhibit tumor control in the NSG tumor bearing
mice. It is possible that the repetitive expansion of TIL for two consecutive 14-day
rapid expansions naturally triggers TIL to further differentiate. Thus, overexpression
of BTLA in TIL containing a large proportion of late-differentiated attributes might not
reflect the normal biology of human CD8+T cell. As such, the high levels of SHP-1
present in late differentiated CD8+T cells potentially gain more interaction with ITIM
and ITSM and result in skewing BTLA toward its inhibitory function.
Generally, co-stimulatory molecules expressed by T cells receive signals from
their ligands presented by APCs, but not the tumor cells since it usually lacks
expression of these ligands. Instead, high expression of ligands for co-inhibitory
molecules by tumor cells can suppress T cell function upon ligation with co-inhibitory
molecules highly presented by T cell upon activation. Since overexpression of modified
BTLA mediated superior tumor control, this is a proof of concept suggesting that
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engagement of BTLA by HVEM on tumor cells could improve TIL function at the
tumor site.
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CHAPTER 7

Functional role of BTLA in T cell priming and memory recall
response
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7.1 Rationale and Hypothesis
Unlike human BTLA, mouse BTLA is not considered as a differentiation maker as its
expression is not detected in mouse naïve T cell, but up-regulated upon TCR
stimulation in a similar fashion than other co-inhibitory molecules such as PD-1 and
CTLA-4. Although the kinetic of expression of mouse BTLA is different from human,
we have showed that expression of BTLA was highly enriched in memory T cell in
both human and mouse. A recent study in patients with active pulmonary tuberculosis
showed that BTLA is highly expressed by the memory T cell subset and linked with a
protective immune response against mycobacterial infection. A survival role of BTLA
has been indicated in a mouse model for acute graft versus host disease (GVHD) (201).
BTLA KO donor lymphocytes failed to engraft in host body due to impaired reexpression of IL-7R, a critical receptor for homeostasis of naïve T cells and memory T
cell development. Additionally, BTLA-HVEM ligation was shown to promote T cell
expansion and survival during bacterial infection in a listeria model (204). From these
findings, we hypothesize that BTLA could play a role in memory T cell development.
To this end, we utilize a mouse model for vaccination to examine the generation of
memory T cells and the memory recall response following vaccination. In this study,
we vaccinated C57BL/6 mice with gp100 melanoma peptide following the adoptive
transfer of bulk splenocytes from either Pmel-1 BTLA WT or Pmel-1 BTLA KO
mouse, transgenic for the TCR recognizing the gp100 peptide used for vaccination.
Pmel-1 T cells were tracked in peripheral blood following priming and boosting to
determine memory recall response following vaccination.
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7.2 Results
Memory recall response is defective in BTLA deficient T cells.
We and others showed that BTLA is mainly expressed by the memory T cell subset in
both human and mouse. Previous studies have implied the association of BTLA and
memory T cell generation in several disease models including GVHD, bacterial
infection, and cancer. In this study, we sought to conduct an experiment to determine
the role of BTLA in memory recall response using mouse model for vaccination. Pmel1 mice were crossed with C57BL/6 BTLA KO mice to generate Pmel-1 BTLA KO
mice. Half million of splenocytes from either Pmel-1 WT or Pmel-1 BTLA KO were
adoptively transferred into c57BL/6 recipient mice. On the following day, mice were
vaccinated with gp100 peptide together with anti-mouse CD40. Imiquimod cream 5%
was also applied on the vaccination site to boost the innate immune response.
Additionally, IL-2 was also provide to support in vivo T cell proliferation following
vaccination. The frequency of Pmel-1 T cells was determined in peripheral blood every
other day after vaccination (Figure 7A and B). On day 20 following the first priming,
we observed significantly higher frequency of Pmel-1 WT in peripheral blood when
compared with Pmel-1 BTLA KO. The frequency of both Pmel-1 WT and Pmel-1
BTLA KO declined and disappeared by day 30. Boost vaccination was performed on
day 60 following the first priming. We observed that Pmel-1 WT T cells were detected
in the peripheral blood within two days following boosting. However, the frequency of
Pmel-1 BTLA KO T cells remained unchanged (Figure 7C). To determine the long
term memory response, we determined the existence of Pmel-1 T cells in the spleen on
day 120. We found significantly higher percentage of Pmel-1 WT T cells in spleen as
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compared to Pmel-1 BTLA KO T cells (Figure 7D). This result suggests that BTLA is
critical for generation of a memory T cell pool in both priming and memory recall
response. Our finding has strengthen the notion that BTLA is not only a T cell
differentiation marker, but its function is also important in memory T cell development.
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B
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D

Figure 7. Defect of memory recall response of BTLA deficient T cells.
Schematic diagram depicting experimental design of mouse model for vaccination. A
non-myeloablative dose (350 cGy) of radiation is given to induce lymphopenia. The
next day, half a million of either (A) Pmel-1 Thy 1.1. wild type splenocytes or (B)
Pmel-1 BTLA KO splenocytes were adoptively transferred into C57BL/6 mouse
recipients (i.v.). On the following day, the recipients were vaccinated with gp100
peptide (100µg) together with anti-CD40 (50 µg) and imiquimod (50 mg).
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Recombinant human IL-2 at 1.2 X106 IU was administered once, and 6 x 105 IU twice
daily for the next 2 days (i.p.). Peripheral blood was collected every other day to
determine the frequency of circulating Pmel-1 Thy 1.1 T cells. On day 60, the mice
were vaccinated with gp100 peptide, and peripheral blood was collected every other
day until Pmel-1 T cells were no longer detected. On day 120, the mice were
euthanized, and spleens were collected to determine the presence of Pmel-1 Thy 1.1 T
cells. (C) Plot graph depicts the percentage of CD3+CD8+Pmel+ T cells in the peripheral
blood following the priming (first peak from day 15 to day 30) and boosting (second
peak from day 60 to 70). The frequency of CD3+CD8+Pmel+T cells was significantly
higher in C57BL/6 mouse recipients receiving Pmel-1 Thy 1.1. wild type splenocytes
as compared to those receiving Pmel-1 Thy 1.1. BTLA KO splenocytes. (D)
Comparison of the percentage of CD3+CD8+Pmel+ T cell in spleen on day 120 of mice
receiving either Pmel-1 Thy 1.1. wild type splenocytes or Pmel-1 Thy 1.1. BTLA KO
splenocytes. Pmel-1 Thy 1.1. BTLA KO splenocytes failed to develop memory recall
response following vaccination and boosting.
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Discussion
Generation of memory T cells is critical for highly effective immune response.
In this study, we found that mouse transferred with BTLA deficient splenocytes before
vaccination failed to develop antigen-specific CD8+ memory T cells, suggesting that
BTLA plays a pivotal role in memory T cell development. It is known that BTLA is a
co-inhibitory molecule; however, our data has shown that BTLA can also mediate
positive signal through its Grb2 motif. It has been clearly shown that optimal antigenic
and co-stimulatory signals are involved in memory T cell development, particularly
during naïve T cell priming. The weak TCR signal has been shown to inhibit memory
T cell development; on the contrary, extremely strong signal resulted in skewing toward
terminally differentiated effector T cell development (138). We have shown that BTLA
contains motifs that can transduce both positive and negative signal. This data suggest
that BTLA (unlike PD-1) induces both pro-survival positive signals but also inhibitory
signals through the recruitment of SHP1 and 2. Thus, BTLA acts more like a rheostat
reducing TCR signaling during strong antigenic stimulation while also inducing cell
survival signaling. This rheostat property of BTLA could play an important role for
memory T cell development in producing a balanced TCR signal favoring memory T
cell generation.
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CHAPTER 8

Overall discussion and future directions
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8.1 Overall discussion
Our clinical observation on the association of an improved outcome to TIL ACT in
melanoma patients with the infusion of higher numbers of CD8+BTLA+ TIL has
brought up an intriguing question of how this co-inhibitory molecule could benefit TIL
therapy as its known function is to inhibit T cell function. Recent literature uncovered
another role of BTLA as a T cell differentiation marker. It has been shown that BTLA
is highly enriched in naïve and central memory T cells, but down-regulated upon T cell
expansion and differentiation (142). Several studies in T cell therapy and cancer
immunology clearly demonstrated that adoptive transfer of less differentiated T cell
improves T cell persistence, resulting in superior anti-tumor immunity and tumor
burden control. Similarly, we also observe that CD8+BTLA+TIL subset persisted in the
peripheral blood longer than its CD8+BTLA-TIL subset counterpart, indicating that the
less differentiated CD8+BTLA+TIL subset indeed play a role in clinical outcome (121,
141, 143, 223-227).
In this study, while we have demonstrated that CD8+BTLA+TIL and CD8+BTLA-TIL
subsets had comparable in vitro tumor killing capacity, CD8+BTLA+TIL displayed
superior in vivo tumor control using NSG tumor bearing mouse model with increased
persistence following transfer in MART-1 antigen-specific setting, which reproduced
the exclusive advantage of CD8+BTLA+ in ACT treated patients. We did not fully
understand why the in vitro tumor killing observations did not agree with the in vivo
tumor burden control. We hypothesized that in vitro tumor killing was performed in a
bulk setting between tumor cells and T cells during such a short time (3 h) that it might
not fully predict the fate of T cell following subsequent killing of multiple tumor
targets, which occurred in mouse model as well as in melanoma patients. To this end,
168

we sought to use a nanowell array-based cytolysis assay conducted at the single cell
level in order to study the dynamic interactions between tumor targets and effector T
cells at high-throughput setting. Our data demonstrated that CD8+BTLA+TIL were
more active at seeking the tumor, but once a contact is established with the target they
took more time than their BTLA- counterpart to produce apoptosis of the target cell. In
fact, we observed that CD8+BTLA-TIL subset was more effective in tumor killing only
at early time point (first 250 mins) as compared to CD8+BTLA+TIL counterpart.
However, after careful analysis of the ability of the T cells to kill more than one target,
we found that the CD8+BTLA+TIL subset conferred superior ability for repetitive
killing of multiple tumor targets.
We have demonstrated that CD8+BTLA+TIL manifested enhanced mitochondrial
function and spare respiratory capacity (SRC) and preferentially used an oxidative
phosphorylation (OXPHOS) pathway for energy generation, which was more efficient
than the glycolysis pathway utilized by T effector cells (228, 229). A recent study
indicated that increased SRC was strongly associated with a superior bioenergetic
capacity, which helped improve T cell survival and motility under hypoxic conditions
(230). This property could help explain both the decreased time in finding a tumor
target and increased resistance to apoptosis following engagement and subsequent
killing of multiple tumor targets. Our result demonstrates for the first time that
CD8+BTLA+ subset is a “serial killing T cell”. The potentially intrinsic property of this
subset provides an intriguing possibility for why infusion of large numbers of
CD8+BTLA+TIL positively correlates with clinical response to TIL ACT in metastatic
melanoma patients. This supports the notion that the minimally differentiated
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phenotype of CD8+BTLA+TIL has less capacity for rapid tumor cytolysis as compared
with

more

differentiated,

and

short-lived,

CD8+BTLA-TIL,

but

is

more

bioenergetically efficient.
The use of CD8+BTLA+ and CD8+BTLA- is impossible to discrete the intrinsic
property of less differentiated T cell from BTLA signaling pathway. Because gene
silencing of BTLA using lentiviral vector exhibits relatively low efficiency of gene
delivery in TIL, this obstacle limits our understanding of the role of BTLA signaling
pathway in less differentiated T cells.
Thus, we utilize the genetically modified BTLA constructs to dissect the dichotomy of
positive and negative signaling motifs of BTLA, Grb2 and ITIM and ITISM
respectively. We did not observe any major differences in the in vitro killing capacity
and cytotoxic cytokine production between BTLA KO T cells versus BTLA KO T cells
overexpressing BTLA WT or its mutants, this suggests that BTLA signaling does not
affect tumor killing capability. Our findings are consistent with the previous report
showing that the BTLA blockade in gamma delta T cells had no effect on the tumor
lysis.
We observed a slight decrease in T cell proliferation in WT as compared with EM, and
the inhibitory effect was even more pronounced when the Grb2 motif was defective. In
contrast, malfunction of ITIM and ITSM motifs significantly enhanced T cell
proliferation. Previous studies in both human and mouse settings indicated that CD8+
T cells were intrinsically less susceptible to BTLA-mediated inhibition as compared to
CD4+ T cells. This might explain the minimal inhibition of WT as compared to EM in
CD8+ T cells in terms of proliferation. In addition, we noticed that T cells with deficient
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Grb2 motifs remarkably decreased IL-2 production. Interestingly, we found that
production of IL-2 in BTLA WT was significantly higher than empty vector control. A
previous report has shown that Grb2-linked SLP-76 and Vav interaction was involved
in IL-2 production. This suggested that the presence of Grb2 is potentially linked to IL2 production without influence from ITIM and ITSM (218, 231, 232). Our previous
work had shown higher IL-2 production in BTLA+CD8+ TIL and the current study
reveals that the Grb2 motif of BTLA is responsible for the BTLA-dependent IL-2
production which makes the Grb2 motif functionally active and critically important in
T cell proliferation.
Because we found a positive role for the Grb2 motif of BTLA, we further wondered
whether there was a distinct downstream signaling pathway exhibited from Grb2 motif.
When comparing the differentially expressed proteins in activated T cells transduced
with the different BTLA constructs and comparing with BTLA WT, we noticed that
the Akt signaling pathway was remarkably attenuated in BTLA ∆Grb2, while the
phosphorylation of Src was enhanced in BTLA ∆ITSM. A previous report
demonstrated that ITIM and ITSM motifs of PD-1 inhibited signals through Akt and
MAPK. This suggested that the Akt pathway in BTLA was likely targeted by SHP1/2,
similar to what was found in PD-1. From our data, it is clear that the phosphorylation
of Src increased when ITIM and ITSM domain is abrogated, but this could result from
either the effect of Grb2 signal transduction or the deficient dephosphorylation of
SHP1/2 recruited through ITIM and ITSM motifs. It was not possible to distinguish the
overlapping downstream signaling pathway when BTLA WT was used as a reference
to compare with ∆ITSM. Instead, we found an increased phosphorylation of Src when
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directly comparing ∆ITSM to EM, suggesting that Grb2 motif is potentially responsible
for the increased Src phosphorylation. It has been demonstrated that the interaction
between cells stimulated with Fibronectin (222). Overexpression of Grb2 in osteoclasts
was also shown to promote phosphorylation of Src at Y416 and the opposite result was
obtained when Grb2 expression was disrupted.
Our data in mouse BTLA signaling are in line with signaling in human TIL as we
observed attenuation of MAPK, NF-kB, and Akt signaling proteins, but
phosphorylation of Src was enhanced when stimulated with anti-CD3 and HVEM as
compared to CD3 alone. This suggested that the downstream signaling pathway of
BTLA in mice and humans possibly share similar targets.
As is consistent with the positive function of the Grb2 motif, we demonstrated that TIL
overexpressing disrupted ITIM and ITSM had superior in vivo tumor burden control
while the disruption of Grb2 domain led to the least effective tumor control. It is
possible that the signals from the Grb2 motif helped mediate tumor control at tumor
sites where TIL interacted with melanoma cells highly expressing HVEM. The fact that
the BTLA WT group in this experiment did not control the tumor better than the empty
vector group may have to do with the preparation of the cells. The TIL need to undergo
two 14-day rapid expansions successively to allow for vector transduction first
following by sorting and secondary expansion of the vector positive population. At the
end of this four week expansion process the T cell product will be more differentiated
whereby we will have late differentiated TIL expressing BTLA and therefore trump the
usual “less differentiated” phenotype of the BTLA+ TIL.

172

Our study sheds light on a dual role of BTLA as both a co-stimulatory and co-inhibitory
molecule. The integration of the positive and negative signals transduced by BTLA will
promote survival and IL-2 secretion while reducing proliferation and effector cytokine
production. In addition, inherited properties of minimally differentiated phenotype of
BTLA+ subset display enhanced apoptosis resistance and efficient bioenergetics
provide survival advantage following subsequent tumor killing. Since BTLA
expression is regulated by the differentiation status of the T cell such that it is only
expressed at early stages of differentiation, it is not expected to impact the survival or
function of late effector T cells. This places BTLA in a different category than other
checkpoint blockade molecules such as PD-1 or CTLA-4, which are up-regulated
following T cell activation (184, 233). In general, co-stimulatory molecules expressed
by T cells receive signals from their ligands presented by antigen-presenting cells
(APCs). Tumor cells generally lack expression of those co-stimulatory molecule
ligands. In contrast, tumor cells highly expressing co-inhibitory ligands can suppress T
cell function in tumor environments upon ligation with co-inhibitory molecules such
as PD-1 and TIM-3. In contrast, BTLA’s ligand, HVEM, is expressed widely by
melanoma tumor cells. This findings support the concept that intrinsic attribute of less
differentiated CD8+BTLA+ subset together with engagement of HVEM on melanoma
cells could provide a costimulatory signal to BTLA+CD8+ TIL to promote IL-2
secretion, survival and anti-tumor function.
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8.2 Future directions
Our data reveal that BTLA provides advantage in both intrinsic attribute of less
differentiated T cells as well as signaling pathway. These properties help T cell to resist
apoptosis and mediate killing of multiple tumor targets with enhanced IL-2 production
and cell proliferation. Overall our findings partially explain the observation of better
clinical outcome of melanoma patients infused with high proportion of
CD8+BTLA+TIL subset (134). Both intrinsic properties of BTLA and its positive
signaling pathway through Grb2 motif could contribute to superior clinical responses.
On the basis of this finding, I propose two strategies that might potentially improve the
efficacy of ACT; I) De-acceleration of T cell differentiation during REP II)
Overexpression of BTLA or other inhibitory molecules with genetically modified endo
domain.
De-acceleration of T cell differentiation during REP
Several studies have demonstrated that the transfer of less differentiated T cells
improved in vivo tumor control. In consistent with our clinical observation, patients
treated with TIL of a less differentiated T cell phenotype (CD8+BTLA+) exhibited
superior clinical response with enhanced persistence following TIL transfer as
compared to CD8+BTLA- counterpart. During massive T cell expansion, the effect of
anti-CD3 activation together with IL-2 promote T cells to undergo proliferation and
differentiation (234). Repetitive T cell activation can initiate terminal differentiation
resulting in telomere shortening and defect in proliferation, and become clonal deletion
eventually (137). This could explain our findings demonstrating that less differentiated
TIL subset with high expression of BTLA persist longer than those of more
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differentiated phenotype. Thus, an approach to attenuate T cell differentiation during T
cell expansion is desirable for T cell therapy. Several strategies have been reported to
target cellular signaling pathways that promote T cell differentiation. It has been shown
that sustained Akt activation enhanced mTOR phosphorylation and down-regulation of
IL-7R expression (235). This resulted in promoting terminal differentiation of effector
CD8+ T cells and impaired development of memory T cell pools. On the other hand,
inhibition of Akt signaling pathway has been shown to up-regulate CD62L expression
and enhance gene signature of human memory T cell (236). In addition, Akt inhibition
also altered T cell metabolism by augmenting mitochondrial spare respiratory capacity
and oxidative phosphorylation pathway, which is mainly utilized by memory T cells.
Adoptive transfer of human TIL previously expanded with Akt inhibitor has
demonstrated superior in vivo persistence and tumor burden control using NSG mouse
model. Consistently, another study also demonstrated that inhibition of Akt signaling
pathway can attenuate differentiation of minor histocompatibility antigens (MiHAs)
specific CD8+ T cells following rapid expansion for 14 days. In addition, Akt-inhibited
MiHA specific CD8+ T cells also exhibited superior anti-tumor capacity following
adoptive T cell transfer (237). This suggest that sustained Akt signaling pathway can
promote terminal differentiation of T cell by altering transcriptome, metabolism,
phenotype, and function.
It has been shown that inhibition of mammalian Target of Rapamycin complex 1
(mTORC1) and activation of Wnt signaling pathway can promote the in vitro
generation of stem cell-like memory T cells (Tscm). CD4+Tscm cells expanded with
mTORC1 inhibitor (Rapamycin) conferred longer term persistence following adoptive
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transfer. Furthermore, expanded Tscm also preferentially utilized mitochondria fatty
oxidation rather than glycolysis, which is preferably used by effector T cells. The study
of mTORC1 gene silencing using siRNA also showed enhanced differentiation of
CD8+ T cells into memory phenotype and augmented potent antitumor effect.
Interestingly, the combination of 4-1BB aptamer with mTORC1 gene silencing, was
found to be synergistically inhibiting mTOR activity and resulted in improved
antitumor immunity (238). In vaccination model, it has been demonstrated that using
OX-40 agonist in combination with mTOR inhibitor (Rapamycin) boosted the
generation of memory T cell pool and protective immunity following Vaccinia Vaccine
challenge (239).
Overall current studies demonstrate the advantage of suppressing Akt-mTOR pathway
in the generation of less differentiated T cell phenotype and stem-cell like phenotype.
It appears that the inhibition of Akt and mTOR can alter the metabolic pathway to
mitochondria oxidative phosphorylation, which is much more bioenergetically efficient
as compared to the glycolysis pathway. More importantly, expanded T cell with either
Akt inhibitor or mTOR inhibitor exhibited superior persistence following adoptive
transfer with enhanced antitumor immunity. Therefore, targeting Akt and mTOR could
be an effective strategy to help generate less differentiated TIL and stem cell like
phenotype.
Overexpression of co-inhibitory molecules with modified endodomain
Less differentiated T cells have intrinsic attributes that enhance survival following
tumor cell killing such as apoptosis resistance, superior IL-2 production, and enhanced
replicative proliferation. We have demonstrated that the transduction of BTLA bearing
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non-functional ITIM and ITSM motifs transduced positive signals with enhanced IL-2
production and T cell proliferation. Thus, intrinsic attribute and positive signaling of
BTLA are critical to TIL function and linked to positive clinical response in ACT
treated patients. It is known that tumor microenvironment is immunosuppressive.
Engagement of co-inhibitory molecules on T cell and their ligand expressed by tumor
cells attenuates T function. Using tumor NSG mouse model for adoptive transfer, we
have shown that CD8+BTLA- overexpressing BTLA with inactivated ITIM and ITSM
motifs conferred superior in vivo tumor control, while overexpression of BTLA WT in
TIL failed to improve tumor control as compared to non-treatment group. This suggests
that engagement of BTLA and HVEM in tumor site affect TIL function in mediating
tumor control (Figure 8A). This proof of principle allows us to generate a strategy to
modify the endodomain of inhibitory molecules by substitution with endodomain of
positive co-stimulatory molecule such as CD40, CD27, CD28, 4-1BB, and etc. (Figure
8B). Because co-stimulatory molecule only transduces its downstream signal during
TCR activation, this context acts selectively and specifically upon engagement of T
cell and tumor cell.
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A

B

Figure 8. Overexpression of co-inhibitory molecules with modified endodomain.
(A) Schematic diagram depicts the interaction between TIL and melanoma tumor cell
targets. Engagement between BTLA expressed by TIL and HVEM expressed by
melanoma tumor cells exhibits both a positive and negative signal. (B) Schematic
diagram demonstrates interaction between the TIL and melanoma tumor cell targets.
Engagement between co-inhibitory molecules with modified endodomain expressed by
TIL and HVEM expressed by melanoma tumor cells exhibits positive signals that
promote TIL effector function.
178

CHAPTER 9: MATERIALS and METHODS

179

Materials and Methods
Reagents.
Cell lines. Platinum E cell line, 526 Melanoma tumor line, and autologous tumor cell
line #2549 were maintained in Roswell Park Memorial Institute (RPMI) supplemented
with 10% fetal bovine serum (FBS) (Gemini bio product), 10 mM HEPES (Gibco™),
10 mM Penicillin-streptomycin (Gibco™), and 10 mM Glutamine (Gibco™), and 0.05
mM Beta-mercaptoethanol(Gibco™). Platinum-E retro packing cell line was purchased
from Cellbiolabs. MEL 526 tumor line was obtained from Dr Steven A. Rosenberg at
the National Cancer Institute. B16F10 and B16OVA cell lines were generously
provided by Dr. Willem Overwijk (MD Anderson Cancer Center). Autologous primary
melanoma tumor cell line #2549 was generated at M.D. Anderson Cancer Center from
a tumor sample of a patient enrolled on an ongoing adoptive T cell therapy study (IRB
#2004-0069, lab06-0755).
Patient tumor sample acquisition. Tumor samples were obtained from patients with
Stage IIIc and Stage IV melanoma undergoing surgery at The University of Texas MD
Anderson Cancer Center according to an Institutional Review Board-approved protocol
and with patient consent (IRB# LAB06-0755)
Generation of tumor infiltrating lymphocytes (TIL). Fragments from melanoma
tumors were cut into 1 to 2 millimeters. Each fragment was placed into a single wells
in 24-well-culture plates (Falcon) and maintained with RPMI supplemented with 10%
heat inactivated Human AB serum (Gemini bio product), IL-2 6000 IU/ml
(Aldesleukin, Novartis), 10 mM HEPES, 10 mM Penicillin-streptomycin (Gibco™),
and 10 mM Glutamine (Gibco™).
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Animal. The NOD/SCIDγc-/- (NSG) mice were obtained from the Jackson Laboratory.
NOD/SCIDγc-/- (NSG) mice were given autoclaved food and acidified autoclaved
water. The BTLA-OT.1 KO mouse were kindly provided from Dr. Roza Nurieva (MD
Anderson Cancer Center). All mice were housed in a specific pathogen-free facility at
The University of Texas M.D. Anderson Cancer Center.
Retroviral constructs of BTLA wild type and mutants. Human BTLA and murine
BTLA were amplified from MGC fully sequenced human BTLA and murine BTLA
(Open biosystem) respectively by PCR with primers hBTLA-F and R and mBTLA-F
and R. The PCR products were cloned into pRVKM retroviral vectors. To generate
BTLA mutants, we substituted tyrosine for phenyl alanine in either Grb2 motifs or
ITIM and ITSM motifs of BTLA cytoplasmic tails. These included human ∆Grb2
mutants (Y226F and Y243F), human ∆ ITIM and ITSM mutants (Y243F, Y257F, and
Y282F), murine ∆Grb2 mutants (Y245F), and murine ∆ ITIM and ITSM mutants
(Y274F, and Y299F). Sequence of all constructs were validated by DNA sequencing.
DNA sequencing of mouse and human BTLA and their mutants
TAT and TTC are genetic codes of tyrosine and phenylalanine respectively. Red, Blue,
and Green represent either tyrosine or phenylalanine of Grb2, ITIM, and ITSM motifs
respectively.
Wild type human BTLA
ATGAAGACATTGCCTGCCATGCTTGGAACTGGGAAATTATTTTGGGTCTTC
TTCTTAATCCCATATCTGGACATCTGGAACATCCATGGGAAAGAATCATG
TGATGTACAGCTTTATATAAAGAGACAATCTGAACACTCCATCTTAGCAG
GAGATCCCTTTGAACTAGAATGCCCTGTGAAATACTGTGCTAACAGGCCT
CATGTGACTTGGTGCAAGCTCAATGGAACAACATGTGTAAAACTTGAAGA
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TAGACAAACAAGTTGGAAGGAAGAGAAGAACATTTCATTTTTCATTCTAC
ATTTTGAACCAGTGCTTCCTAATGACAATGGGTCATACCGCTGTTCTGCAA
ATTTTCAGTCTAATCTCATTGAAAGCCACTCAACAACTCTTTATGTGACAG
ATGTAAAAAGTGCCTCAGAACGACCCTCCAAGGACGAAATGGCAAGCAG
ACCCTGGCTCCTGTATAGTTTACTTCCTTTGGGGGGATTGCCTCTACTCAT
CACTACCTGTTTCTGCCTGTTCTGCTGCCTGAGAAGGCACCAAGGAAAGC
AAAATGAACTCTCTGACACAGCAGGAAGGGAAATTAACCTGGTTGATGCT
CACCTTAAGAGTGAGCAAACAGAAGCAAGCACCAGGCAAAATTCCCAAG
TACTGCTATCAGAAACTGGAATTTATGATAATGACCCTGACCTTTGTTTCA
GGATGCAGGAAGGGTCTGAAGTTTATTCTAATCCATGCCTGGAAGAAAAC
AAACCAGGCATTGTTTATGCTTCCCTGAACCATTCTGTCATTGGACTGAAC
TCAAGACTGGCAAGAAATGTAAAAGAAGCACCAACAGAATATGCATCCA
TATGTGTGAGGAGTGGTGGCGGAAGTGACTACAAGGACGACGATGACAA
GTAA
∆ITIM and ITSM human BTLA
ATGAAGACATTGCCTGCCATGCTTGGAACTGGGAAATTATTTTGGGTCTTC
TTCTTAATCCCATATCTGGACATCTGGAACATCCATGGGAAAGAATCATG
TGATGTACAGCTTTATATAAAGAGACAATCTGAACACTCCATCTTAGCAG
GAGATCCCTTTGAACTAGAATGCCCTGTGAAATACTGTGCTAACAGGCCT
CATGTGACTTGGTGCAAGCTCAATGGAACAACATGTGTAAAACTTGAAGA
TAGACAAACAAGTTGGAAGGAAGAGAAGAACATTTCATTTTTCATTCTAC
ATTTTGAACCAGTGCTTCCTAATGACAATGGGTCATACCGCTGTTCTGCAA
ATTTTCAGTCTAATCTCATTGAAAGCCACTCAACAACTCTTTATGTGACAG
ATGTAAAAAGTGCCTCAGAACGACCCTCCAAGGACGAAATGGCAAGCAG
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ACCCTGGCTCCTGTATAGTTTACTTCCTTTGGGGGGATTGCCTCTACTCAT
CACTACCTGTTTCTGCCTGTTCTGCTGCCTGAGAAGGCACCAAGGAAAGC
AAAATGAACTCTCTGACACAGCAGGAAGGGAAATTAACCTGGTTGATGCT
CACCTTAAGAGTGAGCAAACAGAAGCAAGCACCAGGCAAAATTCCCAAG
TACTGCTATCAGAAACTGGAATTTATGATAATGACCCTGACCTTTGTTTCA
GGATGCAGGAAGGGTCTGAAGTTTATTCTAATCCATGCCTGGAAGAAAAC
AAACCAGGCATTGTTTTCGCTTCCCTGAACCATTCTGTCATTGGACTGAAC
TCAAGACTGGCAAGAAATGTAAAAGAAGCACCAACAGAATTCGCATCCA
TATGTGTGAGGAGTGGTGGCGGAAGTGACTACAAGGACGACGATGACAA
GTAA
∆Grb2 human BTLA
ATGAAGACATTGCCTGCCATGCTTGGAACTGGGAAATTATTTTGGGTCTTC
TTCTTAATCCCATATCTGGACATCTGGAACATCCATGGGAAAGAATCATG
TGATGTACAGCTTTATATAAAGAGACAATCTGAACACTCCATCTTAGCAG
GAGATCCCTTTGAACTAGAATGCCCTGTGAAATACTGTGCTAACAGGCCT
CATGTGACTTGGTGCAAGCTCAATGGAACAACATGTGTAAAACTTGAAGA
TAGACAAACAAGTTGGAAGGAAGAGAAGAACATTTCATTTTTCATTCTAC
ATTTTGAACCAGTGCTTCCTAATGACAATGGGTCATACCGCTGTTCTGCAA
ATTTTCAGTCTAATCTCATTGAAAGCCACTCAACAACTCTTTATGTGACAG
ATGTAAAAAGTGCCTCAGAACGACCCTCCAAGGACGAAATGGCAAGCAG
ACCCTGGCTCCTGTATAGTTTACTTCCTTTGGGGGGATTGCCTCTACTCAT
CACTACCTGTTTCTGCCTGTTCTGCTGCCTGAGAAGGCACCAAGGAAAGC
AAAATGAACTCTCTGACACAGCAGGAAGGGAAATTAACCTGGTTGATGCT
CACCTTAAGAGTGAGCAAACAGAAGCAAGCACCAGGCAAAATTCCCAAG
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TACTGCTATCAGAAACTGGAATTTTCGATAATGACCCTGACCTTTGTTTCA
GGATGCAGGAAGGGTCTGAAGTTTTCTCTAATCCATGCCTGGAAGAAAAC
AAACCAGGCATTGTTTATGCTTCCCTGAACCATTCTGTCATTGGACTGAAC
TCAAGACTGGCAAGAAATGTAAAAGAAGCACCAACAGAATATGCATCCA
TATGTGTGAGGAGTGGTGGCGGAAGTGACTACAAGGACGACGATGACAA
GTAA
Wild type mouse BTLA
ATGAAGACAGTGCCTGCCATGCTTGGGACTCCTCGGTTATTTAGGGAATT
CTTCATCCTCCATCTGGGCCTCTGGAGCATCCTTTGTGAGAAAGCTACTAA
GAGGAATGATGAAGAGTGTCCAGTGCAACTTACTATTACGAGGAATTCCA
AACAGTCTGCCAGGACAGGAGAGTTATTTAAAATTCAATGTCCTGTGAAA
TACTGTGTTCATAGACCTAATGTGACTTGGTGTAAGCACAATGGAACAAT
CTGTGTACCCCTTGAGGTTAGCCCTCAGCTATACACTAGTTGGGAAGAAA
ATCAATCAGTTCCGGTTTTTGTTCTCCACTTTAAACCAATACATCTCAGTG
ATAATGGGTCGTATAGCTGTTCTACAAACTTCAATTCTCAAGTTATTAATA
GCCATTCAGTAACCATCCATGTGACAGAAAGGACTCAAAACTCTTCAGAA
CACCCACTAATAACAGTATCTGACATCCCAGATGCCACCAATGCCTCAGG
ACCATCCACCATGGAAGAGAGGCCAGGCAGGACTTGGCTGCTTTACACCT
TGCTTCCTTTGGGGGCATTGCTTCTGCTCCTTGCCTGTGTCTGCCTGCTCTG
CTTTCTGAAAAGGATCCAAGGGAAAGAAAAGAAGCCTTCTGACTTGGCAG
GAAGGGACACTAACCTGGTTGATATTCCAGCCAGTTCCAGGACAAATCAC
CAAGCACTGCCATCAGGAACTGGAATTTATGATAATGATCCCTGGTCTAG
CATGCAGGATGAATCTGAATTGACAATTAGCTTGCAATCAGAGAGAAACA
ACCAGGGCATTGTTTATGCTTCTTTGAACCATTGTGTTATTGGAAGGAATC
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CAAGACAGGAAAACAACATGCAGGAGGCACCCACAGAATATGCATCCAT
TTGTGTGAGAAGTGGTGGCGGAAGTGACTACAAGGACGACGATGACAAG
TAA
∆ITIM and ITSM mouse BTLA
ATGAAGACAGTGCCTGCCATGCTTGGGACTCCTCGGTTATTTAGGGAATT
CTTCATCCTCCATCTGGGCCTCTGGAGCATCCTTTGTGAGAAAGCTACTAA
GAGGAATGATGAAGAGTGTCCAGTGCAACTTACTATTACGAGGAATTCCA
AACAGTCTGCCAGGACAGGAGAGTTATTTAAAATTCAATGTCCTGTGAAA
TACTGTGTTCATAGACCTAATGTGACTTGGTGTAAGCACAATGGAACAAT
CTGTGTACCCCTTGAGGTTAGCCCTCAGCTATACACTAGTTGGGAAGAAA
ATCAATCAGTTCCGGTTTTTGTTCTCCACTTTAAACCAATACATCTCAGTG
ATAATGGGTCGTATAGCTGTTCTACAAACTTCAATTCTCAAGTTATTAATA
GCCATTCAGTAACCATCCATGTGACAGAAAGGACTCAAAACTCTTCAGAA
CACCCACTAATAACAGTATCTGACATCCCAGATGCCACCAATGCCTCAGG
ACCATCCACCATGGAAGAGAGGCCAGGCAGGACTTGGCTGCTTTACACCT
TGCTTCCTTTGGGGGCATTGCTTCTGCTCCTTGCCTGTGTCTGCCTGCTCTG
CTTTCTGAAAAGGATCCAAGGGAAAGAAAAGAAGCCTTCTGACTTGGCAG
GAAGGGACACTAACCTGGTTGATATTCCAGCCAGTTCCAGGACAAATCAC
CAAGCACTGCCATCAGGAACTGGAATTTATGATAATGATCCCTGGTCTAG
CATGCAGGATGAATCTGAATTGACAATTAGCTTGCAATCAGAGAGAAACA
ACCAGGGCATTGTTTTCGCTTCTTTGAACCATTGTGTTATTGGAAGGAATC
CAAGACAGGAAAACAACATGCAGGAGGCACCCACAGAATTCGCATCCAT
TTGTGTGAGAAGTGGTGGCGGAAGTGACTACAAGGACGACGATGACAAG
TAA
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∆Grb2 mouse BTLA
ATGAAGACAGTGCCTGCCATGCTTGGGACTCCTCGGTTATTTAGGGAATT
CTTCATCCTCCATCTGGGCCTCTGGAGCATCCTTTGTGAGAAAGCTACTAA
GAGGAATGATGAAGAGTGTCCAGTGCAACTTACTATTACGAGGAATTCCA
AACAGTCTGCCAGGACAGGAGAGTTATTTAAAATTCAATGTCCTGTGAAA
TACTGTGTTCATAGACCTAATGTGACTTGGTGTAAGCACAATGGAACAAT
CTGTGTACCCCTTGAGGTTAGCCCTCAGCTATACACTAGTTGGGAAGAAA
ATCAATCAGTTCCGGTTTTTGTTCTCCACTTTAAACCAATACATCTCAGTG
ATAATGGGTCGTATAGCTGTTCTACAAACTTCAATTCTCAAGTTATTAATA
GCCATTCAGTAACCATCCATGTGACAGAAAGGACTCAAAACTCTTCAGAA
CACCCACTAATAACAGTATCTGACATCCCAGATGCCACCAAT
GCCTCAGGACCATCCACCATGGAAGAGAGGCCAGGCAGGACTTGGCTGC
TTTACACCTTGCTTCCTTTGGGGGCATTGCTTCTGCTCCTTGCCTGTGTCTG
CCTGCTCTGCTTTCTGAAAAGGATCCAAGGGAAAGAAAAGAAGCCTTCTG
ACTTGGCAGGAAGGGACACTAACCTGGTTGATATTCCAGCCAGTTCCAGG
ACAAATCACCAAGCACTGCCATCAGGAACTGGAATTTTCGATAATGATCC
CTGGTCTAGCATGCAGGATGAATCTGAATTGACAATTAGCTTGCAATCAG
AGAGAAACAACCAGGGCATTGTTTATGCTTCTTTGAACCATTGTGTTATTG
GAAGGAATCCAAGACAGGAAAACAACATGCAGGAGGCACCCACAGAATA
TGCATCCATTTGTGTGAGAAGTGGTGGCGGAAGTGACTACAAGGACGACG
ATGACAAGTAA
TAT and TTC are genetic codes of tyrosine and phenylalanine respectively. Red, Blue,
and Green represent either tyrosine or phenylalanine of Grb2, ITIM, and ITSM motifs
respectively.
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Amino acid sequencing of mouse and human BTLA and their mutants
Wild type human BTLA
MKTLPAMLGTGKLFWVFFLIPYLDIWNIHGKESCDVQLYIKRQSEHSILAGDP
FELECPVKYCANRPHVTWCKLNGTTCVKLEDRQTSWKEEKNISFFILHFEPVL
PNDNGSYRCSANFQSNLIESHSTTLYVTDVKSASERPSKDEMASRPWLLYSLL
PLGGLPLLITTCFCLFCCLRRHQGKQNELSDTAGREINLVDAHLKSEQTEAST
RQNSQVLLSETGIYDNDPDLCFRMQEGSEVYSNPCLEENKPGIVYASLNHSVI
GLNSRLARNVKEAPTEYASICVRSGGGSDYKDDDDK.
∆ITIM and ITSM human BTLA
MKTLPAMLGTGKLFWVFFLIPYLDIWNIHGKESCDVQLYIKRQSEHSILAGDP
FELECPVKYCANRPHVTWCKLNGTTCVKLEDRQTSWKEEKNISFFILHFEPVL
PNDNGSYRCSANFQSNLIESHSTTLYVTDVKSASERPSKDEMASRPWLLYSLL
PLGGLPLLITTCFCLFCCLRRHQGKQNELSDTAGREINLVDAHLKSEQTEAST
RQNSQVLLSETGIYDNDPDLCFRMQEGSEVYSNPCLEENKPGIVFASLNHSVI
GLNSRLARNVKEAPTEFASICVRSGGGSDYKDDDDK.
∆Grb2 human BTLA
MKTLPAMLGTGKLFWVFFLIPYLDIWNIHGKESCDVQLYIKRQSEHSILAGDP
FELECPVKYCANRPHVTWCKLNGTTCVKLEDRQTSWKEEKNISFFILHFEPVL
PNDNGSYRCSANFQSNLIESHSTTLYVTDVKSASERPSKDEMASRPWLLYSLL
PLGGLPLLITTCFCLFCCLRRHQGKQNELSDTAGREINLVDAHLKSEQTEAST
RQNSQVLLSETGIFDNDPDLCFRMQEGSEVFSNPCLEENKPGIVYASLNHSVI
GLNSRLARNVKEAPTEYASICVRSGGGSDYKDDDDK.
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Wild type mouse BTLA
MKTVPAMLGTPRLFREFFILHLGLWSILCEKATKRNDEECPVQLTITRNSKQS
ARTGELFKIQCPVKYCVHRPNVTWCKHNGTICVPLEVSPQLYTSWEENQSVP
VFVLHFKPIHLSDNGSYSCSTNFNSQVINSHSVTIHVTERTQNSSEHPLITVSDI
PDATNASGPSTMEERPGRTWLLYTLLPLGALLLLLACVCLLCFLKRIQGKEK
KPSDLAGRDTNLVDIPASSRTNHQALPSGTGIYDNDPWSSMQDESELTISLQS
ERNNQGIVYASLNHCVIGRNPRQENNMQEAPTEYASICVRSGGGSDYKDDD
DK.
∆ITIM and ITSM mouse BTLA
MKTVPAMLGTPRLFREFFILHLGLWSILCEKATKRNDEECPVQLTITRNSKQS
ARTGELFKIQCPVKYCVHRPNVTWCKHNGTICVPLEVSPQLYTSWEENQSVP
VFVLHFKPIHLSDNGSYSCSTNFNSQVINSHSVTIHVTERTQNSSEHPLITVSDI
PDATNASGPSTMEERPGRTWLLYTLLPLGALLLLLACVCLLCFLKRIQGKEK
KPSDLAGRDTNLVDIPASSRTNHQALPSGTGIYDNDPWSSMQDESELTISLQS
ERNNQGIVFASLNHCVIGRNPRQENNMQEAPTEFASICVRSGGGSDYKDDDD
K.
∆Grb2 mouse BTLA
MKTVPAMLGTPRLFREFFILHLGLWSILCEKATKRNDEECPVQLTITRNSKQS
ARTGELFKIQCPVKYCVHRPNVTWCKHNGTICVPLEVSPQLYTSWEENQSVP
VFVLHFKPIHLSDNGSYSCSTNFNSQVINSHSVTIHVTERTQNSSEHPLITVSDI
PDATNASGPSTMEERPGRTWLLYTLLPLGALLLLLACVCLLCFLKRIQGKEK
KPSDLAGRDTNLVDIPASSRTNHQALPSGTGIFDNDPWSSMQDESELTISLQSE
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RNNQGIVFASLNHCVIGRNPRQENNMQEAPTEYASICVRSGGGSDYKDDDD
K.
Y and F are amino acid codes of tyrosine and phenylalanine respectively. Red, Blue,
and Green represent either tyrosine or phenylalanine of Grb2, ITIM, and ITSM motifs
respectively.
Amino acid sequencing of human co-stimulatory molecules containing Grb2 motif
Human CD28
MLRLLLALNLFPSIQVTGNKILVKQSPMLVAYDNAVNLSYNEKSNGTIIHVKG
KHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSD
YMNMTPRRPGPTRKHYQPYAPPRDFAAYRS
Human ICOS
MKSGLWYFFLFCLRIKVLTGEINGSANYEMFIFHNGGVQILCKYPDIVQQFK
MQLLKGGQILCDLTKTKGSGNTVSIKSLKFCHSQLSNNSVSFFLYNLDHSHA
NYYFCNLSIFDPPPFKVTLTGGYLHIYESQLCCQLKFWLPIGCAAFVVVCILGC
ILICWLTKKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTL
Amino acid sequencing of co-inhibitory molecule containing ITIM and ITSM
motif
Human PD-1
MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNAT
FTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNG
RDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAH
PSPSPRPAGQFQTLVVGVVGGLLGSLVLLVWVLAVICSRAARGTIGARRTGQ

189

PLKEDPSAVPVFSVDYGELDFQWREKTPEPPVPCVPEQTEYATIVFPSGMGTS
SPARRGSADGPRSAQPLRPEDGHCSWPL

Table 3. Primers used to amplify mouse and human BTLA

Retrovirus generation and transduction of human TIL.

Plate-E cells were

transfected with pRVKM retroviral vectors and RD114 plasmids using PolyJet
(Signagen Laboratories) according to manufacturer’s protocol for 60 h. The
supernatants were harvested and concentrated using Vivaspin-20 (Vivaproducts), then
added onto a plate pre-coated with Retronectin (Takara clontech) and centrifuged at
2000 g for 2 h. Pre-activated CD8+BTLA- with anti-human CD3 at a concentration of
300 ng/mL (Clone OKT3, BD PharmingenTM) were then added and centrifuged at 1000
g for 10 min. On the next day, the cells were propagated using the Rapid expansion
protocol (REP) with irradiated PBMC and hIL-2 (Proleukin, Novartis) at 6000 IU for
14 d as previously described (141). Transduced cells were then sorted based on GFP
expression and propagated with the REP protocol.
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Retroviral transduction in mouse T cells. pRVKM retroviral vectors and pEco
plasmids were co-transfected into Plate-E cells using using PolyJet (Signagen
Laboratories). The supernatants were harvested 60 h later and concentrated using
Vivaspin-20 (Vivaproducts). Splenocytes from BTLA-KO OT.1 mice were cultured
with RPMI1640 with 10% FBS and hIL-2 at 300IU/ml, and activated with anti-mouse
CD3 at concentration of 0.3 ug/ml (Clone 145-2C11, BD PharmingenTM) for 24 h. The
cells were then infected with a concentrated retrovirus and further expanded in
RPMI1640 with 10% FBS and hIL-2 for 3 days. The cells were sorted based on the
expression of GFP using a FACSAria (BD Bioscience) and propagated with hIL-2 at
300 IU/ml for 5 days.
Reverse phase protein array. Murine BTLA KO OT.1 cells overexpressing BTLA
WT or mutants were re-stimulated with either 10 ng/ml anti-mouse CD3 (Clone 1452C11, BD PharmingenTM) alone or with recombinant Fc mouse HVEM (R&D systems)
plate-bound for 12 h prior to harvest with cell lysis buffer (kindly provided by RPPA
core facility at The University of Texas M.D. Anderson Cancer Center). The cell
lysates were centrifuged at 14,000 rpm for 10 minutes at 4C. For human TIL, four
TIL lines were stained with anti-CD8 (clone RPA-T8, BD Biosciences), anti-BTLA
(clone J168, BD Bioscience), and Sytox blue (Molecular ProbeTM) under aseptic
condition. The cells were sorted based on expression of CD8+BTLA- using FACSAria
(BD Biosciences). On the next day, sorted TIL were re-stimulated with anti-human
CD3 (clone OKT-3, BD Bioscience) with or without recombinant Fc mouse HVEM
(R&D systems) for 30 minutes. The cells were harvested as previously described
above.
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Surface marker staining
TIL were washed twice with 2 ml FWB for 5 minutes at 1400 rpm. The cell were
stained with T cell surface markers with the cocktail antibody of anti-human CD3
(clone BD Pharmingen), anti-human CD8( clone BD Pharmingen), anti-BTLA (clone
J168, BD Pharmingen). Amcyan Aqua (Molecular Probes, Life Technologies) was
used to selectively gate live cells. Staining was performed on ice for 25 minutes. The
cells were washed twice with FWB to remove an excessed unbound antibodies for 5
minutes at 1400 rpm. The samples were fixed with 1% para-formaldehyde solution
prior to acquire acquire using a BD FACScanto II flow cytometer machine. For
tetramer staining, the cells were washed with FWB previously described, and stained
with a MART-1 peptide HLA-A0201 tetramer (Beckman-Coulter) prior to normally
stain with surface markers.
Intracellular cytokine staining. Overexpressing BTLA WT or mutants in BTLA-/OT-1 T cells were re-activated with either DC pulsed with OVA peptide (SIINFEKL)
(Polysciences) or DC alone at a ratio of 1 to 40 in the presence of BD™ GolgiStop™
according to the manufacturer’s instruction. After 4 hours, cells were fixed and
permeabilized using BD Cytofix/CytopermTM kits (BD Biosciences Cat: 554722) and
subsequently stained with anti-mouse IFN-γ and anti-mouse TNF-α (BD Pharmigen).
Cytokine multiplex assays. Murine BTLA KO OT.1 cells overexpressing BTLA WT
or mutants were re-stimulated with either 10 ng/ml anti-mouse CD3 (Clone 145-2C11,
BD PharmingenTM) alone or with recombinant Fc mouse HVEM (R&D systems) platebound for 24 h. Supernatants were collected to quantify the secreted cytokines using a
MILLPLEX multiplex assay according to manufacturer protocol (Millipore).
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Killing assays. T cells were co-cultured with tumor cells labeled with efluor670® at
ratio of 1 to 1, 1 to 3, and 1 to 10. After 3 h, the cells were fixed and permeabilized
(BD Cytofix/Cytoperm), then stained with anti-cleaved caspase-3 (clone CPP32, BD
Biosciences), and analyzed by a BD FACSCanto II (BD Biosciences). The data was
analyzed using FlowJo software (TreeStar).
Cell proliferation assay. Murine BTLA-/- OT-1 expressing BTLA WT or mutants
were labeled with efluor670® and re-stimulated with DC alone or DC pulsed with
OVA peptide (SIINFEKL) at a ratio of 1 to 40 for 48 h prior to being analyzed using a
BD FACSCanto II (BD Biosciences). The data was analyzed using FlowJo software
(TreeStar).
Nanowell array-based cytolytic assay. TIL and Tumor cells were labeled with 1
µmol/L of red fluorescence dye (PKH26, Sigma) and 1 µl of green fluorescence dye
(PKH68, Sigma) respectively. The cells were loaded onto nanowell at concentration of
1x106/mL. Target cell cytolysis mediated by TIL was monitored using a Carl Zeiss
Axio Observer fitted with Hamamatsu EM-CCD camera using 10 x 0.3 NA objective.
Apoptotic cells became green when stained with Annexin V conjugated with Alexa
647as previously described.
Adoptive Transfer and IL-2 treatment. The NOD/SCIDγc-/- (NSG) mice in each
experiment contained 5 to 8, 10-12 week-old female mice per group. We were
subcutaneously engrafted with either 10 x 106 526 melanoma tumors or 10 x 106
autologous melanoma tumors. On day 12, either 5 x106 sorted CD8+BTLA+ or sorted
CD8+BTLA- were adoptively transferred into tumor-bearing mice through the tail vein.
In the virally transduced TIL experiment, either sorted CD8+GFP+WT, CD8+GFP+∆
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Grb2, CD8+GFP+∆ ITSM, or CD8+GFP+empty vector controls were transferred
instead. Recombinant human IL-2 (Proleukin, Novartis) was administered
intraperitoneally at a concentration of 6 x105 I.U. immediately after TIL transfer twice
daily for three day. Tumor size was measured every other day using calipers. Mice were
sacrificed when tumors exceeded 15 mm diameter. Peripheral blood was collected
every other day, washed with 1X PBS twice, and lysed with ACK lysis buffer. The
cells were stained for human surface markers, CD45, CD8, and Aqua (viability) for 20
minutes on ice. After, the cells were washed with 1XPBS twice prior to acquire using
a BD FACScanto II flow cytometer machine. The data was analyzed using FlowJo
software (TreeStar).
Statistical Analysis
For all survival curve analysis data, we used the log rank test to compare distribution
of two groups. We applied Linear Models and Empirical Bayes Methods to compare
the differential protein expression from RPPA data sets. Difference in the percentage
of positive cells producing IFN-γ and TNF-α was analyzed using an ANOVA, and a
two-tailed Student’s t-test was used to determine statistical significance for other
analyses.
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